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Pyruvate carboxylase is a metabolically important enzyme that has been implicated in a 
wide range of diseases and infections such as cancer, diabetes and listeriosis. Despite the 
importance of pyruvate carboxylase in these diseases and infections, there are no 
selective and potent small molecule effectors available to study pyruvate carboxylase 
both in vitro and in vivo. Effective small molecule effectors of pyruvate carboxylase will 
expand the biochemical toolkit to facilitate the investigation of the structure, regulation 
and specific cellular role of pyruvate carboxylase. To discover small molecule effectors 
of pyruvate carboxylase, a novel fixed time assay was developed. The assay is based on 
the reaction of the diazonium salt, Fast Violet B, with the final product of the pyruvate 
carboxylase catalyzed reaction, oxaloacetate. This robust assay was validated and was 
used to screen numerous compounds in a high throughput format. In addition to high-
throughput screening, a structure-based drug design project was implemented to 
specifically target the unique carboxyltransferase domain of pyruvate carboxylase, 
leading to the discovery of potent competitive inhibitors with respect to pyruvate. These 
compounds provide the foundation for chemical probes that target pyruvate carboxylase 
and have the potential to benefit a wide range of in vitro and in vivo studies that are 
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 1 
CHAPTER 1: INTRODUCTION 
 
 
1.1. The Metabolic Context of Pyruvate Carboxylase 
 
 
Pyruvate carboxylase (PC) was first discovered in liver homogenates by Utter and 
Keech in 1959, when it was established that pyruvate could become carboxylated to form 
oxaloacetate (OAA) in the presence of Mg2+, ATP, acetyl CoA and CO2 (Utter and Keech 
1960). PC is an important anaplerotic enzyme that replenishes OAA as it is withdrawn 
from the TCA cycle to become a precursor in lipid and amino acid biosynthetic pathways 
(Jitrapakdee et al. 2008). PC catalyzes the first step of gluconeogenesis in a wide range of 
organisms including prokaryotes and eukaryotes (Zeczycki, St. Maurice, and Attwood 
2010). PC is primarily located in the mitochondria in eukaryotes and in the cytosol of 
prokaryotes (Zeczycki, St. Maurice, and Attwood 2010). In eukaryotic gluconeogenesis, 
as pyruvate enters the mitochondria, it is carboxylated to OAA by PC (Jitrapakdee et al. 
2008). Depending on the levels of NADH in the mitochondria and cytoplasm, OAA is 
converted to either malate or phosphoenolpyruvate (PEP) (Jitrapakdee et al. 2008). If 
there are high levels of NADH in the mitochondria and low levels of NADH in the 
cytoplasm, malate dehydrogenase (MDH) converts OAA to malate (Jitrapakdee et al. 
2008). Malate is subsequently transported out of the mitochondria and converted back to 
OAA with the reduction of NAD+ to NADH (Jitrapakdee et al. 2008). Cytosolic 
phosphoenolpyruvate carboxykinase (PEPCK) catalyzes the conversion of OAA to PEP 
which is accordingly converted back to pyruvate, allowing the cycle to replenish NADH 
levels in the cytoplasm (Jitrapakdee, Vidal-Puig, and Wallace 2006, Jitrapakdee et al. 
2008, Yang, Kalhan, and Hanson 2009). The accumulation of NADH in the cytoplasm 
promotes the reduction of 1,3-bisphosphoglycerate to glyceraldehyde 3-phosphate as part 
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of gluconeogenesis (Jitrapakdee et al. 2008). If there are low levels of NADH in the 
mitochondria, OAA is converted to PEP by mitochondrial PEPCK and transported by the 
tricarboxylic acid anion carrier system to the cytoplasm where it is sequentially converted 
to glucose in the reverse pathway of glycolysis (see Figure 1-1). 
Individuals who are born with mutated versions of PC and are PC deficient have 
shorter lifespans with symptoms ranging from severe lactic acidaemia, hypoglycemia and 
mental retardation (Marin-Valencia, Roe, and Pascual 2010, Robinson 2006). As there is 
a reduction in pyruvate carboxylation to OAA in PC deficient individuals, the buildup of 
pyruvate is converted to lactate by lactate dehydrogenase (LDH) resulting in lactic 
acidaemia (Habarou et al. 2015). Hypoglycemia results from the lack of OAA production 
and subsequent gluconeogenesis, reducing the amount of glucose available to the body 
(Owen, Kalhan, and Hanson 2002). Additionally, reduced OAA pools impact fatty acid 
synthesis, as OAA is an essential precursor to lipid biosynthesis, resulting in a plethora of 
developmental issues including mental retardation (Jitrapakdee et al. 2008). Aberrant PC 
expression has been implicated in diseases such as diabetes and cancer, and in certain 
bacteria where the metabolic function of PC is essential to maintain infection (see Table 












Figure 1-1. The role of PC in gluconeogenesis. PC catalyzes the conversion of 
pyruvate to OAA in the TCA cycle. This reaction replenishes TCA cycle intermediates 
that are withdrawn for other biosynthetic pathways. PC plays an important role in 
gluconeogenesis (indicated in purple). In conditions where cytosolic NADH levels are 
low, OAA is converted to malate by MDH and shuttled out of the mitochondria, 
represented by the double blue circle, to the cytosol via the malate transporter, 
represented by the green cylinder, where it is subsequently converted back to OAA. OAA 
in the cytosol is converted to PEP by PEPCK to continue the cycle of NADH generation 
in the cytosol. In conditions where cytosol NADH levels are high, mitochondrial PEPCK 
will convert OAA to PEP in the first committed step of gluconeogenesis, represented by 
the dashed purple line. OAA is transported to the cytosol by the tricarboxylic acid anion 




1.1.1. Diabetes  
 
 
Pancreatic b-cells are responsible for secreting insulin to maintain glucose 
homeostasis within the body (Henquin 2000). Diabetes results when there is an 
insufficient amount of insulin secreted to meet the demands of increased glucose in the 
blood or due an inadequate systemic response to circulating insulin (Henquin 2000). 
Alternatively, hypoglycemia results when too much insulin has been released (Henquin 
2000). This signaling mechanism between glucose levels and insulin secretion is 
regulated by anaplerotic processes (Flamez et al. 2002, Farfari et al. 2000). Despite being 
incapable of carrying out gluconeogenesis due to PEPCK (MacDonald et al. 1992, 
MacDonald et al. 2005) and fructose-1,6-bisphosphatase deficiency (MacDonald et al. 
2005), pancreatic b-cells express PC at levels that are almost equivalent to those in the 
gluconeogenic tissues of the liver and kidneys. PC is responsible for converting almost 
half of the pyruvate that enters pancreatic b-cells to OAA in rats (Khan, Ling, and 
Landau 1996), but that role appears to be decreased 20-30% in human islet cells 
compared to the rodent model (MacDonald et al. 2011). PC is an important enzyme that 
facilitates the anaplerotic control mechanism of insulin secretion (Jensen et al. 2006). 
OAA that is formed by the PC-catalyzed reaction is important in pyruvate cycling where 
it is converted to malate, citrate or isocitrate through various mitochondrial and cytosolic 
enzymes (Lu et al. 2002). This pyruvate cycling generates a high NADPH: NADP and 
ATP:ADP ratio that regulates glucose-stimulated insulin secretion (Xu et al. 2008, Hasan 
et al. 2008). Studies have found that PC expression is decreased in type 2 diabetes and is 
correlated to an impairment of glucose-induced insulin release (MacDonald, Efendic, and 
Ostenson 1996, Han and Liu 2010, Fransson et al. 2006). Not only does PC regulate 
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insulin release in the pancreas, it also controls hepatic gluconeogenesis (Lao-On, 
Attwood, and Jitrapakdee 2018). In conditions of insulin resistance, excessive lipolysis in 
white adipose tissue results in the accumulation of free fatty acids in the plasma that are 
oxidized in the liver (Wallace, Easterbrook-Smith, and Keech 1985). Acetyl CoA is 
generated through this oxidation process and acts as an allosteric activator of PC, 
increasing PC activity (Kumashiro et al. 2013). An increase in PC activity results in an 
increase of gluconeogenesis, leading to hyperglycemia (Kumashiro et al. 2013). 
Hyperglycemia impairs insulin secretion from the pancreas (Jitrapakdee, Vidal-Puig, and 
Wallace 2006). 
            
1.1.2 Cancer  
 
 
A classic hallmark of cancer is the ability of cancer cells to reprogram their 
metabolism (Pavlova and Thompson 2016, DeBerardinis and Chandel 2016). An example 
of this reprogramming is demonstrated by the Warburg effect. The Warburg effect is a 
common observation that cancer cells will predominately utilize glycolysis for pyruvate 
production that is converted to lactate by LDH, even under aerobic conditions (Kim and 
Dang 2006). Additionally, cancer cells adapt to increase their nutrient intake to support 
proliferation and biomass formation. With the increased demand for energy, cancer cells 
alter the way in which they direct glycolytic and TCA cycle intermediates for the 
biosynthesis of fatty acids, amino acids, nucleotides and the production of NADPH 
(Vander Heiden, Cantley, and Thompson 2009). Consequently, anaplerotic routes play an 
important role in sustaining the TCA cycle while many of its intermediates are withdrawn 
(Cheng et al. 2011). However, the preference for particular anaplerotic routes, such as 
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pyruvate carboxylation by PC, is specific for different types of cancer (Pavlova and 
Thompson 2016).  
 
1.1.2.1 Breast Cancer  
 
 
The leading cause of cancer related death for women is breast cancer (Jemal et al. 
2011). A majority of those deaths are a result of breast cancer metastasis to the blood, 
bone or brain (Scully et al. 2012). PC is abundantly expressed in breast cancer cells that 
are highly invasive such as MDA-MB-435 and MDA-MB-231 cell lines, but is not 
abundant in non-aggressive cell lines such as MCF-7 and SKBR3 (Phannasil et al. 2015). 
Cell lines that are highly invasive and aggressive depend on the anaplerotic mechanisms 
of PC (Phannasil et al. 2015) whereas cell lines such as MCF-7 are more dependent on 
glutamine-dependent anaplerosis (Forbes et al. 2006). Furthermore, it was found that the 
size and motility of tumors are related to the expression of PC in breast cancer cells. 
When PC was overexpressed in MCF-7 cells, the cells increased in size, motility and 
invasion (Phannasil et al. 2015). Alternatively Christen et al. suggested that PC 
expression in cancer cells is controlled by the in vivo microenvironment in certain types 
of tissues (Christen et al. 2016). For example, the authors compared primary breast 
cancer cells located in the breast tissue and the same type of cells that had metastasized to 
the lung, noting that there was an increase in PC expression and PC-dependent 
anaplerosis in the lung metastases (Christen et al. 2016). While it is still unclear how PC 
expression is regulated and the exact role of PC-dependent anaplerosis in breast cancer, 
recent studies suggest that PC is important in the metastasis of certain types of breast 
cancer cells (Christen et al. 2016).      
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1.1.2.2 Lung Cancer  
 
 
Similarly to breast cancer, PC expression levels have been found to be increased 
in lung cancer tissue (Fan et al. 2009). In particular, PC expression has been found to be 
3- to 10-fold higher in early stages of non-small-cell lung cancer (NSCLC) than when 
compared to noncancerous lung tissue (Sellers et al. 2015). NSCLC accounts for the most 
frequent type of lung cancer in non-smokers and constitutes 80-85% of all lung cancer 
cases (Ettinger et al. 2017). Sellers et al. confirmed that when PC expression was reduced 
via shRNA in NSCLC cell lines, there was a decrease in cell proliferation with a 
reduction in nucleotide and lipid biosynthesis, consistent with a decrease in PC-
dependent anaplerosis (Sellers et al. 2015). 
 
1.1.2.3 Succinate Dehydrogenase-Deficient Cancer  
 
 
As it was stated previously, cancer cells adapt to increase their nutrient intake to 
support proliferation and biomass formation by altering the way in which they direct 
glycolytic and TCA cycle intermediates. Succinate dehydrogenase (SDH) oxidizes the 
conversion of succinate to fumarate in the TCA cycle and is important in maintaining a 
fully functional TCA cycle (Rutter, Winge, and Schiffman 2010) Mutations in SDH lead 
to an increase in succinate and surprisingly have been associated with certain types of 
cancers such as neuroendocrine neoplasms, gastrointestinal tumors and renal carcinomas 
(Cardaci et al. 2015, Lussey-Lepoutre et al. 2015). Cancer cells that are SDH deficient 
have an interrupted TCA cycle and despite the deficiencies in aspartate, citrate and 
malate, are still capable of sustaining cellular proliferation to establish an oncogenic 
phenotype (Lussey-Lepoutre et al. 2015). Due to this metabolic interruption, cancer cells 
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metabolically reprogram anaplerotic routes that are important in replenishing TCA cycle 
intermediates. SDH deficiency, in particular, results in a critical dependency on PC 
anaplerosis (Cardaci et al. 2015, Lussey-Lepoutre et al. 2015). SDH-deficient cancer cells 
increase the carboxylation of pyruvate through PC that generates OAA to replenish TCA 
cycle intermediates and to supply OAA for aspartate synthesis (Cardaci et al. 2015, 
Lussey-Lepoutre et al. 2015). The interrupted TCA cycle in SDH-deficient cancers are 
solely dependent on PC for aspartate biosynthesis (Cardaci et al. 2015, Lussey-Lepoutre 
et al. 2015). Cardaci et al. demonstrated that silencing of PC expression significantly 
reduced cellular growth in SDH-deficient cancer cell in vitro while having little effect on 
the wild-type cells (Cardaci et al. 2015), highlighting the metabolic vulnerably of SDH-
deficient cancer cells and the potential of PC to be targeted for SDH-deficient cancers.  
 
1.1.3 Viral Infections  
 
 
PC is an important metabolic host enzyme and scaffold for certain viral infections 
(Lao-On, Attwood, and Jitrapakdee 2018). Herpes simplex virus type I (HSVI) 
reprograms host cells to increase PC expression for viral nucleic acids and protein 
synthesis (Vastag et al. 2011, Grady et al. 2013). Influenza A H1N1 reprograms host cell 
metabolism to not only increase PC-dependent anaplerosis but glutamine-dependent 
anaplerosis as well (Janke et al. 2011). Not only is PC expression increased by certain 
viruses but there is also evidence that PC physically interacts with and acts as a scaffold 
for the nonstructural NS5A protein of hepatitis C virus (HCV) (Yim et al. 2013). NS5A 
interacts with the biotin carboxylase domain of PC (described in Section 1.4) and down-
regulates PC expression (Yim et al. 2013). While counterintuitive, Yim et al. 
hypothesizes that NS5A may act as an on/off switch for PC activity so that HCV can 
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control host metabolism towards virus replication (high PC expression) or viral assembly 
(low PC expression) (Yim et al. 2013). Interestingly, PC is also important in activating an 
antiviral immune response against RNA viruses such as Influenza A, human enterovirus 
71 (EV71) and vesicular stomatitis virus (VSV) (Cao et al. 2016). PC suppresses the 
replication of RNA viruses by targeting the mitochondrial antiviral signaling protein 
(MAVS) signalosome and triggers the release of nuclear factor kappa B (NF-kB), 
resulting in increased interferon and cytokine levels (Cao et al. 2016).  The interaction of 
MAVS with PC seems to be due to structural scaffolding that is independent of PC 
activity (Cao et al. 2016), highlighting the importance of PC as a structural scaffold in 
cellular systems. 
 
1.1.4 Bacterial Infections 
 
 
PC is found in a wide range of bacteria, but not in enteric bacteria that utilize 
phosphoenolpyruvate carboxylase (PEPC) to convert PEP directly to OAA thus 
excluding the need for PC (Jitrapakdee et al. 2008). In particular, PC is important in the 
growth of Bacillus subtilis (Diesterhaft and Freese 1973), Pseudomonas aeruginosa 
(Choi et al. 2016, Kukavica-Ibrulj et al. 2008, Phibbs, Feary, and Blevins 1974) 
Staphylococcus aureus (Benton et al. 2004), Listeria monocytogenes (Schar et al. 2010, 
Whiteley et al. 2017) and Lactococcus lactis (Choi et al. 2017). S. aureus and L. 
monocytogenes are pathogenic bacteria that can cause serious infections such as 
antibiotic-resistant skin infections (Choo and Chambers 2016) and listeriosis (Cossart and 
Lebreton 2014), respectively. Studies have linked bacterial metabolism to virulence for 
microbes such as S. aureus and L. monocytogenes (Eisenreich et al. 2010, Schar et al. 
2010, Sureka et al. 2014, Whiteley et al. 2017). This relationship between metabolism 
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and pathogenicity is well exemplified in L. monocytogenes (Schar et al. 2010, Sureka et 
al. 2014, Whiteley et al. 2017). L. monocytogenes has an interrupted citric acid cycle 
much like SDH deficient cancer cells, except L. monocytogenes does not encode for a-
ketoglutarate dehydrogenase. PC is crucial for L. monocytogenes growth inside host cells 
during infection as it is the predominate source of OAA generation within the bacterium. 
L. monocytogenes cannot utilize host OAA as the bacterium apparently lacks OAA 
permease (s) (Schar et al. 2010). Due to the interrupted TCA cycle, L. monocytogenes is 
metabolically vulnerable, and PC deficient bacteria are attenuated in mouse sepsis models  
(Schar et al. 2010).  
 





Tissue/Organism PC Expression 
 
Type 2 Diabetes 
 
Pancreatic b-cells Decreased 
 






Metastasized tumors Increased 
 










L. monocytogenes Essential 
*Indicates interrupted TCA cycle  
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1.2 Pyruvate Carboxylase Structure and Function  
 
 
PC is a multifunctional, biotin dependent enzyme that exists predominately in the 
a4 form which consists of four identical polypeptide chains organized together to form a 
homotetramer of ~500kDa (Jitrapakdee et al. 2008) . Each subunit contains a biotin 
carboxylase (BC), biotin carboxyl carrier protein (BCCP), carboxyltransferase (CT) and 
allosteric domain. The homotetramer is organized such that there are two layers, each 
containing two subunits with CT/CT and BC/BC domain interface interactions between 
the top and bottom layer (St Maurice et al. 2007) (see Figure 1-2A). The MgATP-
dependent carboxylation of pyruvate by HCO3- to form OAA occurs in two distinct active 
sites, the BC domain and the CT domain (Jitrapakdee et al. 2008). Biotin, which is 
covalently attached to a specific lysine residue in the BCCP domain, is carboxylated in 
the BC domain to form carboxybiotin (Jitrapakdee et al. 2008). The carboxybiotin is 
subsequently transferred via the BCCP domain to the CT domain where pyruvate is 
carboxylated to form OAA (Jitrapakdee et al. 2008) (see Figure 1-2B).  
The BC domain structures are conserved across biotin dependent enzymes (Tong 
2013) and have similar structural architectures that contain an ATP-grasp fold 
(Jitrapakdee et al. 2008).  It is assumed that all biotin dependent enzymes catalyze the 
first partial reaction of the MgATP-dependent carboxylation of biotin from HCO3-  
through similar mechanisms (Menefee and Zeczycki 2013). For the first partial reaction 
of the PC domain that results in the carboxylation of biotin, the BC domain requires free 
Mg2+, MgATP, HCO3-, and biotin to be bound in the BC domain (Menefee and Zeczycki 
2013). The binding of the BC domain substrates induces a closed conformation for biotin 
carboxylation to occur through the formation of carboxyphosphate and biotin enolate 
 12 
intermediate. After biotin has been carboxylated to carboxybiotin, it is transferred to the 
CT domain for the second partial reaction where pyruvate is carboxylated to form OAA.   
The core structure of the CT domain consists of a TIM-barrel that forms a funnel-
like structure (Jitrapakdee et al. 2008). Centered at the base of the funnel is an essential 
catalytic Mn2+/Zn2+ metal ion that was proposed to stabilize the enolpyruvate 
intermediate through a bidentate interaction (Mildvan, Scrutton, and Utter 1966, Yong-
Biao et al. 2004), but recent crystal structures demonstrate that this interaction does not 
occur (Lietzan and St Maurice 2013b). Before pyruvate binds, the CT domain is in an 
open conformation and upon pyruvate binding, the CT domain adopts a closed 
conformation that promotes the carboxylation of pyruvate to form OAA (Lietzan and St 
Maurice 2013a). The transition between this open and closed state is centered within the 
flexible loop region of Arg621-Asn630 (RePC residue numbering). Based on the overlay 
structures of RePC (St Maurice et al. 2007), RePCDBCDBCCP (Lietzan and St Maurice 
2013a, b), LmPC (Sureka et al. 2014), and SaPCDBC (unpublished) without pyruvate 
present, Arg621 is either disordered or occupies multiple conformations. When pyruvate 
binds, the position of Arg621 becomes fixed through a salt bridge with the carboxyl 
moiety of pyruvate and the guanidinium side-chain of the arginine, while Gln552 and 
Arg548 are within hydrogen bonding distance of the carbonyl oxygen of pyruvate (Lietzan 
and St Maurice 2013b) (see Figure 1-3A). Additionally, crystal structures of PC with 
pyruvate bound in the CT domain demonstrate that Tyr628 rotates to form a hydrogen 
bond with Asp590 (Xiang and Tong 2008a, Lietzan and St Maurice 2013b, a) (see Figure 
1-3B). The carbonyl oxygen of pyruvate is oriented toward the tightly bound metal ion 
and this positioning of pyruvate with respect the metal ion is observed to be bridged by a 
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water molecule (Lietzan and St Maurice 2013a). The binding mechanism has been 
proposed to induce the closed conformation of the CT domain such that Arg621, Gln552 
and Arg548 are responsible for stabilizing the enolpyruvate intermediate while Tyr628 and 
Asp590 are responsible for establishing a substrate-induced binding pocket for 
carboxybiotin (Lietzan and St Maurice 2013a). Once bound, carboxybiotin is 
subsequently decarboxylated to form an anionic enol intermediate that is stabilized by 
Gln844, Ser884 and Lys866 (Zeczycki et al. 2009). Thr882 acts as general acid to protonate 
the biotin enol intermediate and as a general base to shuttle a proton from pyruvate to 
biotin, forming the enolpyruvate intermediate (Zeczycki et al. 2009). The enolpyruvate 


































Figure 1-2. The Structure and Function of a4 PC 
 
Figure 1-2. The structure and function of a4 PC. A) Surface representation of the 
homotetramer of SaPC (pdb i.d. 3bg5). The top layer or “top face” of the homotetramer is 
composed of two individual subunits. The bottom layer or “bottom face” is also 
composed of two individual subunits (yellow surface representation). Each subunit 
contains a BC domain (cyan), allosteric domain (blue), CT domain (green), and BCCP 
domain (gray). One subunit of the homotetramer has been outlined in black. B) Cartoon 
representation of one subunit of the homotetramer and the general scheme of the BC and 
CT domain reaction. The BC domain catalyzes the MgATP- and HCO3-  -dependent 
carboxylation of biotin. The carboxybiotin is subsequently transferred to the CT domain 
by the swinging arm movement of the BCCP domain where pyruvate is carboxylated to 










Figure 1-3. Comparison of the Closed and Open Conformation of the Six Key 




Figure 1-3. Comparison of the closed and open conformation of the six key catalytic 
amino acids, Arg621, Gln552, Arg548, Tyr628 and Asp590 in the CT domain of SaPC (pdb i.d. 
3bg5) A) Upon the binding of pyruvate, the CT domain adopts a closed conformation 
where the carboxyl moiety of pyruvate forms a salt bridge with the guanidinium side-
chain of Arg621 and the carbonyl oxygen of pyruvate is within hydrogen bonding distance 
of Arg548 and Gln552. These residues are responsible for stabilizing the enolpyruvate 
intermediate. In the closed conformation, Tyr628 forms a hydrogen bond with Asp590.  B) 
The contrast between the open (light purple) and closed conformation (green) can be seen 








The studies described in Section 1.1 highlight the importance of PC expression in 
diabetes, cancer and listeriosis that are sustained as a result of aberrant or essential PC 
expression. PC has been implicated in these diseases and infections primarily through 
genetic tools such as knockouts, antisense oligonucleotides, and siRNAs that target the 
PC gene. For example, the essential role of PC in listeriosis was determined by genome 
sequence analysis (Glaser et al. 2001) and insertional mutagenesis of pycA, the gene 
encoding PC, in L. monocytogenes (Schar et al. 2010). Pyruvate carboxylation by PC was 
shown to be the exclusive route of OAA formation in L. monocytogenes (Schar et al. 
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2010). Without PC, the bacterium could no longer effectively replicate inside host cells, 
leading to an attenuated rate of virulence in mouse sepsis models (Schar et al. 2010). 
Additionally, genetic manipulation of the pycA gene in L. monocytogenes when 
compared to wild-type L. monocytogenes, was shown to have reduced glucose 
metabolism as indicated by the downregulation of glycolysis genes, but the authors were 
unable to identify the exact cause of this observation (Schar et al. 2010). PC is an 
important scaffold for other metabolic enzymes such as MDH and aspartate 
aminotransferase (Fahien, Davis, and Laboy 1993). The differential regulation of 
glucose-controlled genes in the pycA mutant could have been a consequence of removing 
PC as a scaffold for MDH and aspartate aminotransferase or as direct consequence of 
removing the catalytic activity of PC from L. monocytogenes.  
As a result of not only the catalytic, but structurally relevant role of PC as a 
scaffold, genetic tools such as knockouts, siRNAs and ASO that reduce PC expression 
levels are likely to impact multiple cellular systems. It is difficult to know the exact role 
that PC activity has in cancer, diabetes or bacterial infections, independent of PC 
expression. In other words, attempts to study the role of PC activity using genetic tools 
also impact PC expression. Small molecule effectors of PC have the potential to 
circumvent issues that arise with genetic manipulation of PC. The advantage of small 
molecule regulation as compared to gene knockout or silencing is that small molecules 
can alter specific catalytic functions without eliminating the gene product from the 
cellular system, thus precluding unintentional effects, such as a change in MDH or 
aspartate aminotransferase activity in the cell. Currently, there are no known specific and 
potent small molecules that can regulate PC activity without affecting other enzymes in 
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the cellular context. For example, in certain bacteria like L. monocytogenes and L. lactis, 
cyclic-di-AMP (c-di-AMP) is a recently discovered allosteric regulator that decreases PC 
activity with a KD value of 8 µM (Sureka et al. 2014, Choi et al. 2017), making it one of 
the most potent inhibitors of PC to be documented. However, even with a compound like 
c-di-AMP that has been used both in vivo and in vitro to elucidate the importance of PC 
in bacterial metabolism, it is difficult to assess the direct and specific role of PC. This is 
due to c-di-AMP not being specific for PC and binding to a broad range of proteins 
(Commichau et al. 2015). Experiments that have utilized L. monocytogenes PC knockouts 
to study the relationship between c-di-AMP and PC in the cellular context of bacterial 
metabolism are still subject to off target effects and to the possible downstream 
consequences of disrupting other enzymatic systems. For example, upon cellular 
infection of host cells, L. monocytogenes releases c-di-AMP that has a wide range of 
consequences not only for L. monocytogenes, but for the host cell as well (Radoshevich 
and Cossart 2018, Woodward, Iavarone, and Portnoy 2010). Specific and potent small 
molecules that can regulate PC activity without affecting other enzymes in the cellular 
context would be able to specifically activate and inhibit PC activity, while avoiding 
disruption of PC expression.   
 
1.4 Methods for Small Molecule Probe Discovery  
 
 
There are many screening approaches that can be taken to discover novel, potent 
and specific small molecule effectors of PC. These methods vary by the primary assay 
that is applied in the screen, the type of molecules that are being screened against, the 
detection system and the sampling availability of small molecules (Keseru and Makara 
2006). The type of small molecules that can be screened against can be broadly classified 
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as drug-like or fragment-like compounds (Rees et al. 2004, Lamoree and Hubbard 2017, 
Keseru and Makara 2006). Drug-like compounds have molecular weights that average in 
the low 300s and have drug-like physicochemical and structural properties (Lipinski 
2004, Carr and Jhoti 2002). Drug-like compounds are typically associated with high-
throughput screening (HTS) procedures where large libraries of up to 10,000-100,000 
compounds can be assessed per day with miniaturized screening assays and automatic 
robotic systems (Mayr and Bojanic 2009). Fragment-like compounds are smaller and are 
more likely to bind to a wider range of targets due to the lack of additional functional 
groups that may spatially prevent binding (Lamoree and Hubbard 2017). Fragment-like 
compounds are useful in fragment-based lead discovery or structure-based drug design 
(SBDD) that can further improve fragment hits for selectivity and potency by adding 
functional groups to the fragment (Lamoree and Hubbard 2017).  
Fragment-like and drug-like compounds can be used in bioassay-based screening, 
affinity screening or in silico screening. Bioassay-based screening includes the rigorous 
development and validation of an analytical method that measures a biological process 
(Janzen 2014). These screening assays are typically biochemical assays that measure 
enzyme activity or cell-based assays that screen for phenotypes in cells, tissues and whole 
organisms (Janzen 2014). Zebrafish are an example of a whole organisms that have been 
utilized successfully in cell-based screening assays. Zebrafish larvae in particular, are 
ideal whole organisms for screening as they are small enough to be dispensed in 96-well 
plates, are permeable to compounds and are transparent for non-invasive imaging 
(Mathias, Saxena, and Mumm 2012). Bioassay-based screening that is utilized in HTS 
can be beneficial for discovering compound hits that are more specific for a biological 
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process, but assay optimization and hit confirmation can be difficult in biological systems 
(Janzen 2014).  
Affinity or biophysical assays are based on physical interactions between the 
screened compound and selected target rather than the effect on a biological system (Carr 
and Jhoti 2002). Techniques for affinity assays include nuclear magnetic resonance 
(NMR) (Carr and Jhoti 2002), mass spectrometry (MS) (Jonas, LaMarr, and Ozbal 2009) 
and X-ray crystallography (Caliandro et al. 2013). NMR and X-ray crystallography in 
particular, are useful for SBDD and fragment-based screening approaches (Carr and Jhoti 
2002). The advantage with affinity assays is the structural information that is discovered 
through the screening process. For example, structure activity relationships (SAR) in 
NMR studies can assess where a ligand is binding, and X-ray crystallography can provide 
binding orientations of molecular fragments. X-ray crystal structures in particular, greatly 
enhance the ability to generate lead compounds (Carr and Jhoti 2002). Fragment-like 
compounds can be screened individually or as cocktails (combination of 4-8 compounds) 
by soaking the compounds with crystals and observing for electron density in the binding 
site for any small molecules (Carr and Jhoti 2002). However, X-ray crystallography is 
resource intensive and the number of compounds that are able to be screened with this 
method are limited. 
In silico assays, or computational assays, require a knowledge-driven approach 
based on available structural information of either the desired ligands or known target 
selection (Congreve, Murray, and Blundell 2005). In silico assays are beneficial due to 
their ability to screen numerous diverse compounds computationally and can be utilized 
for quantitative structure-activity relationships (Ekins, Mestres, and Testa 2007). This 
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method involves docking compounds into a known active site (ligand-based screening) or 
screening for a target that will computationally bind to a compound that is of interest 
(target-based screening) (Ekins, Mestres, and Testa 2007). Target-based screening is 
more limited as there are not as many protein structures available as there are compound 
structures (Ekins, Mestres, and Testa 2007). However, in silico assays may be limited by 
the ability to test the predictive targets or compounds in biological assays.   
Acetyl CoA carboxylase (ACC) is an example of a biotin dependent enzyme that 
has been targeted in a variety of screening methods, one of which has resulted in the 
successful discovery of potent small molecule inhibitors (Marjanovic et al. 2010, 
Harriman et al. 2016). ACC catalyzes the conversion of acetyl CoA to malonyl CoA 
through two distinct half reactions, the carboxylation of biotin with HCO3- in the BC 
domain and the subsequent transfer of the carboxyl group by the BCCP domain to 
carboxylate acetyl CoA in the CT domain (Li and Cronan 1992). This reaction catalyzes 
the first committed step in fatty acid biosynthesis (Li and Cronan 1992). While there are 
several examples of assays that have been developed to detect ACC activity in a high-
throughput manner in cell-based (Marjanovic et al. 2010), biochemical (Kroeger, 
Zarzycki, and Fuchs 2011, Marjanovic et al. 2010) and in silico assays (Vyas et al. 2017) 
only one will be discussed further. A validated HTS assay has been developed that 
specifically targets the CT domain of ACC based on a modified coupled enzyme assay 
that measures the reverse reaction of the CT domain in which biocytin reacts with 
malonyl CoA to form carboxybiotin and acetyl CoA. Citrate synthase was coupled to this 
reaction and catalyzed the reaction of acetyl CoA to CoA and citrate. CoA levels were 
detected by 5,5-Dithiobis(2-nitrobenzoic acid) (DTNB) and the signal was measured at 
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412 nm (Santoro et al. 2006). In addition to the development of screening assays for 
ACC, a potent allosteric inhibitor (ND-630) for ACC, was identified through SBDD 
(Harriman et al. 2016). This compound disrupts the protein-protein interactions at the BC 
dimerization site of ACC and inhibits enzyme activity (Harriman et al. 2016). ND-630 
has been transitioned to in vivo studies where it reduced weight gain and improved 
insulin sensitivity in diet-induced obese rats (Harriman et al. 2016).    
ACC is an excellent example of a biotin dependent enzyme that has been the 
target of a variety of screening approaches and demonstrates the success of developing 
HTS assays, compound development and validation of lead compounds applied to in vivo 
studies. It demonstrates that similar methods can be taken to discover novel small 
molecule effectors of PC. We have taken two approaches to discover novel, potent and 
specific small molecule effectors of PC that will be discussed further in this dissertation: 
1) HTS and 2) SBDD. HTS is a method that can find small molecule effectors that have 
novel binding sites or modes of action, and lead to new insights into the regulation and 
mechanism of PC. SBDD in contrast, is a rational approach that takes advantage of small 
molecule effectors bound to PC. Based on available structural information, we can 
discover and design small molecules to be more potent and specific for PC.  
 
1.5 Overview  
 
 
PC is metabolically important enzyme that has been implicated in a wide range of 
diseases and infections such as cancer, diabetes and listeriosis. Despite the importance of 
PC in these diseases and infections, there are no specific and potent small molecule 
effectors available to study pyruvate carboxylase both in vivo and in vitro. Small 
molecule effectors of pyruvate carboxylase can benefit studies that investigate the 
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structure, regulation and specific cellular role of PC in diseases and infections. To 
discover small molecule effectors of PC, a novel fixed time assay has been developed. 
The assay is based on the reaction of the diazonium salt, Fast Violet B (FVB), with OAA, 
the final product of the PC catalyzed reaction. The assay is robust, validated and has been 
applied to screen numerous compounds in a high throughput format. SBDD was 
implemented to specifically target the unique CT domain of PC, and lead to the discovery 
of potent inhibitors that are competitive with respect to pyruvate. These compounds can 
provide the foundation for chemical probes development that specifically targets PC. 
These compounds have the potential to benefit a wide range of in vivo and in vitro studies 




























CHAPTER 2: MATERIALS AND METHODS 
 
 
2.1 General Protein Purification Method 
 
 
Rhizobium etli PC (RePC) was co-expressed from a modified pET-17b-(His)9 
vector (Chapman-Smith et al. 1994) with a pCY216 vector (St Maurice et al. 2007) 
encoding E. coli biotin protein ligase (BirA) in E. coli BL21Star(DE3) cells. S. aureus PC 
(SaPC) (Xiang and Tong 2008b), SaPC truncations with the removal of the BC and/or 
BCCP domain (SaPCDBC and SaPCDBCDBCCP) and L. monocytogenes (PC) LmPC 
were co-expressed from a pET-28a vector with a pCY216 vector in E. coli 
BL21Star(DE3) cells. RePC, LmPC, SaPC, SaPCDBC and SaPCDBCDBCCP were 
purified using Ni2+-affinity and anion exchange chromatography as previously described 
(Lietzan et al. 2011). In all cases, harvested cells were re-suspended in a lysis buffer 
containing 20 mM Tris (pH 7.8), 5 mM imidazole, 200 mM NaCl, 0.5 mM EGTA, 6 mM 
2-mercaptoethanol, lysozyme (300 µg/mL), 1 mM phenylmethane-sulfonyl fluoride 
(PMSF), 1 µM pepstatin A, and 5 µM proteinase inhibior E-64. Cells were disrupted by 
sonication and the cell lysate was cleared by centrifugation at 4°C prior to loading onto a 
10 mL Ni2+-NTA Profinity resin column (Bio-Rad Laboratories). The column was 
washed with 150 mL of lysis buffer followed by 150 mL of wash buffer (20 mM Tris (pH 
7.8), 20 mM imidazole, 200 mM NaCl, 0.5 mM EGTA, 6 mM 2-mercaptoethanol). The 
RePC enzyme was eluted from the column in elution buffer (20 mM Tris (pH 7.8), 250 
mM imidazole, 200 mM NaCl, 0.5 mM EGTA, 6 mM 2-mercaptoethanol) with an 88 mL 
gradient of 20 mM imidazole wash buffer to 250 mM imidazole elution buffer. For SaPC, 
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SaPCDBC, SaPCDBCDBCCP and LmPC, the enzymes were eluted in a single step 
elution with 25 - 30 mL elution buffer.  
All purified protein samples were pooled and dialyzed overnight in 1 L of Q-
Sepharose buffer containing 20 mM triethanolamine (pH 8.0), 50 mM NaCl, 1 mM 
EGTA, and 2 mM DTT at 4°C in preparation for anion exchange chromatography. 
Protein was loaded on a 10 mL column of Q-Sepharose Fast Flow resin (GE Healthcare) 
and the column was washed with 60 mL of Q-Sepharose buffer. The RePC protein was 
eluted from the resin in Q-Sepharose buffer using a linear gradient from 50 mM to 1 M 
NaCl over 88 mL. For SaPC SaPCDBC, SaPCDBCDBCCP and LmPC, the enzymes were 
eluted in a single step elution with 25 - 30 mL of Q-sepharose buffer containing 1 M 
NaCl. Fractions were pooled and dialyzed against a storage buffer consisting of 10 mM 
Tris (pH 7.8), 150 mM KCl, 3 mM MgCl2, 5% (v/v) glycerol and 2 mM DTT.  An 
Amicon stirred cell with a 30,000-molecular weight cutoff filter was used to concentrate 
protein preparations to a range of 3 - 12 mg/mL. Concentrated protein was flash-frozen in 











CHAPTER 3: THE DEVELOPMENT OF A HIGH-THROUGHPUT SCREENING 






As described in Chapter 1, recent studies have linked aberrant PC activity to 
several diseases and infections, such as type 2 diabetes, listeriosis, and certain types of 
cancers (Cheng et al. 2011, Christen et al. 2016, Farfari et al. 2000, Jensen et al. 2006, 
Phannasil et al. 2015, Schar et al. 2010, Xu et al. 2008, Lao-On, Attwood, and 
Jitrapakdee 2018). Studies focused on the role of PC in insulin secretion and tumor cell 
proliferation have revealed a strong correlation between reduced PC expression/activity 
and decreased insulin release, while enhanced PC expression and activity has been 
associated with tumor cell proliferation and breast cancer metastases (Hasan et al. 2008, 
Phannasil et al. 2015, Cheng et al. 2011, Christen et al. 2016). Additionally, PC is the 
primary enzyme that produces OAA in L. monocytogenes, a facultative intracellular 
bacterium, and has been shown to be vital for the bacterium's pathogenicity as PC-
deficient L. monocytogenes mutants are unable to replicate in host cells (Whiteley et al. 
2017, Schar et al. 2010, Sureka et al. 2014).   
 While there is a growing realization that PC activity is implicated in a wide range 
of diseases and infections, at present, there are no specific and potent small molecule 
effectors available to study altered PC activity in vitro or in vivo. A number of small 
molecules are known to alter PC activity (Zeczycki, Maurice, and Attwood 2010, Choi et 
al. 2017, Zeczycki, St. Maurice, and Attwood 2010), but none of these demonstrate good 
binding affinities and many of them are promiscuous, binding to multiple targets in 
addition to PC. Oxalate for example, is an inhibitor of PC with a Ki value of 12 µM 
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(chicken liver PC (Zeczycki, St. Maurice, and Attwood 2010)), but is also a known metal 
chelator (Makkar, Siddhuraju, and Becker 2007) that inhibits LDH (Novoa et al. 1959) 
and transcarboxylase (Northrop and Wood 1969). Specific and potent small molecule 
effectors of PC have great potential to be used as biochemical tools to aid in delineating 
the structure, mechanism, and regulation, as well as its role in infection and disease. The 
development of a high-throughput assay is an important prerequisite in discovering new 
and potent effectors of PC activity.  
Several well-established coupled-enzyme assays are available to study PC activity 
(Zeczycki, Menefee, Adina-Zada, et al. 2011, Attwood and Cleland 1986a), but none of 
these are well suited to HTS of small molecule effectors. The carboxylation of pyruvate 
in PC is typically measured by coupling the formation of the product, OAA, to the MDH 
catalyzed reduction of OAA to malate and oxidation of NADH to NAD+ (Attwood and 
Cleland 1986b) (see Figure 3-1). This can be readily observed by measuring the change 
in absorbance of NADH at 340 nm (Attwood and Cleland 1986a). In addition, there are a 
variety of other coupled-enzyme assays that can measure the specific half-reactions 
catalyzed in either the BC or CT domains. For example, an LDH-coupled assay can be 
used to determine the rate of OAA decarboxylation in the CT domain by the NADH-
dependent reduction of pyruvate to lactate. Similarly, a glucose-6-phospate 
dehydrogenase / phosphoglucomutase / phosphorylase coupled assay system can be used 
to determine the rate of MgATP cleavage in the BC domain (Zeczycki, Menefee, Adina-
Zada, et al. 2011). These coupled-enzyme assays are generally inappropriate for 
screening large libraries of small molecules. For instance, the inclusion of secondary 
coupling enzymes raises the potential for small molecules to target the coupling enzyme 
 27 
instead of, or in addition to, the target enzyme. While counter-screens of small molecules 
against the coupling enzyme are routinely implemented in HTS programs, these represent 
an additional step that must be performed to eliminate false positives (Glickman 2004, 
Acker and Auld 2014).  Furthermore, the vast majority of coupled-enzyme assays make 
use of redox enzymes that act on NAD/NADH, requiring absorbance changes to be 
monitored at 340 nm. This wavelength is suboptimal for the small assay volumes typical 
of HTS assays, where short path lengths and low extinction coefficients limit the signal 
window in a multi-well plate format (Inglese et al. 2007, Simeonov and Davis 2004, 
Simeonov et al. 2008). Additionally, absorbance at 340 nm is subject to interference from 
small molecules, dust particles and standard assay components (Inglese et al. 2007, 
Simeonov et al. 2008), resulting in a decreased signal to noise ratio and an increased 













Figure 3-1. Use of Malate Dehydrogenase to Assay Pyruvate Carboxylation  
 
Figure 3-1. Use of malate dehydrogenase to assay pyruvate carboxylation. MDH reduces 
OAA to malate while oxidizing NADH to NAD+. Initial velocities of PC are measured 
through the decrease in absorbance of NADH at 340 nm. PC and MDH have been 
highlighted to demonstrate the ability of small molecules to not only target PC, but also 
to cross-react with MDH. Thus, a counter-screen for MDH would have to be established 
if this assay was to be used as a primary screening assay.  
 
To overcome the limitations associated with using coupled-enzyme assays, a 
novel fixed-time assay has been developed (Wyatt, Arnold, and St Maurice 2018). After 
the assay was optimized in a 96-well plate format, it was subsequently modified to a 384-
well plate format to decrease the demand on materials while increasing the efficiency 
with which small molecules could be tested. The assay is based on the reaction of OAA, 
the product of the PC-catalyzed reaction, with Fast Violet B, a diazonium salt which 
produces a colored adduct with an absorbance maximum at 530 nm (see Figure 3-2). 
Diazonium salts have previously been used to detect OAA formation in other enzymatic 
systems such as phosphoenolpyruvate carboxylase and glutamic oxalacetic transaminase 
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(Sax and Moore 1967, Cockburn et al. 1990, Lombarts and Peters 1971, Norris, 
Atkinson, and Smith 1975, Babson et al. 1962a) , but FVB has never been applied to 
determine PC activity. This chapter outlines the development of a fixed-time, FVB-based 
assay to detect PC activity in a manner that is amenable to analyzing numerous small 
molecule effectors of PC. The assay readout is stable for an extended time period and 
accurately reports on enzyme activity from a single data point. The FVB fixed-time assay 
is reproducible, sensitive and responsive to known effectors of PC. The assay was used to 
screen a series of small molecule libraries that established the FVB assay as an excellent 
primary assay to use in a concerted HTS program against PC in the future. 
 





























3.2 Materials and Methods  
 
 
3.2.1 Preparation of Assay Reagents and Solutions 
 
 
All assay reagents and solutions were prepared separately and maintained at 22 °C 
for the full duration of the experiments. All substrates, effectors and enzyme were freshly 
dissolved and diluted in assay buffer containing 50 mM Bis-Tris (pH 7.7), 150 mM KCl, 
3.0 mM MgCl2, 0.5% triton X-100, and 1% DMSO. The final concentrations of enzyme, 
substrates and effectors are in total assay volume (100 µL) before the addition of EDTA 
and FVB. The final concentration of enzyme in the assay was 10 µg/mL, except for 
LmPC where the final concentration of enzyme in the assay was 50 µg/mL.  Where noted, 
oxalate and acetyl coenzyme A (Crystal Chem Inc., Elk Grove, IL) were included in the 
assay at a final concentration of 5 mM and 0.25 mM, respectively. The substrate solution 
containing NaHCO3, pyruvate and ATP was added to the assay at a final concentration of 
25 mM, 2 mM, and 1 mM, respectively. EDTA was prepared in assay buffer and served 
to inactivate the enzyme-catalyzed reaction at a final concentration of 12.7 mM. Fast 
Violet B Salt (FVB; Santa Cruz Biotechnology) was prepared at a stock concentration of 
46 mM in DMSO. After vortexing the FVB stock solution to dissolve the dye, it was 
centrifuged at 9,300 ×g for one minute and the clarified supernatant was separated from 
the salt pellet. The resulting FVB stock solution was protected from light exposure until it 









3.2.2 Assay Procedures   
 
 
 For all experiments other than the evaluation Library of Pharmacologically 
Active Compounds (LOPAC, Sigma) screens, the Microsource Discovery and Prestwick 
screens (University of Wisconsin-Milwaukee (UWM)) and the National Cancer Institute 
Developmental Therapeutics Program (NCI DTP) screen, 30 µL enzyme stock solution 
was added to each well in 96-well, flat clear bottom, polystyrene microplates (Santa Cruz 
Biotechnology) followed by the addition of 10 µL of the effectors (oxalate for inhibition, 
acetyl CoA for activation, assay buffer for the un-inhibited or un-activated reaction, and 
EDTA for measurement of the background signal). To initiate the enzyme-catalyzed 
reaction, 60 µL of a substrate stock solution containing pyruvate, HCO3- and ATP in 
assay buffer was added to each well. After one hour, the enzyme reaction was inactivated 
by the addition of 10 µL of EDTA, followed by the addition of 10 µL of FVB for a total 
volume of 120 µL.  The plates were sealed with microseal ‘B’ adhesive seals (Bio-Rad) 
and incubated for 2 hours at 22 °C, prior to measuring absorbance values at 530 nm with 
a multi-well plate reader.  All plates and reagents were kept at 22 °C for the duration of 
the experiments. Reagents were dispensed using an automated liquid handling system 
(MultiFlo FX, Biotek) except for the effectors which were manually added using a hand-
held, multi-channel micropipette. The 96-well plate format was modified to a 384-well 
plate format and all of the steps described above are identical except that the volumes 
were decreased by half so that the final volume was 60 µL. For the screens performed at 
UWM (the LOPAC and Microsource Discovery Prestwick screens), the procedure was 
slightly modified to incorporate a pintool (V&P Scientific) in combination with an Evo 
system (Tecan Life Sciences) to transfer the controls. After the addition of the controls, 
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70 µL of the substrate stock solution was added to the wells to initiate the enzyme 
reaction.  
The screen provided by the NCI DTP, contained a mechanistic (1 mM stock of 
compounds), oncology (10 mM stock of compounds), natural product (10 mM stock of 
compounds) and diversity (10 mM stock of compounds) set for a total of 2,954 
compounds that were screened in the 384-well plate format. Slight modifications were 
made to the 384-well plate FVB assay procedure in screening compounds from the DTP. 
After the addition of 15 µL of enzyme, 5 µL of controls and compounds were added to a 
final concentration of 100 µM for the mechanistic set in the screen. For the natural 
products, oncology and diversity set, 1 µL of controls and compounds were added to a 
final concentration of 200 µM in the screen. After the addition of the controls, 30 µL of 
the substrate stock was added for the mechanistic set while 34 µL of the substrate stock 
was added for the natural products, oncology and diversity set to initiate the enzyme 
reaction. After one hour, the enzyme reaction was inactivated by the addition of 5 µL of 
EDTA, followed by the addition of 5 µL of FVB for a total volume of 60 µL.  Reagents 
were dispensed using an automatic liquid handling system (MultiFlo FX, Biotek) except 
for the controls and compounds, which were manually added using a hand-held, multi-
channel micropipette. 
 
3.2.3 Data analysis  
 
 
The assay signal quality was statistically evaluated using the Z-factor value as 
described by Equation 1 (Zhang, Chung, and Oldenburg 1999), where ss and sc represent 
 33 
the standard deviations for the sample and control, respectively, and µs and µc represent 
the means for the sample and control, respectively. 
Z= 1 − (&'()	&'+)
|-(.	-+|
     [1] 
A Z-factor between 0.5 and 1.0 indicates that the signals in the assay have a large 
signal difference between the sample and the control, in addition to low standard 
deviations. Z-factors in this range indicate that an assay is excellent for screening. To 
determine the agreement of the assay in measuring PC activity, a kcat and KM for pyruvate 
were determined by the following method: 
1. An OAA standard curve was established to relate absorbance values at 530 nm to 
the OAA concentration: y = a + bx, where y is absorbance, a is the intercept, b is 
the slope of the line and x is OAA concentration. Rewritten: 
Abs = a + b[OAA] 
Solving for [OAA]: 
[OAA]= 9:;.<
:
     [2] 
The standard curve that was used for these calculations was the standard curve 
that was linear with 0-400 µM of OAA (described in the results) as the 
absorbance range to determine kcat and KM was well within that range.  
2. To determine the kcat and KM values using the FVB assay, the enzyme-catalyzed 
reaction at varying concentrations of pyruvate was inactivated at different time 
intervals. The absorbance values were then converted to [OAA] using equation 
[2] determined from the standard curve. Initial velocities ([OAA]/minute) were 
determined for each substrate concentration and plotted against pyruvate 
concentration. The following equations were used to determine kcat and KM values, 
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where [E]T represents the total enzyme concentration, vi represents initial velocity, 









     [4] 
The validation experiments were designed and evaluated according to the 
recommendations of the “Assay Guidance Manual” from the National Center for 
Advancing Translational Sciences (NCATS), which includes all necessary pre-configured 
spreadsheets for analysis of the inter-plate and inter-day experiments (Sittampalam et al. 
2012).  
 For the LOPAC screen, percent activation and percent inhibition were calculated 
according to the equations [5] and [6], where µC, µE and µR represent the means for the 
control (addition of acetyl CoA or oxalate), effector (screened small molecule), and 
reaction (the unaffected reaction), respectively:  
Percent	activation = 100 − UVWX	–	WZ
WX.W[
\ × 100]   [5] 
Percent	inhibition = 100 − UVWZ	–	WX
W[.WX
\ × 100]   [6] 
To determine the potency of specific effectors, the FVB assay was performed at 
varying effector concentrations. The dose-dependent response curves were evaluated 
using IC50 and EC50 equations, according to equation [7]:  
Y = bottom+ Hab.:aHHac
d)de(fghiXjk lB)	∗	noff	pfgqr)
   [7] 
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3.3 Results  
 
 
To accelerate the discovery of novel small molecule effectors of PC, it was 
necessary to establish an assay that can accurately measure PC activity in a high-
throughput manner. Several diazonium salts have previously been utilized to detect OAA 
formation (Babson et al. 1962a, Cockburn et al. 1990, Norris, Atkinson, and Smith 1975, 
Sax and Moore 1967), but to the best of our knowledge, they have never been applied to 
assay PC activity.  Consequently, we sought to develop and validate a novel fixed-time 
assay to measure PC activity via the formation of a colored adduct between the reaction 
product, OAA, and the diazonium salt, FVB.  
 
3.3.1 Optimization and Validation of the Fast Violet B (FVB) Assay  
 
 
FVB formed a colored adduct with OAA with an absorbance maximum at 530 
nm, consistent with what has been reported in previous studies (see Figure 3-3A) (Sax 
and Moore 1967, Cockburn et al. 1990). None of the other assay components (HCO3-, 
pyruvate, ATP) contributed substantially to the absorbance at 530 nm in the presence of 
FVB, resulting in a large signal to noise ratio for OAA under all assay conditions. The 
absorbance at 530 nm was linear over a wide range of OAA concentrations between 1 ~ 
400 µM, but deviated from linearity at OAA concentrations greater than ~ 400 µM (see 
Figure 3-3B). This deviation from linearity has previously been reported (Sax and Moore 
1967). Because of this deviation, the accuracy of the assay is expected to decrease at 
concentrations of OAA in excess of 400 µM. As such, the assay was designed to maintain 
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an upper limit of OD530 ~1 to maximize the signal window while ensuring accuracy. In 
this range, the assay is both reliable and sensitive in measuring OAA formation as a 
function of PC activity.  
An assay procedure was developed according to the schematic described in Figure 
3-4. Assay conditions were optimized for a 120 µL reaction volume in a 96-well format. 
The assay comprises three overall steps: 1) a PC catalyzed reaction, 2) PC inactivation 
with EDTA, and 3) incubation with FVB. PC was first added to the wells, followed by 
the addition of the small molecule effector before the addition of substrates. The addition 
of the small molecules in this order facilitated the pre-incubation of the enzyme with 
effector molecules to account for potential slow-binding activators or inhibitors 
(Glickman 2004). The reagent volumes at each step were carefully considered in order to 
maximize the amenability of the assay for automated systems and HTS procedures 
(Glickman 2004). The assays were established and optimized primarily using hand-held 
multi-channel pipettes, with the ultimate goal of transitioning these steps over to 
automated liquid dispensing systems. The enzymatic reaction was initiated by the 
addition of a large volume of substrates, to facilitate rapid and complete mixing in each 
well. EDTA was used to inactivate the reaction. EDTA is a metal ion chelating agent that 
sequesters essential Mg2+ ions from the BC domain active site of PC, immediately 
rendering the enzyme inactive (Osmani 1984) (see Figure 3-5). Previous studies have 
also demonstrated that EDTA assists in preventing diazonium salt precipitation (Sax and 
Moore 1967). Following enzyme inactivation, FVB was added and absorbance was 




Figure 3-3. FVB Absorbance Spectrum and OAA Standard Curve 
 
Figure 3-3. Absorbance spectrum and OAA standard curve in the presence of 4 mM 
FVB. A) The background absorbance (yellow) in the assay was measured by the addition 
of the substrates (2.0 mM pyruvate, 1.0 mM ATP and 25 mM HCO3- and assay buffer. 
The absorbance spectra recorded in assay buffer in the presence of 2.0 mM pyruvate, 1.0 
mM ATP and 25 mM HCO3- at varying concentrations of OAA are shown for 0.3 mM 
(pink), 0.6 mM (red) and 1.2 mM (purple) OAA.  B) The absorbance (530 nm) of the 
FVB-OAA adduct responds linearly to OAA concentrations between 1-400 µM (solid 
line, R2=0.99), while the dependence of absorbance on concentration begins to deviate 
from linearity at concentrations greater than 400 µM. This deviation can be approximated 
by a second standard curve between 400 – 800 µM (dashed line, R2=0.96). The error bars 

















Figure 3-4. 96-Well Fixed-Time Assay Procedure 
Figure 3-4. 96-well fixed-time assay procedure. The PC-catalyzed reaction is initiated by 
the addition of substrates (2 mM pyruvate, 1 mM ATP, and 25 mM NaHCO3). After one 
hour, the PC-catalyzed reaction is inactivated by the addition of 12.7 mM EDTA. FVB is 
subsequently added to a final concentration of 4 mM for two hours prior to reading the 
absorbance of the FVB-OAA colored adduct at 530 nm. The procedure for 384-well 
plates is identical except that the volumes for each step are reduced by half, to a final 
volume of 60 µL. This procedure can be performed with manual pipettes or an automated 


















Figure 3-5. Immediate inactivation of the PC catalyzed reaction with EDTA. EDTA 
inactivation was assessed using the malate dehydrogenase coupled enzyme assay (see 
Figure 3-1). EDTA (5mM) was added to a PC reaction with 12 mM pyruvate, 3.0mM 
ATP, 25 mM HCO3- , and 10 units/mL MDH after 350 seconds (PC Reaction + EDTA) 
for a noticeable immediate inactivation of the reaction. A control for the PC reaction was 
determined with the addition of assay buffer at 400 seconds (PC Reaction + AB).  In 
order to determine if the addition of EDTA inactivated malate dehydrogenase (MDH), 
EDTA (5 mM) was added to a MDH reaction with 12 mM pyruvate, 3.0mM ATP, 25 
mM HCO3- , 3 mM OAA and 0.1 units/mL MDH. MDH was added at 200 seconds to 
initiate the reaction, followed by the addition of EDTA at 250 seconds as demonstrated 
by the break in curvature. (MDH Reaction + EDTA). Continuation of the MDH reaction 
past 250 seconds indicated that MDH was not affected by 5 mM EDTA, thus the 




To test the ability of the assay to detect activators and inhibitors of PC, the assay 
procedure was validated by measuring the FVB-OAA colored adduct in the presence of 
acetyl CoA (activator) and oxalate (inhibitor). The background reaction was measured in 
the presence of inactivating EDTA and resulted in similar absorbance values (~0.2 Abs) 
as the inhibited reaction in the presence of 5 mM oxalate. The activated reaction in the 
presence of 0.25 mM acetyl CoA resulted in an increase in absorbance (~1.0-1.2 Abs) 
when compared to the unaltered reaction without any small molecule effectors added 
(~0.5-0.6). These results strongly support that the FVB assay can be simultaneously 
utilized to screen for both activators and inhibitors in a HTS program (see Figure 3-6).  
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Figure 3-6. FVB Assay Optimization  
 
Figure 3-6. FVB assay optimization. The FVB assay can be used to measure both 
inhibition and activation of the PC-catalyzed reaction. A) Visual representation of an 
inhibited, unaltered and activated PC reaction, indicating the corresponding relative 
levels of OAA production and FVB-OAA formation. B) The primary assay method was 
evaluated in the presence of established effectors of PC activity. The “background” signal 
was determined from the reaction of PC in the in the presence of 12.7 mM EDTA. The 
“reaction” signal was determined from the reaction of PC in the absence of any effectors. 
The “activation” signal was determined from the reaction of PC in the presence of the 
activator, acetyl CoA (0.25 mM). The “inhibition” signal was determined from the 
reaction of PC in the presence of the inhibitor, oxalate (5 mM). The error bars represent 
the standard deviation of the signal across eight wells. The differences between the group 




To confirm the reliability of this assay, steady-state kinetic constants were 
determined for Rhizobium etli PC (RePC). RePC was used to optimize the 96-well plate 
assay due to well-established protein purification procedures that afford relatively high 
yields of protein. Additionally, RePC has been extensively structurally and kinetically 
characterized in the presence of both oxalate and acetyl CoA, serving as an ideal model 
system for validation. The KM value for pyruvate (1.5 ± 0.3 mM) and the kcat value (120 ± 
20 min-1) were determined for RePC (see Figure 3-7) and were consistent with previously 
reported values (Zeczycki, Menefee, Jitrapakdee, et al. 2011, Zeczycki et al. 2009). 
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Figure 3-7. FVB Determined Steady State Kinetic Parameters for R. etli PC  
 
 
Figure 3-7. Steady state kinetic parameters for R. etli PC determined using the FVB-
based fixed-time assay. A) Initial velocities for the PC catalyzed reaction measured at 
varying concentrations of pyruvate, 0.47 mM (light blue), 0.95 mM (green), 1.9 mM 
(purple), 2.5 mM (red), 3.4 mM (blue), 4.5 mM (pink) and 6 mM (black). Solid lines 
represent initial velocity and the dashed lines represent the fit to the overall data. B) A 
plot of initial velocities as a function of pyruvate concentration yields a KM value for 
pyruvate of 1.5 ± 0.3 mM and a kcat value of 120 ± 20 min-1. The error bars represent the 
standard deviation of the initial velocities determined in panel A in triplicate. 
 
 
Oxalate (inhibitor) and acetyl CoA (activator) are established small molecule 
effectors of PC. These were used to test the reliability and signal window of the assay as 
a prerequisite for its application in small molecule dose-dependent measurements. The 
IC50 value for oxalate (97 µM) and the EC50 value for acetyl CoA (45 µM) were 
determined for RePC (see Figure 3-8). These values are consistent with published KD and 
KA values, 130µM (Lietzan and St Maurice 2013b) and 10 µM (Adina-Zada, Zeczycki, 
and Attwood 2012) respectively), thus further confirming the reliability of this method. 
Additionally, successful use of the assay in a dose-dependent response manner 
demonstrates the potential of the assay to be utilized as a secondary assay in screening, as 
steep dose-response curves can be informative in eliminating promiscuous aggregators 
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(Shoichet 2006). This will be beneficial to use for elimination of false-positives and to 
further investigate more potent small molecule effectors.   
 
Figure 3-8. Dose Dependent Response with Known Effectors of RePC 
 
 
         
Figure 3-8. Dose dependent response with known effectors of RePC. In all plots, the error 
bars represent the standard deviation of the signal across eight wells. A) Titration of 
acetyl CoA gives an EC50 value for acetyl CoA of 42 µM. B) Titration of oxalate gives an 
IC50 value for oxalate of 95 µM.  
 
 
Assays that are transitioned to HTS need to not only be reliable, accurate and 
sensitive but also robust, reproducible and statistically validated (Zhang, Chung, and 
Oldenburg 1999). To assess the quality of the assay to be transitioned to a HTS platform, 
PC was statistically evaluated in the presence of both acetyl CoA and oxalate. Z-factors 
can be utilized to compare, evaluate and validate the suitability of an assay for HTS. A Z-
factor score of 0.5-1.0 indicates that the assay has a high dynamic range and low 
variation in the signal measurements and is an excellent assay. Z’-factors are used to 
determine the overall quality of the assay without interference from small molecule 
effectors. Alternatively, Z-factors take into account the signal separation and error of the 
assay when used with small molecule activators or inhibitors. In order to determine the 
robustness and quality of the assay, Z-factors and Z’-factors were calculated for RePC, 
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LmPC and SaPC (see Table 3-1). PC enzymes from multiple source organisms were 
selected to determine the suitability of various bacterial PC enzyme for HTS. The 
excellent Z-factors for RePC, LmPC and SaPC demonstrate that this assay is amenable to 
high-throughput screening for both activators and inhibitors of PC enzymes from a range 
of organisms. The results suggest, however, that assay conditions may need to be 
individually optimized for PC enzymes from different species, as demonstrated by the 
increased enzyme concentration (50 µg/mL) required to obtain high Z-factors in the assay  
catalyzed by LmPC.  
 
Table 3-1. Z- Factors Determined for the Assay of Bacterial PC Enzymes 
 
 
In consideration of using this assay in a HTS context, a series of additional 
optimization and validation tests were performed using automatic liquid dispensing 
protocols. These tests included DMSO compatibility, reagent stability and signal 
variability across multiple days for the assay. Most small molecules from screening 
libraries are dissolved in DMSO and are added at fixed concentrations in the screening 
assays. Thus, it was necessary to evaluate the tolerance of PC for DMSO  (Sittampalam 
et al. 2012). PC activity was not affected by the presence of 1% DMSO (see Figure 3-9) 
and our laboratory has commonly observed that PC activity is unaffected by 5% DMSO. 
Additionally, it was beneficial to establish the stability of the reagents and assay signal 













Rhizobium etli 10 0.86 0.85 0.87 Excellent 
Listeria monocytogenes 50 0.70 0.77 0.70 Excellent 
Staphylococcus aureus 10 0.87 0.87 0.87 Excellent 
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screen (Sittampalam et al. 2012). Optimal conditions for reagent stability were tested for 
solutions kept at 22 °C and on ice (see Figure A1). All reagents were stable at 22 °C for 
up to 8 hours, and the final measured absorbance values were stable between 2-5 hours of 
incubation with FVB (see Figure 3-10).  
A series of plate uniformity tests were performed to assess the signal variability of 
the FVB assay across multiple days with various plate templates that evaluate the 
maximum, mid-point and minimum signals of the inhibited and activated PC reaction. 
While Z-factors are used to determine the suitability and robustness of an assay to be 
transitioned to HTS, plate uniformity assessments determine the reproducibility of the 
assay that includes the reproducibility of the Z-factors. Plate uniformity assessments can 
indicate whether or not the signal windows, Z-factors and spatial uniformity of each plate 
will be sufficient to detect potential activators and inhibitors during the screening 
process. A three-day plate uniformity assessment using the interleaved-signal format 
(Sittampalam et al. 2012) was performed in the presence of the inhibitor, oxalate, and 
demonstrated that the signal windows, Z-factors and spatial uniformity met the criteria 
for consistent plate readouts across multiple plates and days (see Figure 3-10A). A two-
day validation test was performed for activation in the presence of acetyl CoA and also 
demonstrated consistent plate readouts across multiple plates and days (see Figure 3-10B) 












Figure 3-9. Pyruvate carboxylase tolerance of 1% DMSO. The background signal (black) 
is the inactivated PC reaction in the presence of 12.7 mM EDTA. The reaction signal 
(grey) is the PC reaction in the absence of added effectors. The activation signal (green) 
is the PC reaction in the presence of the activator, acetyl CoA (0.25 mM). The 
inactivation signal (blue) is the PC reaction in the presence of the inhibitor, oxalate (5 
mM). Pyruvate carboxylase activity, measured using the FVB-based assay, is unaffected 
by the presence of 1% DMSO. The error bars represent the standard deviation of the 























Figure 3-10. Reagent and signal stability for the FVB-based assay. In all plots, the 
background signal (black) represents the inactivated PC reaction in the presence of 12.7 
mM EDTA. The reaction signal (grey) represents the PC reaction in the absence of 
effectors. The activation signal (green) represents the PC reaction in the presence of the 
activator, acetyl CoA (0.25 mM). The inactivation signal (blue) represents the PC 
reaction in the presence of the inhibitor, oxalate (5 mM). The error bars represent the 
standard deviation of the signal across eight wells. A) All reagents used in the FVB-based 
assay are stable under all conditions for up to 8 hours at 22 °C. Time 0 represents the first 
assay that was ran with freshly prepared reagents and the measured absorbance values are 
consistent for all reactions for up to 480 minutes when using the reagents that were 
prepared at time 0. B)  Incubation times between 120 and 300 minutes yield consistent 
absorbance measurements, indicating that the FVB-OAA color adduct is stable for an 
extended time period, permitting the measurement of plates at any time between 2 - 5 


























Figure 3-11. Plate uniformity validation tests for RePC with oxalate and acetyl CoA. 
Both plate uniformity tests reveal consistent signals across all plates and across multiple 
days. Well number 0-96, 97-192 and 193-288 refer to Day 1, Day 2 and Day 3, 
respectively. No edge or drift effects were observed, and all statistical measures are 
acceptable. A) 3-day inhibition plate uniformity assessment with 5 mM oxalate for the 
minimal signal (blue diamonds), 90 µM oxalate for the IC50 signal (pink squares) and the 
uninhibited PC reaction for the maximal signal (green triangles). B) 2-day activation 
plate uniformity assessment with 250 µM acetyl CoA as the maximal signal (green 
triangles), 50 µM acetyl CoA for the EC50 signal (pink squares) and the uninhibited PC 




The FVB assay was used to screen RePC against a LOPAC library to validate the 
responsiveness of the assay to a library of well-characterized bioactive compounds. RePC 
was screened against the LOPAC library on three separate occasions and reproducibly 
identified two inhibitors in all three iterations of the screen (see Figure 3-12D). 
Consistent activation and inhibition signals were obtained for individual plate controls 
across all 16 plates and all plates had excellent Z-factors (see Figure 3-12 A and B). The 
screen identified several compounds that resulted in 70-91% inhibition (see Figure 3-12 
D). The two hit compounds, cisplatin and pyriplatin, were confirmed by dose-dependent 
response assays, yielding IC50 values of 22 µM and 30 µM respectively (see Figure 3-13). 
While the steep dose-response curve for both of these compounds suggests that they are 
likely acting as non-specific alkylating agents (Pujol, Carestia, and Daurès 2000, Porrata 
and Adjei 2001) or promiscuous aggregators (Shoichet 2006), the results from the pilot 
screen nevertheless indicate that the assay can reproducibly and reliably identify an 
appropriate number of potential inhibitor hit compounds. The LOPAC pilot screen did 
not identify any potential activators for RePC, indicating that a larger, more diverse 
library is required to screen for activators (see Figure 3-12 C). All optimization and 
validation results indicate that the assay is reproducible, reliable and sufficiently sensitive 











Figure 3-12. LOPAC (Library of Pharmacologically Active Compounds) Screen 





Figure 3-12. LOPAC (Library of Pharmacologically Active Compounds) screen results 
for inhibitors and activators of Rhizobium etli PC. A) Absorbance signals for individual 
plate controls. The maximal signal is determined in the presence of 250 µM acetyl CoA 
(pink squares), the normal PC reaction is determined in the absence of effectors (purple 
squares) and the inhibited reaction is determined in the presence of 5 mM oxalate (blue 
squares). The error bars represent the standard deviation of the signal across eight wells.  
B) Z-factors fall in a range considered to be excellent (0.6 – 0.8) and are consistent across 
all 16 plates. C) Results of the percent of activation of Screen 1 from the LOPAC screen 
D) Combined inhibition data from three individual LOPAC screens (Screen 1, Screen 2 
and Screen 3). The dashed line represents a threshold of 3× the standard deviation for the 
combined data, equivalent to 45% inhibition. Two compounds consistently exceeded this 










Figure 3-13. Dose dependent response for the two inhibitors, cisplatin and pyriplatin, 
identified in the LOPAC screen. The error bars represent the standard deviation of the 
signal across eight wells. A) Dose-dependent response for the inhibition of R. etli PC in 
the presence of cisplatin results in an IC50 value of 22 µM. B) Dose-dependent response 
for the inhibition of R. etli PC in the presence of pyriplatin results in an IC50 value of 30 
µM. C) Chemical structures of the hit compounds and the percent of inhibition measured 
in each of the three independent screens. 
 
 
3.3.2 Screening of Compound Libraries 
 
  
A small molecule library consisting of ~10,000 compounds was available to 
screen against RePC at the Milwaukee Institute for Drug Discovery at the UWM. The 
screen consisted of unique compounds synthesized at UWM and compounds from the 
LOPAC, Microsource Discovery and Prestwick library collection. While the library 
contained unique compounds, it also had built in redundancy from the LOPAC screen to 
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cross validate the performance of the assay with multiple libraries. Due to the large 
number of compounds in the library, a 96-well plate screening format would have 
required an unwieldy ~125 plates. To reduce the resource demands associated with 
screening larger compound libraries, the 96-well plate format was transitioned to a 384-
well plate format, optimized and validated for RePC (see Table A1 and Figures A2-A4). 
The validated 384-well plate FVB assay was used to screen the small molecule library at 
UWM against RePC (see Figure A5). Z-factor scores were excellent across all plates and 
the individual plate controls had consistent absorbance values. Despite the larger number 
of compounds in the library, the screen did not reveal any hits for RePC activation (see 
Figure A5).  The screen did however, result in two potential inhibitors (see Figure A6). 
Based on the previous hit rate from the LOPAC screen (~1 hit/500 compounds), it was 
notable that this larger screen resulted in a much lower hit rate (~1 hit/5,000 compounds). 
Since it had previously been established that the FVB assay could be utilized with 
other PC enzymes such as SaPC and LmPC (see Table 3-1), the screen performed at 
UWM was transitioned to screen against LmPC with the goal of establishing a higher 
compound hit rate. Additionally, it had become evident from the SBDD project that many 
compounds displayed higher potency against SaPC or LmPC than against RePC 
(described in Chapter 4). The screen performed at UWM did reveal more potential hits 
for inhibitors of LmPC (~3 hits/1,000 compounds) than of RePC (see Figure A6). The 
screen was not applied to the detection of potential activators, based on the absence of 
any observed activators in the screening results against RePC. Unfortunately, the hits 
could not be confirmed in secondary assays because the compounds were not made 
available for follow up studies. Synthesizing these potential hit compounds would have 
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required a major investment of resources and the compounds themselves were no longer 
stored by the laboratory that performed the initial synthesis (Frankowski et al. 2011). 
Nevertheless, these efforts to screen a modest-sized ~10 000 compound library 
demonstrated that the assay itself is highly suitable as a primary screen in a high 
throughput setting. An overview of the screening process is diagrammed in Figure 3-14.  
 
Figure 3-14. Screening Process for Pyruvate Carboxylase Small Molecule Effectors 
 
Figure 3-14. Screening process for pyruvate carboxylase small molecule effectors.  
 
 
 A small library of mechanistic, oncology, natural product and diversity sets (total 
of 2,954 compounds) were obtained through the National Cancer Institute Developmental 
Therapeutics Program (NCI DTP) (http://dtp.cancer.gov). The NCI DTP compounds 
were screened for inhibitors of SaPC (see Figure 3-15A). The activity of SaPC enabled 
an increased signal to noise ratio in the FVB assay when compared to LmPC, requiring 
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less enzyme for screening (10 µg/mL for SaPC versus 50 µg/mL for LmPC). As 
previously discussed, compounds from the displayed higher potency against SaPC or 
LmPC than against RePC (described in Chapter 4), thus SaPC was the most appropriate 
target for the NCI DTP screen.  Approximately 20 hit compounds were identified (greater 
than 80% inhibition) from the mechanistic, oncology, natural product and diversity sets. 
A total of 15 hit compounds were obtained from the NCI DTP for follow up studies. 
These 15 compounds were selected based on their a-keto acid functional group as related 
to the rational drug design project described in Chapter 4 or based on chemical features 
that were common to multiple hit compounds. For example, in Figure 3-15C, Compounds 
70 and 71 display this similar scaffold that is highlighted in teal. While a majority of the 
hit compounds came from the mechanistic and diversity set, two hit compounds were 
identified from the oncology set: cisplatin and oxaliplatin. Cisplatin was also 
reproducibly identified as a PC inhibitor in the LOPAC screens against RePC (see Figure 
3-13A), lending further confidence to the reliability of this assay in identifying genuine 
PC inhibitors. While cisplatin is not a promising lead compound for further studies due to 
its promiscuity (Lee et al. 2017), it served as additional validation that the FVB assay can 
consistently detect valid inhibitors across multiple screens.  
From the dose-dependent response of the 15 selected hit compounds, 7 were 
identified as having IC50 values < 10 µM, indicating the potential of the inhibitors to be 
used as first-generation small molecule inhibitors of PC (see Figure 3-15). Of the 7 potent 
compounds, five were identified from the mechanistic set (compounds 60, 61, 69, 70 and 
71) and two were identified from the diversity set (compounds 65 and 66). However, 
subsequent analysis of the NCI DTP compounds through mass spectrometry and nuclear 
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magnetic resonance (NMR) demonstrated that all of the hit compounds were impure 
(work done in collaboration with the Chemistry Department at Marquette University) and 
were therefore unreliable hit compounds to continue to pursue. While it may have seemed 
promising that the hit compounds all had IC50 values < 10 µM and decent IC50 curves, it 
was difficult to determine what component of the compounds were causing inhibition due 
to the compound impurity. The compounds from NCI DTP are sourced as an open 
chemical repository, meaning the compounds have been donated from various academic 
and industrial sources. The NCI DTP cannot guarantee the quality of the compounds as 
they have not been reanalyzed by the NCI DTP for the purity or accuracy of the 
compound structure. Despite the inability to pursue reliable screening results, a 
recommended process for screening large libraries and hit compound follow up are 
described in Chapter 5 and could lead to a successful future direction in a HTS discovery 











Figure 3-15. NCI DTP screen against SaPC. A) Screening data for inhibition of the NCI 
DTP compound library. The dashed line represents 2×	standard deviation of all the data. 
Hit compounds were identified as resulting in inhibition greater than 2´ the standard 
deviation, which corresponds to greater than 80% inhibition. The hit threshold limit is 
usually expressed as 3× the standard deviation away from the mean of all the data. 
However, this was lowered to 2× so that there were a number of reasonable hits that 
could be followed up on in the secondary assays. B) Dose dependent response of the 7 
NCI DTP confirmed hit compounds. Compound 60 (black), Compound 61 (grey), 
Compound 65 (periwinkle), Compound 66 (pink), Compound 69 (blue), Compound 70 
(red), and Compound 71 (green). The error bars represent the standard deviation of the 
signal across eight wells. C) Chemical structures of the compounds and the 
corresponding IC50 values. Compounds containing the a-keto functional group are 
highlighted in red (Compounds 61, 65 and 66) while compounds selected based on their 




3.4 Discussion  
 
 
 A novel, fixed time assay for PC has been developed that is reliable, sensitive and 
robust. The assay monitors the production of OAA through the formation of a colored 
adduct between OAA and the commercially available diazonium salt of FVB.  This offers 
a simple assay to detect PC activity through monitoring the increase in absorbance at 530 
nm. The assay can be utilized as an alternative method to coupled-enzyme assays to 
detect PC activity. Additionally, the assay can readily be transitioned to a multi-well plate 
format where the reagent stability, accuracy and reproducibility is ideal for use in high-
throughput screening of small molecule libraries for both activators and inhibitors of PC 
activity. 
While diazonium salts have previously been used to detect the production of 
OAA, they have not specifically been applied to assay PC activity. Diazonium salts such 
as Fast Red KL, Fast Ponceau L and Fast Violet B have been used to detect OAA 
production from aspartate transaminase (Lombarts and Peters 1971, Babson et al. 1962b, 
Amador and Salvatore 1971, Sax and Moore 1967). Fast Violet B, in particular, has also 
been utilized to assess phosphoenolpyruvate carboxylase activity and has previously been 
optimized in a microtiter plate assay (Norris, Atkinson, and Smith 1975, Cockburn et al. 
1990). Fast Violet B was selected as the optimal diazonium salt to assay PC activity 
based the stability of the FVB-OAA color adduct, the low signal to noise ratio of OAA 
with pyruvate, and the amenability of FVB to be transitioned to a 96-well plate format. 
The choice of Fast Violet B over other diazonium salts in this assay is based on several 
unique features. Fast Violet B has been demonstrated to be stable over an optimal pH 
range for PC activity with the addition of either EDTA or detergent (pH 7.0-7.5) 
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(Cockburn et al. 1990, Babson et al. 1962b, Lombarts and Peters 1971, Scrutton, 
Olmsted, and Utter 1969). Alternatively, Fast Red KL and Fast Ponceau L were most 
stable over a pH range of 4.2- 4.6 (Lombarts and Peters 1971, Sax and Moore 1967, 
Babson et al. 1962b, Amador and Salvatore 1971). While acidic Fast Red KL or Fast 
Ponceau L could potentially be added in the current protocol following PC inactivation, 
the acidic conditions would have the potential to promote PC precipitation and 
aggregation which could obscure the signal to noise window of the assay (Scrutton, 
Olmsted, and Utter 1969). Additionally, previous studies demonstrated that Fast Violet B 
had a broad absorption peak between 490-540 nm compared to the narrower absorption 
peaks of Fast Red KL and Fast Ponceau L (455-467 nm respectively)(Sax and Moore 
1967, Lombarts and Peters 1971). As previously described, many assay components 
absorb at lower wavelengths. Thus, selecting a diazonium salt with a higher wavelength 
serves to maximize the signal to noise ratio of the assay. Lastly, FVB has previously been 
used in a microtiter plate-based assay for phosponenolpyruvate carboxylase, indicating 
that it is amenable to the smaller reaction volumes typical of a high throughput screening 
assay.  
The FVB-based assay is capable of accurately measuring steady state kinetics in 
PC, consistent with a study by Amador and Salvatore (1971) that compared the activity 
of aspartate aminotransferase measured by FVB and Fast Ponceau L to the rates 
determined by a MDH coupled-enzyme assay.  Thus, the FVB fixed-time assay is not 
only an ideal primary assay to use in a HTS program, but it can also be employed as an 
alternative to the coupled-enzyme assay typically used for standard kinetic measurements 
of PC activity. In instances where assay conditions interfere with the coupled-enzyme, 
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the FVB assay is an ideal alternative assay to measure PC activity. A prime example is 
when small molecule effectors also inhibit/activate MDH or LDH, precluding accurate 
initial velocity determinations in PC. Oxalate, for example, inhibits both PC and the 
coupling enzyme, LDH (Novoa et al. 1959). Several additional a-keto acids are inhibitors 
of PC (Lietzan and St Maurice 2013b) and serve as a promising scaffold for rational drug 
design, as described in Chapter 4. However,  MDH and LDH have been shown to reduce 
aromatic a-keto acids (Friedrich et al. 1987). These examples highlight the importance of 
developing additional enzyme assays that are free of secondary coupling enzymes that 
might otherwise be subject to cross-reactivity.  
While it has many advantages, the FVB assay also has several limitations that 
must be carefully considered. It has previously been demonstrated that FVB also forms a 
color adduct with a-ketoglutarate (Sax and Moore 1967) and occasionally produced false 
positives due to ketosis in serums (Amador and Salvatore 1971). Therefore, FVB has the 
potential for cross-reactivity with nucleophilic compounds. Additionally, FVB reacts 
with high concentrations (> 250 µM) of acetyl CoA and CoA, resulting in a decrease in 
absorbance of the FVB-OAA color adduct (see Figure A8). Thus, small molecule 
activators may be difficult to identify if their interference with FVB-OAA colored adduct 
formation offsets their enhancement of PC activity. This may be one reason why PC 
activators were not observed in the LOPAC screen. It is also likely, however, that it is 
simply more difficult to find activators of PC as allosteric ligands are generally more 
difficult to detect in HTS (Alt 2016). Allosteric activators, like acetyl Co-A, have very 
specific interactions for PC (Adina-Zada, Zeczycki, and Attwood 2012, Zeczycki, 
Menefee, Jitrapakdee, et al. 2011), meaning that even the slightest modification to acetyl 
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CoA can cause a complete change in the degree of activation. For example, RePC was 
activated 6-fold by acetyl CoA while it was only activated 2-fold by CoA (see Table A3). 
If allosteric activators are not specific for PC in the screening process, they may exhibit a 
small to negligible change in the assay signal.  
Lastly, consideration should be given to determining the appropriate 
concentration of substrates to be used in the FVB assay when it is being applied either to 
kinetic measures or being used as a HTS primary screen. Here, the assay has been 
performed at 2 mM pyruvate, which is less than the saturating concentrations of 5 – 20 
mM pyruvate, depending on the source of the PC enzyme. This sub-saturating 
concentration of pyruvate maximizes the signal to noise ratio of the assay for RePC but, 
notably, has not been optimized for LmPC or SaPC. The concentration of the substrates in 
an assay can impact the number and type of inhibitors that are identified in a screening 
process (Acker and Auld 2014, Yang, Copeland, and Lai 2009). In particular, the assay 
substrate concentrations should be considered in relationship to their KM values, as this 
will influence the type of inhibitors that are identified. For example, a competitive 
inhibitor is mutually exclusive with the substrate. Alternatively, uncompetitive inhibitors 
bind only after the substrate binds to enzyme. At saturating substrate concentrations, 
there is a higher substrate occupancy in the active site, increasing the likelihood of 
finding uncompetitive inhibitors and decreasing the likelihood of finding competitive 
inhibitors. It was determined by Yang et al. that performing inhibitor screens at substrate 
concentrations near to the KM value is ideal to optimize the identification of competitive, 
non-competitive and uncompetitive inhibitors (Yang, Copeland, and Lai 2009). This 
could explain in part why there was a higher percentage of inhibitor hits from the screen 
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against SaPC compared to RePC or LmPC. The SaPC KM value for pyruvate is 2 mM, 
equal to the substrate concentration that was used in the FVB assay. The SaPC screen 
may, therefore, have detected a wider range of inhibitors on account of the pyruvate 
concentration matching the KM value for SaPC. The pyruvate KM value for LmPC and 
RePC is 0.68 mM and 0.75 mM, respectively (see Table A2). In screens directed against 
these enzymes, the 2 mM pyruvate concentrations were higher than the pyruvate KM 
values for RePC and LmPC. It is possible, therefore, that those screens were biased 
toward uncompetitive inhibitors at the exclusion of a wider range of inhibitor types, such 
as competitive inhibitors.  
The increased number of hit compounds from the NCI DTP screen may be a 
result of the low quality of compounds in the screen. A large number of hit compounds 
from the NCI DTP screen were determined to be impure. Compound degradation or 
uncertainty may be a more prominent feature of the NCI DTP library for reasons 
previously described, resulting in a higher degree of non-specific inhibition. Ultimately, it 
is difficult to draw direct comparisons on the hit rate between three separate screens that 
used RePC (UWM), LmPC (UWM) and SaPC (NCI DTP), given that different screens 
and enzymes were used. Interestingly, while RePC and LmPC have similar KM values for 
pyruvate, they had quite different hit rates despite being screened against the same 
library. This suggests that individual PC enzymes may have varying susceptibilities to 
small molecule inhibition. This issue is investigated further in Chapter 4. Regardless, 
prior to embarking on any future screening projects it will be important to consider the 
substrate concentrations, the KM values of the substrates, the type of inhibitors that are 
desired and the source of the enzyme. 
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In conclusion, a novel-fixed time assay to detect PC activity has been established. 
This assay can be used to screen for small molecule effectors of PC or as an alternative 
method to measure steady state enzyme kinetics. The development and validation of this 
assay has enabled a HTS procedure and is extensively used to assess inhibitors in the 
rational drug design project described in Chapter 4. The small molecules that are 
discovered and developed through these projects can be used as valuable biochemical 
tools to further investigate the regulation, structure and the role PC plays in certain types 

















CHAPTER 4: A STRUCTURE-BASED DRUG DESIGN APPROACH TO 






PC is an important anaplerotic enzyme that catalyzes the conversion of pyruvate 
to OAA in a wide range of organisms (Jitrapakdee et al. 2008). Studies have linked PC 
activity to a number of diseases and infections including certain types of cancer, type 2 
diabetes, and listeriosis that are sustained as a result of aberrant or essential PC 
expression in cells (Schar et al. 2010, Kumashiro et al. 2013, Cheng et al. 2011). PC has 
been implicated in these diseases as a result of studies using genetic tools such as 
knockouts, antisense oligonucleotides, and siRNAs that target the PC gene (Schar et al. 
2010, Cheng et al. 2011, Hasan et al. 2008, Kumashiro et al. 2013). While genetic 
manipulations of PC have validated it as a target for the treatment of these diseases and 
infections, genetic tools alone are unable to identify the precise mechanistic role that PC 
plays in vivo. 
 PC is a protein scaffold for a number of metabolic enzymes (Fahien, Davis, and 
Laboy 1993), has a moonlighting function that is important in the assembly of the 
peroxisomal enzyme, alcohol oxidase (Huberts et al. 2010), interacts with proteins 
important in the mitochondrial antiviral signaling pathway (Cao et al. 2016), and binds to 
the pleiotropic protein, prohibitin (Vessal et al. 2006). Thus, a reduction in PC expression 
levels is likely to impact multiple cellular systems. It is, therefore, difficult to clearly 
establish whether the phenotypes observed in response to genetic manipulation of PC are 
a result of changes in PC catalytic activity or of changes in peripheral metabolic and/or 
 63 
cell signaling pathways. Additionally, genetic tools can only be utilized in vivo and 
cannot be applied to study the structure or regulation of PC in vitro.  
The development of specific and potent small molecule effectors of PC has the 
potential to expand the limited range of chemical probes currently available to study PC 
both in vitro and in vivo. Small molecules have the advantage of altering specific 
catalytic functions of PC without reducing/eliminating the gene product from the cellular 
system, thus precluding unintentional effects on other metabolic and signaling enzymes 
in the cell. To date, attempts to use small molecule effectors to study PC directly in 
cellular studies have made use of non-specific inhibitors of PC expression/activity, all of 
which have the potential to interact with other metabolic enzymes (Choi et al. 2017, 
Sureka et al. 2014, Whiteley et al. 2017, Ferrandina et al. 1997, Farfari et al. 2000, 
Flamez et al. 2002, Wilmanski et al. 2017).  
Phenylacetate, in particular, has been applied in studies of insulin release and a 
substantial amount (>5mM) is needed to partially inhibit PC and decrease insulin 
secretion (Farfari et al. 2000, Lu et al. 2002). At these concentrations, it is anticipated that 
many cellular systems will be affected by the addition of phenylacetate (Harrison et al. 
1998, Di Benedetto et al. 2001), such as the induction of cell cycle arrest (Park et al. 
2004) and inhibition of nitric oxide synthase (Pahan et al. 1997). Other compounds such 
as 1α,25-dihydroxyvitamin D, downregulate PC expression in oncogene transfected 
breast epithelial cells (Wilmanski et al. 2017), but it is unknown if the compound directly 
affects PC activity. In certain bacteria like L. monocytogenes and L. lactis, cyclic-di-AMP 
is an allosteric regulator that decreases PC activity with a KD value of 8 µM (Sureka et al. 
2014), making it one of the most potent inhibitors of PC to be documented. However, 
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even with a relatively potent compound like c-di-AMP that has been used both in vivo 
and in vitro, it is difficult to conclude on the direct and specific role PC plays in bacterial 
metabolism as it bind to a broad range of proteins (Commichau et al. 2015).  
Like most metabolic studies, a single methodology to study PC both in vivo and in 
vitro is insufficient to definitively characterize the role PC plays not only in L. 
monocytogenes, but in other systems as well. This highlights the value of expanding the 
biochemical toolkit to study PC both in and outside the cellular context. The method we 
have taken to expand the ways in which to study PC is through the development of potent 
and specific small molecule effectors of PC activity. Since the HTS approach is still 
being developed, a SBDD approach that specifically targeted the unique CT domain of 
PC has been implemented. The BC domain is conserved across biotin-dependent 
enzymes, while the CT domain structures of biotin-dependent enzymes are unique for the 
various substrates that are utilized throughout the enzyme family (Tong 2013). By 
targeting the CT domain of PC rather than the BC domain, small molecules effectors of 
PC are more likely to be specific for PC and limited in their interactions with other 
biotin-dependent enzymes. 
To initiate a SBDD project, structures of pyruvate, 3-bromopyruvate (3BP), 
oxalate and 3-hydroxypyruvate (3HP) bound in the CT domain of RePCDBCDBCCP 
(Lietzan and St Maurice 2013b) (see Figure 4-1), were applied to discover novel 
inhibitors of PC. Oxalate, oxamate 3HP and 3BP are a-keto acids that are all bound in 
the active site in an orientation similar to that of pyruvate (see Section 1.2 for a review of 
pyruvate binding in the CT domain) (Lietzan and St Maurice 2013a, Lietzan, Lin, and St 
Maurice 2014) . Oxalate is a noncompetitive inhibitor with respect to pyruvate with a Ki 
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value of 70 µM for yeast PC (Ruiz-Amil et al. 1965), 50-130 µM for rat liver PC 
(McClure et al. 1971) and 12 µM for chicken liver PC (Scrutton, Olmsted, and Utter 
1969).  3HP is a noncompetitive inhibitor with respect to pyruvate with a Ki value of 5.4 
mM for Thiobacillus novellus PC (Charles, Willer, and Schafer 1984). To the best of our 
knowledge, 3BP has never been kinetically characterized as an inhibitor of PC. While the 
structure of 3BP bound in the CT domain of PC suggests it is likely to be a competitive or 
noncompetitive/mixed type inhibitor, prior studies did not kinetically determine 
inhibition of 3BP with PC (Lietzan and St Maurice 2013b).  
Based on the specific interactions of the a-keto acids with the catalytic amino 
acids in the CT domain, it was hypothesized that a-keto acids discovered through the 
SBDD project would be specific competitive or noncompetitive/mixed type inhibitors for 
the unique CT domain of PC. Reversible small molecule inhibitors can either be 
competitive, uncompetitive, noncompetitive or mixed type (Ring, Wrighton, and 
Mohutsky 2014). Competitive inhibitors can only bind to the enzyme and prevent the 
binding of a substrate while uncompetitive inhibitors can only bind to the enzyme-
substrate complex and prevent product formation/release. Alternatively, noncompetitive 
inhibitors can bind to both the enzyme and enzyme-substrate complex with equal affinity 










Figure 4-1. Structures of a- Keto Acid Substrates and Inhibitors of PC 
 
Figure 4-1. Structures of a- Keto Acid Substrates and Inhibitors of PC. Pyruvate (green; 
pdb i.d. 3bg5-SaPC) (orange; pdb i.d. 4jx5-RePC), oxalate (pink; pdb i.d. 4mfd-RePC), 3-
bromopyruvate (teal; pdb i.d. 4mim-RePC) and 3-hydroxypyruvate (yellow; pdb i.d. 
4mfe-RePC) have previously been structurally characterized in the CT domain of RePC 
and SaPC. The metal ion is either Zn2+ or Mn2+, depending on the organism. PC from 
bacteria and yeast predominantly utilize Zn2+, while PC from vertebrates prefer Mn2+ 



















Figure 4-2. Possible Modes of Inhibition of a Small Molecule with Respect to 
Pyruvate in PC 
 
Figure 4-2. Possible modes of inhibition of a small molecule with respect to pyruvate in 
PC. There four modes of inhibition that are possible for an inhibitor of PC with respect to 
pyruvate. Small molecule inhibitors can either be competitive, uncompetitive, 
noncompetitive or mixed type. The Lineweaver-Burk plots shown are an example of the 
double-reciprocal plots of the enzyme kinetics that demonstrate the four distinct patterns 












Over 200 compounds have been found, developed and screened for PC inhibition 
through SBDD. The FVB assay was the primary assay utilized for the initial screening of 
the compounds. If the compounds inhibited PC in the primary assay, they were 
transitioned to the secondary assays that included the MDH and LDH assay. Compounds 
that were the most potent were kinetically and structurally characterized (see Figure 4-3 
for the screening process overview). Using SBDD, we have discovered and developed 
several promising first generation small molecule inhibitors of PC. 
 




Figure 4-3. PC assays and rational drug design screening overview. A) The FVB assay 
served as the initial primary assay to detect inhibitors of PC and was thoroughly 
described in Chapter 3. The secondary coupled enzyme assays were used to assay 
specific PC domain activity. The MDH assay measures pyruvate carboxylation while the 
LDH assay measures OAA decarboxylation in the CT domain. B) Diagram of the 
screening flow process. The inhibition of metalloenzymes in the screening flow will be 









4.2.1 Collaborations and Contributions 
 
 
Many of the compounds described in this chapter were synthesized by the 
Donaldson and Dockendorff laboratories in the Marquette University Chemistry 
Department. Compounds 1-85, oxalate, 3-bromopyruvate and 3-hydroxypyruvate were 
ordered either through the NCI DTP or Sigma-Aldrich. Compounds numbered 86 and 
greater were synthesized in the Dockendorff and Donaldson laboratories. The synthetic 
efforts were led by graduate students Daniel Burkett and Ricardo Rosas, and included 
several undergraduate students, most notably Anson Bautista and Ryan Engel.  An online 
Excel spreadsheet is maintained by the St. Maurice and Donaldson labs to track the 
original of the compounds, the identity of the synthetic chemist, and the inhibition results, 
can be located through the ME(D)3 group sharepoint site. Mallory Mews (MM), working 
under my mentorship and supervision, contributed to the determination of many of the 
IC50 values described in this chapter. In all cases, these contributions are clearly noted in 
the relevant tables and figures. As it will be indicated (*) refers to the IC50 values that 
were solely collected by MM, whereas, (**) refers to compounds that had been originally 
screened by the author of this dissertation, Brittney Wyatt (BW) and followed up on by 
MM.    
 4.2.2 Screening compounds for inhibition using the primary FVB assay  
 
 
The FVB assay in the 384-well plate format was utilized as the primary assay to 
screen for small molecule inhibitors of PC. The 384-well plate procedure has been 
described thoroughly in Chapter 3. To determine whether the compounds interfered with 
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formation of the FVB-OAA colored adduct itself, the procedure was slightly modified. 
Instead of the addition of 15 µL enzyme, 15 µL of OAA was added to a final 
concentration of 200 µM in the assay. This functioned to assess the possible interference 
of the compounds with forming an FVB-OAA colored adduct at 530 nm. All other steps 
were identical to the previously described FVB assay protocol.  
 
 4.2.3 Pyruvate Carboxylation MDH Assay 
  
 
 The carboxylation of pyruvate in full-length PC (SaPC, LmPC and RePC) was 
measured by coupling the formation of OAA to the reaction catalyzed by MDH, which 
converts OAA to malate and oxidizes NADH to NAD+ (see Figure 3-1). This can be 
readily observed by measuring the change in absorbance of NADH at 340 nm. All MDH 
assays were performed at 22 °C in 96-well plate format for a total reaction volume of 200 
µL. Assay conditions consisted of 100 mM Tris (pH 7.8), 7 mM MgCl2, 150 mM KCl 
and 0.005% Triton x-100. The procedure for the 96-well plate MDH assay was as 
follows: 1) addition of 20 µL PC to a final concentration of 10 µg/mL-30 µg/mL 
depending on PC activity, 2) addition of 20 µL of compound to varying final 
concentrations, 3) addition of 20 µL of MDH to a final concentration of 20 U/mL, and 
lastly 4) addition of 140 µL of substrates to initiate the reaction (pyruvate, HCO3-, ATP 
and NADH to a final concentration of 12 mM, 25 mM, 2.5 mM and 0.25 mM 
respectively). For Ki determinations, the procedure was slightly modified as follows: 1) 
addition of 20 µL SaPC to a final concentration of 10 µg/mL, 2) addition of 20 µL of 
compound to varying final concentrations, 3) addition of 20 µL of MDH to a final 
concentration of 20 U/mL, 4) addition of 20 µL of pyruvate to varying final 
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concentrations and 5) addition of 120 µL of substrates to initiate the reaction (HCO3-, 
ATP and NADH to a final concentration of 25 mM, 2.5 mM and 0.25 mM respectively). 
To account for possible compound inhibition of MDH, the procedure was modified as 
follows: 1) addition of 20 µL OAA to a final concentration of 30 mM, 2) addition of 20 
µL of compound to varying final concentrations, 3) addition of 20 µL of MDH to a final 
concentration of 0.275-0.25 U/mL, and 4) addition of 140 µL of substrates to initiate the 
reaction (pyruvate, HCO3-, ATP and NADH to a final concentration of 12 mM, 25 mM, 
2.5 mM and 0.25 mM respectively). Reagents were dispensed manually by a hand-held, 
multi-channel micropipette and absorbance measurements were recorded at 340 nm with 
a Multiskan Ascent spectrophotometer (Thermo). Initial velocity rates were analyzed 
using an Excel template, further described in the 4.2.6 Data Analysis section.  
 




 The CT domain specific decarboxylation of OAA in in full-length (SaPC) and 
truncated (SaPCDBCDBCCP) PC was measured by coupling the formation of pyruvate to 
the reaction catalyzed by LDH, which reduces pyruvate to lactate and oxidizes NADH to 
NAD+. This can be readily observed by measuring the change in absorbance of NADH at 
340 nm. All LDH assays were performed at 22 °C in 96-well plate format for a total 
reaction volume of 200 µL. Assay conditions consisted of 100 mM Tris (pH 7.8) and 
0.005% Triton x-100. The procedure for the 96-well plate LDH assay was as follows: 1) 
addition of 20 µL PC to a final concentration of 100 µg/mL-200 µg/mL depending on PC 
activity, 2) addition of 20 µL of compound to varying final concentrations, 3) addition of 
20 µL of LDH to a final concentration of 10 U/mL, and lastly 4) addition of 140 µL of 
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substrates that included oxamate, OAA and NADH to a final concentration of 0.5 mM, 
0.2 mM and 0.25 mM, respectively. To account for possible compound inhibition of 
LDH or compound reduction by LDH, the procedure was modified as follows: 1) 
addition of 20 µL pyruvate to a final concentration of 50 mM, 2) addition of 20 µL of 
compound to varying final concentrations, 3) addition of 20 µL of LDH to a final 
concentration of 0.05-0.1 U/mL, and 4) addition of 140 µL of NADH to a final 
concentration of 0.25 mM. Reagents were dispensed manually by a hand-held, multi-
channel micropipette and absorbance measurements were recorded at 340 nm with a 
Multiskan Ascent spectrophotometer (Thermo). Initial velocity rates were analyzed using 
an Excel template, further described in the 4.2.8 Data Analysis section. 
 




To create SaPC variants that could be applied in both the LDH assay and 
crystallization studies, a PCR cloning approach was taken to remove the BC domain 
(SaPCDBC) and BC/BCCP domain (SaPCDBCDBCCP). All amino acids are labeled 
according to a T-Coffee alignment (Notredame, Higgins, and Heringa 2000) of the SaPC 
sequence compared to the sequences of other PC enzymes from various organisms. For 
the BC domain truncation (SaPCDBC), it was determined that Ile458 represented the C-
terminal end of the BC domain based on the X-ray crystal structure of SaPC (pdb i.d. = 
3bg5). The SaPCDBC construct therefore begins at Gln459 and this construct contains the 
allosteric domain, the CT domain and the BCCP domain. The gene encoding SaPCDBC 
was cloned into the pET-28a-(His)8-TEV expression vector as follows: a ~2.3 kbp 
fragment was PCR amplified from the wild-type SaPC pET-28a-(His)8-TEV template 
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using the primers 5’- CGCTGCAGCAGCCGTCTCTAGAT -3’ (forward; PstI restriction 
enzyme) and 5’- GCGCTCGAGTCAGTCAGTTGCTTT-3’ (reverse; XhoI restriction 
enzyme). Primers were synthesized by Integrated DNA Technologies (Coralville, IA). 
The PCR amplified fragment and a pET-28a-(His)8-TEV expression vector were digested 
with PstI / XhoI restriction enzymes and digested samples were gel purified. Samples 
were ligated, and clones with the expected insertion were selected by colony PCR.  
The SaPCDBCDBCCP construct was generated by the same procedure with 
several modifications. Since the BC domain truncation was identical to SaPCDBC, the 
SaPCDBCDBCCP construct began at Gln459 as well. To account for the BCCP removal, it 
was determined that Asn1061 represented the C-terminal end of the allosteric domain. The 
construct therefore ended at Asn1061 and a stop codon, TGA, was incorporated at residue 
1062 in the primer design. This construct contains the CT domain and the allosteric 
domain. The gene encoding SaPCDBCDBCCP was cloned into the pET-28a-(His)8-TEV 
expression vector as follows: a ~1.8 kbp fragment was PCR amplified from the wild-type 
SaPC pET-28a-(His)8-TEV template using the primers 5’- 
CGCTGCAGCAGCCGTCTCTAGAT -3’ (forward; PstI restriction enzyme) and 5’- 
GCGCCTCGAGTCAATTTTCATCTTT -3’. (reverse; XhoI restriction enzyme). Primers 
were synthesized by Integrated DNA Technologies (Coralville, IA). The PCR amplified 
fragment and a pET-28a-(His)8-TEV expression vector were digested with PstI / XhoI 
restriction enzymes and digested samples were gel purified. Samples were ligated, and 
clones with the expected insertion were selected by colony PCR. All clones were verified 
by sequencing of the complete gene by Functional Biosciences Inc.  
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4.2.6 X-ray crystallography of SaPCDBC with Compound 98 and 17 
 
 
SaPCDBC was crystallized in the apo form as well as co-crystallized with 
Compound 17. The crystallization conditions for the apo crystals were as follows: 22% 
MePEG 2K, 84 mM MgSO4 and 250 mM ammonium tartrate. The crystallization 
conditions for co-crystallization with Compound 17 were as follows: 26% MePEG 2K, 
84 mM MgSO4 and 250 mM ammonium tartrate. For co-crystallization, Compound 17 
was dissolved in 10 mM Tris (pH 7.8), 150 mM KCl, 3 mM MgCl2, 5% (v/v) glycerol 
and diluted into a 17.7 mg/mL SaPCDBC protein solution to a final concentration of 10 
mM. Crystals were grown by adding 4 µL of crystallization solution to 4 µL of protein 
solution that were situated either on siliconized glass cover slips for hanging drop vapor 
diffusion or on pedestals for sitting drop vapor diffusion. The well volume of each plate 
for all crystallization conditions was 250 µL. Diffusion chambers were sealed using 
vacuum grease. Rectangular crystals grew to full size (~270 µm × 100 µm  × 60 µm) 
after two weeks. The apo crystals were transferred to cryo conditions that contained 
18.2% MePEG 2K, 58.8 MgSO4, 175 mM ammonium tartrate, 5% ethylene glycol and 2-
15 mM of Compound 98. Apo crystals were soaked for 24 hours before being transferred 
to the cryo condition substituted with 20% ethylene glycol and flash cooled in liquid 
nitrogen for data collection. Crystals co-crystallized with Compound 17 were transferred 
to the cryo condition with 20% ethylene glycol and 10 mM of Compound 17 before being 
flash cooled in liquid nitrogen. X-ray diffraction data were collected at the Advanced 
Photon Source (APS, Argonne, IL) beamline LS-CAT (Life Science Collaborative 
Access Team) 21-ID-F on a Mosaic 300 CCD detector at wavelength 0.97872 Å.  
Diffraction images were processed using HKL2000 (Otwinowski and Minor 1997). The 
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structures were determined by molecular replacement using SaPC (pdb 3bg5) as the 
search model with Phaser (McCoy et al. 2007). Following molecular replacement, a 
single round of refinement was performed with REFMAC (Vagin et al. 2004) followed 
by manual model building with COOT (Emsley and Cowtan 2004).  
 
 4.2.7 Computational Docking 
 
 A computational docking study was performed to assess the predicted CT domain 
binding location and relative affinity of the most potent small molecule inhibitors (IC50 
values < 30 µM). As there are two conformational states of the CT domain that have been 
crystallized, the docking study was designed to consider both the open and closed 
conformation of the CT domain. To assess the predicted binding of the compounds in the 
CT domain of SaPC in the closed conformation, the pdb file of SaPC (3bg5) with 
pyruvate was modified. The pdb file was trimmed to include only Chain C of the CT 
domain (residues ~495-1091, pdb labeling) and excluded the BCCP domain from Chain 
D that extended biotin in to the CT domain active site of Chain C. The exclusion of the 
BCCP domain is due to the possible steric hindrance of biotin in the active site that may 
affect the predicted binding of the compounds. In addition to the CT domain, pyruvate 
and the metal ion were included in the modified pdb file. As the original SaPC (3bg5) did 
not include any water molecules in the published crystallized structure, a water molecule 
that is in close proximity to the metal ion from an overlaid RePCDBCDBCCP structure 
(4jx5) was added to the modified pdb file as well. This water molecule is often observed 
to be bridging the interaction between the metal ion and carbonyl oxygen of pyruvate 
(Lietzan and St Maurice 2013b). The docking program treated water molecules as 
displaceable and that parameter was kept as crystallization with the compound, 3BP (pdb 
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4mim), suggests a binding mode that displaces the water molecule and directly interacts 
with the metal ion (Lietzan and St Maurice 2013b). In summary, the model for the closed 
conformation of SaPC included the CT domain of Chain C, a bound metal ion, pyruvate 
and water molecule. This modified pdb file was applied in all computational docking 
studies mentioned in this chapter, unless otherwise stated. Other modifications were 
made to this pdb file such as the removal of the water and/or metal ion and the inclusion 
of the biotin in the CT domain for additional assessment. The docking results from those 
studies are listed in the Appendix, Section B.   
 To assess the predicted binding of the compounds in the CT domain of SaPC in 
the open conformation, the pdb file of SaPCDBC co-crystallized with Compound 17 
(unpublished) without bound pyruvate was modified. The crystal structure of SaPCDBC 
co-crystallized with Compound 17, was determined to be an appropriate model as it 
demonstrated an open conformation of the CT domain. With several rounds of refinement 
there was no clear electron density for Compound 17 in the active site, resulting in a 
crystal structure of SaPCDBC in the open conformation and no bound ligand. The pdb 
file was trimmed to contain only Chain A of the CT domain (residues ~495-1091, pdb 
labeling) and included the metal ion, water and pyruvate molecules from the overlaid 
structure of the modified closed conformation pdb file described above.  
Docking studies were performed with both the closed and open conformations of 
the CT domain through an automated docking program called FORECASTER (Molecular 
Forecaster) (Therrien et al. 2012). This web-based program identified the position of 
pyruvate in the CT domain active site, removed pyruvate and subsequently docked the 
compounds within a cavity zone of the binding site (Corbeil, Englebienne, and Moitessier 
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2007). The compounds used in the docking study were built using Chemdraw 
(PerkinElmer) and saved as MDL Molefiles. Through the FORECASTER web-based 
application, a workflow (“Docking- 2D Molecules to a Rigid Protein (pdb)”) was 
selected that converted the 2D MDL Molefiles to 3D molecules and the pdb file to a mol2 
file. Protein Rotamer Elaboration and Protonation based on Accurate Residue Energy, or 
PREPARE, was utilized as part of the FORECASTER workflow. This software prepared all the 
atom files from the pdb files for suitable mol2 files. In addition to preparing the pdb files, 
PREPARE identified pyruvate in the pdb file by the residue name (PYR), chain location (A 
for open or C for closed conformation), and residue number (2001). The protein mol2 
was subsequently processed by PROtein Conformational Ensemble System Setup, or 
PROCESS, in the FORECASTER workflow to dock the 3D compounds in the binding site of 
the CT domain. The center of the binding site was defined by the center of pyruvate 
present in the active site. After the removal of pyruvate from the active site, a sphere with 
a radius of 15 Å was applied as the default for establishing the binding site cavity. 
FORECASTER utilized a genetic algorithm/hybrid matching algorithm to dock the 
compounds within the established cavity site. Docking scores were reported from 
FORECASTER as the predicted binding energy (DG) and following computational docking, 
the lowest energy pose was visualized in Pymol.  
 
4.2.8 Data Analysis  
 
 
The IC50 values were determined by fitting the data to Equation 7 from Chapter 3. 
An IC50 value is the concentration at which an inhibitor reduces the rate of the enzymatic 
reaction by 50% and is dependent on the substrate concentrations. The Cheng-Prussof 
Equation can be used to estimate a true binding constant or Ki value (Yang, Copeland, 
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and Lai 2009). The Cheng-Prussoff Equation for a competitive inhibitor was used to 






        [8] 
 
Experimental Ki values were determined using global nonlinear regression in 
Graphpad Prism. This allowed multiple data sets to be simultaneously fitted to the desired 
equation by minimizing the sum and sum of squares for all data sets and data points, 
respectively. The model that was used to determine the Ki value of a competitive inhibitor 
was:    
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Where [I] was the inhibitor concentration and was set as an individual parameter for all 
data sets. X and Y refer to the substrate concentration and enzyme activity respectively. 
Vmax, KM and Ki parameters were shared and a best-fit for the entire data set was 
determined. To determine the mixed-type inhibition of oxalate the model used was:  
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                                               [13] 
Where [I] was the inhibitor concentration and was set as an individual parameter for all 
data sets. X and Y refer to the substrate concentration and enzyme activity respectively. 
Vmax, KM, Ki, and a parameters were shared and a best-fit for the entire set of data was 
determined. 
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 To determine initial velocity rates for the MDH and LDH assays in the 96-well 
plate format, the average slope and standard deviations in units of  <:;
;G
 were calculated for 
96-well plate reader data output from a Multiskan Ascent spectrophotometer (Thermo). 




  with a calculated path length for the 96-well 
plates:  
abs = c	 × 	ε	 × 	l                                                [14] 
Where c is the concentration of the enzyme, e is the extinction coefficient for PC (6220 
M-cm-) and l is the path length. As the enzyme activity was recorded in 96-well plates 
and not in 1 mL cuvettes, the path length in 1 mL cuvettes (1 cm) could not be used for 
the 96-well plate. To determine the path length in the 96-well plates, the following ratio, 
Equation 15, was derived based on the absorbance and concentration of NADH in the 1 
mL cuvettes and 96-well plate format. The absorbance of 0.25 mM of NADH in 1 mL 
quartz cuvettes recorded at 340 nm in a UV- 1800 spectrophotometer (Shimadzu 
Scientific Instruments) was represented by:  




ε	 × 	1	cm 
The absorbance of 0.25 mM NADH in the 96-well plate format with 200 µL recorded at 
340 nm in a Multiskan Ascent spectrophotometer was represented by: 
abs = 	 c9 	× 	ε	 × 	l	, where l= unknown  
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As the NADH measured in both formats was prepared from the same stock of NADH, it 
can be assumed that the concentration of NADH was equal between the 1 mL cuvette and 
96-well plate. Therefore, abswell can be rewritten as:  
𝑎𝑏𝑠 = U
𝑎𝑏𝑠
e	 × 	1	cm]	× 	e	 × 	l 
Rewritten:  
l = V <:;
rff
<:;	 ¡r¢¢r
\ cm                                                   [15] 









Based on the structural studies of pyruvate, oxalate, 3HP and 3BP bound in the 
same orientation in the CT domain of PC (Lietzan and St Maurice 2013b), it was 
hypothesized that a-keto acids would act as substrate analog inhibitors. Oxalate, 3HP and 
3BP were confirmed to inhibit RePC, LmPC and SaPC in the 384-well plate FVB assay 
(see Figure 4-4).  Oxalate was the most potent inhibitor for all three bacterial enzymes, 
with IC50 values of 140 µM, 16 µM and 2 µM for RePC, LmPC and SaPC, respectively 
(see Table 4-1). Oxalate did not interfere with the formation of the FVB-OAA colored 
adduct. 3BP was found to also inhibit the bacterial enzymes with IC50 values of 1 mM, 20 
µM and 300 µM for RePC, LmPC and SaPC, respectively, while 3HP slightly inhibited 
the activity of the bacterial enzymes with IC50 values of 2 mM, 1 mM and 600 µM for 
RePC, LmPC and SaPC, respectively. All IC50 values are consistent with published Ki 
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values for oxalate (12-150 µM, (Ruiz-Amil et al. 1965)) and 3HP ( 5.4 mM (Charles, 
Willer, and Schafer 1984)).  
This is the first documented report of IC50 values for 3BP inhibition of bacterial 
PC, with a range of 20 µM -1 mM based on results from the FVB assay. However, as 
discussed in Chapter 3, the FVB assay may be prone to false positives, as the FVB 
diazonium salt has the potential to cross-react with nucleophilic compounds (Amador and 
Salvatore 1971). 3BP in particular, interfered with the FVB-OAA colored adduct with a 
similar dose response to SaPC (see Figure 4-4A). Therefore, the IC50 values determined 
with 3BP may not be accurate in the FVB assay. As the inhibition of 3BP has never 
previously been characterized for PC, 3BP was transitioned to the MDH assay for IC50 
despite the modest inhibition reported in the FVB assay and due to the interference with 
colored adduct formation at concentrations >200 µM. Due to the potent inhibition of 
oxalate with SaPC, it was also transitioned to the MDH assay to confirm the IC50 values. 
Based on the >500 µM IC50 values for all tested bacterial PC enzymes with 3HP and the 
slight inhibition of the FVB-OAA colored adduct at 1 mM, it was determined that 3HP 




Figure 4-4. IC50 Determination for Substrate-Analog Inhibitors of Bacterial PC in 
the FVB Assay 
Figure 4-4. IC50 determination for substrate-analog inhibitors of bacterial PC in the FVB 
assay. For all plots, the RePC inhibited reaction is represented by the green line, the 
LmPC inhibited reaction is represented by the purple line, the SaPC inhibited reaction is 
represented by the teal line and the FVB-OAA colored adduct inhibition is represented by 
the black line. In all panels, the error bars represent the standard deviation across eight 
wells.  A) The IC50 values for 3BP were 1 mM, 20 µM and 300 µM for RePC, LmPC and 
SaPC respectively. The FVB-OAA colored adduct was also inhibited by 3BP with a 
similar dose response as SaPC. B) The IC50 values for 3-HP were 2 mM, 1 mM and 600 
µM for RePC, LmPC and SaPC respectively. The FVB-OAA colored adduct was also 
inhibited by 3-hydroxypyruvate but not to the same extent as 3BP. C) The IC50 values for 
oxalate were 140 µM, 16 µM and 2 µM for RePC, LmPC and SaPC respectively. The 
FVB-OAA colored adduct was not inhibited by oxalate.  
 
In the MDH assay, the IC50 values for oxalate were 51 µM, 21 µM and 3 µM for 
RePC, LmPC and SaPC respectively while the IC50 values for 3BP were 140 µM, 1.1 µM 
and 51 µM for RePC, LmPC and SaPC respectively (see Figure B1). Using the IC50 
values determined in the MDH assay and an assumption of competitive inhibition, the Ki 
values for oxalate and 3BP could be estimated using Equation 8. Based on the structural 
evidence that oxalate and 3BP were bound in the CT domain active site in the same 
orientation as pyruvate, the assumption of competitive inhibition with respect to pyruvate 
was considered to be reasonable. Additionally, as demonstrated in Section 4.3.4, oxalate 
was determined be a mixed type inhibitor that strongly favored competitive inhibition. 
The estimated Ki values for oxalate were 140 µM, 1.1 µM and 0.43 µM for RePC, LmPC 
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and SaPC respectively while the estimated Ki values for 3BP were 7.3 µM, 3 µM and 
0.43 µM for RePC, LmPC and SaPC respectively. The Ki value for oxalate was 
determined kinetically for SaPC in Section 4.3.4 demonstrating that the predictive Ki 
(0.43 µM) value was consistent with the kinetically determined Ki value (0.29 µM). 
Based on these results, PC enzymes from different species may have varying sensitivity 
to certain small molecule inhibitors.  Due to the apparent increased sensitivity of SaPC to 
the inhibitors in the FVB and MDH assay, the remaining studies in this chapter were 
completed with SaPC.  
 
Table 4-1. IC50 Values for oxalate, 3BP and 3HP as determined using the FVB and 
MDH assays  
Compound Assay RePC LmPC SaPC Signal Interference 
3-Bromopyruvate 
FVB 1 .0mM 20 µM 300 µM Yes 
MDH 1.0 mM 7.0 µM **51 µM No 
***Ki 140 µM 1.1 µM 7.1 µM --- 
Oxalate 
FVB 140 µM 16 µM 2 µM No 
MDH 51 µM 21 µM 3 µM No 
***Ki 7.3 µM 3 µM 0.43 µM --- 
3-Hydroxypyruvate FVB 2 mM 1 mM 600 µM Yes 
**Indicates compound was initially screened by BW and evaluated by MM 
***Predicted Ki values from Equation 8 based on the IC50 values from the MDH assay.  
 
 
4.3.2 Scaffold Selection for CT Domain a-Keto Acid Compounds 
 
 
Crystal structures with various a-keto acid substrate analogs bound suggest that 
the CT domain active site of PC is structured to accommodate bulkier functional groups 
at the C-2 or C-3 position. Several a-keto acid containing compounds, modified at the C-
3 position, were evaluated for inhibition of PC activity in order to assess the potential for 
this functional group to serve as a scaffold for PC inhibitor development. The FVB assay 
was utilized to determine IC50 values in the initial assessment of a-keto acid derivatives. 
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Aromatic a-keto acids, such as phenylpyruvic acid (Compound 96), were among the 
most promising of the a-keto acid compounds (see Table 4-2), with an IC50 value of 240 
µM. The importance of the aromatic ring of phenylpyruvic acid can be demonstrated with 
a cyclohexyl ring substitution (α-oxo-cyclohexanepropanoic acid, Compound 140) that 
greatly diminished potency. Even slight modifications to the core structure of 
phenylpyruvic acid such as the removal (phenyglyoxylic acid, Compound 20) or addition 
(2-oxo-4-phenylbutanoic acid, Compound 93) of a carbon between C-2 and the aromatic 
ring resulted in a substantial reduction in inhibition. However, the addition of a hydroxyl 
group in the para position of the aromatic ring greatly decreased the IC50 value (67 µM) 
of 4-hydroxyphenylpyruvic acid (Compound 17) and demonstrated the ability of the 

























































 67 µM 
*  Indicates compound had only been evaluated by undergraduate researcher MM 





























4.3.3 An Initial Structure Activity Series Centered on Aromatic Ring
 Substitutions of Phenylpyruvic Acid.  
  
 
 The CT domain of PC is a member of the broader DRE-TIM (Asp-Arg-Glu triplet 
in the TIM barrel fold) metallolyase protein superfamily (Forouhar et al. 2006). All 
members of this superfamily catalyze reactions that proceed through a stabilized enolate 
intermediate. The CT domain reaction mechanism proceeds through a stabilized 
enolpyruvate intermediate that subsequently becomes carboxylated to form OAA. It is 
promising, then, that phenylpyruvic acids are inhibitory to PC given their propensity to 
exist predominately in the enol form in DMSO (Sciacovelli et al. 1976). To further 
evaluate the characteristics contributing to inhibition, an initial structure activity 
relationship (SAR) study was evaluated for a series of aromatic ring substitutions that 
probed the effect of para, meta and ortho substituted aromatic groups (see Table 4-3). 
These compounds were evaluated using both the primary FVB and secondary MDH 
assays in order to confirm and compare the individual IC50 values.  
 Para and meta substituted phenylpyruvic acids are both known to exist 
predominantly in the enol form while ortho substituted phenylpyruvic acids prefer the 
keto form (Takai et al. 1998, Carpy, Haasbroek, and Oliver 2004). Consistent with these 
chemical features and our hypothesis that compounds with enol-like characteristics will 
have enhanced potency for PC, aromatic compounds substituted in the ortho position  2-
nitrophenylpyruvic acid (Compound 19) and 3-(2-bromophenyl)-2-hydroxy-2-propanoic 
acid (Compound 115)) had higher IC50 values than their para- or meta-substituted 
counterparts. There does not seem to be a preference for para- vs. meta-substituted 
phenylpyruvic acids, suggesting that the enol character at C-2, rather than the steric fit, is 
the most significant contributor to inhibition strength among phenylpyruvic acid 
 87 
derivatives. However, only the bromo and methyl substituents were available for direct 
comparison of para- vs. meta-substitution.  
To further investigate the electronic nature of the inhibitors, a Hammett plot was 
generated for a large series of para-substituted phenylpyruvic acids. A Hammett plot 
reports on the linear free energy relationship between structure and activity by plotting 
the electronic properties of the substitutions against the effect on the reaction (Hammett 
1935). In particular, Hammett substituent constants (s) were reported and plotted against 
the log IC50 values of the compounds from the MDH assay (Hansch, Leo, and Taft 1991) 
(see Figure 4-5). There was a clear linear relationship between the para substituent 
constants and the log IC50 values as demonstrated by the Hammett plot. The positive 
slope of the Hammett plot indicates that the inhibition of the PC reaction was affected by 
the electronic properties of the substitutions, such that electron donating groups tended to 
enhance inhibition while electron withdrawing groups were not as effective. However, 
the linear regression of the line was not forced through 0,0 indicating that there may be 
other factors contributing to the potency of the compounds. While the compounds 
designed through the SAR study were not the most potent inhibitors discovered through 
SBDD and did not require additional follow-up studies, the compounds provided several 
informative insights into the development of potent inhibitors. First, the electron donating 
properties of the para substituted aromatic a-keto acids may have an impact on the 
potency of designed compounds and second, these studies provided additional evidence 




Table 4-3. Aromatic Ring Substitution Structure Activity Relationship of PC 
Inhibitors 
 
                                           
                 Aromatic a-keto acids ring substitutions     
                              R1= Ortho position 
                                        R2= Para position 
           R3= Meta position 
Compound R1 R2 R3 IC50 FVB µM IC50 MDH µM s 
96 H H H 240  130 0 
19 NO2 H H >2 mM >2 mM 0.71 
*110 H NO2 H >1 mM >1 mM 0.778 
*115 Br H H >1 mM >1 mM NA 
**97 H Br H 200 81 0.232 
*108 H H Br 30 8.8 0.32 
*112 H H CH3 360 23 -0.069 
**114 H CH3 H 210 140 -0.170 
*120 H Cl H 280 220 0.227 
*106 H OCH3 H 170 56 -0.268 
*119 H B(OH)2 H 150 77 0.12 
*109 H CF3 H 67 96 0.54 
*107 H F H 100 30 0.062 
**17 H OH H 67 22 -0.37 
**117 H CH3 CH3 98 38 NA 
Color sections represent identical R constituents at different aromatic ring substitute 
positions 
*  Indicates compound had only been evaluated by undergraduate researcher MM 

















Figure 4-5. Para Hammett substituent constants (σ) relationship to IC50 values. IC50 X 
refers to the IC50 values of the various tested compounds compared as a ratio to the IC50 
value of Compound 96 (130 µM). Compound 96 (red) represents the σ value of 0.0 as the 
compound does not contain any para, meta or ortho substitutions. The Hammett plot 
demonstrates a positive linear relationship (R2=0.52) with the reported σ values and IC50 
values determined from the MDH assay. The compounds represented are as followed: 
Compound 110 (lime green), Compound 120 (pink), Compound 97 (orange), Compound 
119 (grey), Compound 17 (green), Compound 114 (blue), Compound 106 (black), 

















 4.3.4 Potent First Generation Small Molecule Inhibitors of PC 
 
 
 The initial SAR study validated the promising inhibitory potential of a-keto acids 
and established that enolic character contributes meaningfully to inhibitor potency. As a 
consequence, additional a-keto acids, with increased steric bulk, were tested for PC 
inhibition in the MDH assay. This included a-oxo-2-quinolinepropanoic acid (Compound 
98) and benzene-1,4-dipropanoic acid (Compound 122) (See Table 4-4).  PC tolerated the 
additional bulk of the quinoline-derived compound as evidenced by the 8 µM IC50 value 
for Compound 98, representing the most potent inhibitor of PC developed through 
SBDD. The high affinity of Compound 98 may derive from the quinolinyl nitrogen, 
which is capable of forming an intramolecular hydrogen bond to stabilize the enol form 
of this compound (see Figure 4-6). The most potent compounds, oxalate and Compound 
98, and representative compounds from SAR, 4-hydroxyphenylpyruvic acid (Compound 
17) and 2-hydroxy-3-(4-methylphenyl)-2-propenoic acid (Compound 114) were 
advanced for further structural and kinetic analysis. Compound 17 and 114 were selected 
due to their low IC50 values (22 µM and 17 µM respectively) in the MDH assay and for 
their low Hammett substituent constant (-0.37 and -0.17) compared to the other SAR 
compounds. The structural and kinetic analysis included determination of the Ki value 














Table 4-4. Ki and Docking Values for Select Small Molecule Inhibitors of PC 
**Indicates compound was initially screened by BW and evaluated by MM for IC50 
values only. All docking and Ki determinations were made by BW.  
***Predicted Ki values from Equation 8 based on the IC50 values from the MDH assay.  







51 ***7 -28/-37 
122 
 
23  ***3 -44/-65 
**17 
  
22 ***3  -25/-42 
**114 
 
17 2.4 ***2.4 -22/-43 
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 While the compounds described above were assumed to target the CT domain of 
PC and directly outcompete the substrate, the IC50 values were unable to determine 
whether these inhibitors are directly targeting the CT domain and were unable to assess 
the mode of inhibition (competitive, noncompetitive, mixed-type, etc.). As described in 
Section 4.2.5, a truncated form of SaPC was generated that lacked the BC and BCCP 
domain (SaPCDBCDBCCP) to facilitate inhibition assays of the CT domain in isolation, 
via a LDH coupled enzyme assay. The LDH assay measures the rate of oxamate-induced 
OAA decarboxylation in the CT domain. Oxamate promotes OAA decarboxylation by 
accepting the carboxyl group from OAA to form pyruvate and carbamyl oxamate 
(Lietzan, Lin, and St Maurice 2014). If a-keto acids specifically inhibit the CT domain of 
PC, we would expect to see inhibition of SaPCDBCDBCCP via the LDH coupled enzyme 
assay. As demonstrated in Figure 4-7A (black columns), the CT domain enzyme activity 
is inhibited in the presence of oxalate, as expected. Compound 98 also inhibited the CT 
domain reaction, but to a lesser extent. Surprisingly, Compound 17 enhanced the CT 
domain reaction. While oxamate accelerates the decarboxylation of OAA, it is also an 
inhibitor of both LDH and PC (Lietzan, Lin, and St Maurice 2014, Zeczycki, Maurice, 
and Attwood 2010, Zeczycki, St. Maurice, and Attwood 2010). Consequently, oxamate 
was removed from the LDH assay (grey columns) resulting in decreased overall reaction 
rates. Surprisingly, in the absence of oxamate, both Compound 98 and 17 appeared to 
enhance the rate of OAA decarboxylation. These results suggested possible cross-
reactivity with the LDH coupling enzyme. To further investigate this possibility, LDH 
(without PC present) was assayed in the presence of these compounds. It was determined 
that Compound 17 inhibited LDH at concentrations greater than 1 mM (see Figure 4-7B) 
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and, furthermore, acted as substrates for LDH (see Figure 4-7C). Consistent with these 
observations, it has previously been demonstrated that LDH is able to directly reduce 
aromatic a-keto acids in the presence of NADH (Friedrich et al. 1987). Compound 17 
was progressed towards crystallization studies as high concentrations of the compound 
can be easily dissolved in crystallization solutions, but due to its interactions with LDH, 
were removed from further kinetic studies. These findings greatly complicate the use of 
an LDH-coupled assay to assess CT domain specific inhibition in PC and lead to the 
conclusion that the LDH assay is inappropriate for assessing CT domain inhibitors of PC.  
Alternative methods were, therefore, required in order to clarify the target site of 
















Figure 4-7. LDH Assay Inhibition and Substrate Range 
 
 
Figure 4-7. LDH assay inhibition and substrate range. A) Initial determination of 
compound inhibition in the presence of the indicated compound and 0.5 mM oxamate, 
0.2 mM OAA, 0.25 mM NADH and 100 µg/mL SaPCDBCDBCCP is represented by the 
black columns. The grey columns represent compound inhibition in the absence of 
oxamate and in the presence of the indicated compounds and 0.2 mM OAA, 0.25 mM 
NADH and 100 µg/mL SaPCDBCDBCCP. B) Direct inhibition of LDH by individual 
compounds was determined in the presence of 0.05 U/mL of LDH in the presence of 50 
mM pyruvate and 0.25 mM NADH. At high concentrations, Compound 17 showed 
evidence of LDH inhibition. C) The ability of LDH to use the compounds as substrates 
was determined with 0.05 U/mL of LDH in the presence of 0.25 mM NADH. Compound 




Based on our hypothesis that the compounds are competitive inhibitors with 
respect to pyruvate, Ki values, predictive Ki values and the mode of inhibition were 
determined for the compounds described in Table 4-4 (see Figure B2 and B3). Oxalate is 
known to bind in the CT domain of PC and was used as comparison. Oxalate was a 
mixed type inhibitor that strongly favored competitive inhibition with a Ki value of 0.29 
µM. The a value derived from a global fit of the data to Equation 12 indicated that 
oxalate is primarily a competitive inhibitor with respect to pyruvate. The a values from 
the mixed-type model can determine the degree to which the inhibitor changes the 
affinity of PC for pyruvate. If the a value is 1, then the inhibitor has no influence on the 
affinity of pyruvate, resulting in classic noncompetitive inhibition. As the a value 
approaches 0, the inhibitor will significantly increase the affinity of PC for pyruvate, 
resulting in uncompetitive inhibition. As the a value approaches infinity, the inhibitor 
will significantly decrease the affinity of PC for pyruvate, resulting in competitive 
inhibition. In the case of oxalate, the a value was very large, indicating that the inhibitors 
strongly favored competitive inhibition. These results differ from previous reports of 
classic noncompetitive inhibition of PC by oxalate with respect to pyruvate (Ruiz-Amil et 
al. 1965). The differences are attributed to the substantially higher purity of PC relative to 
what was available in 1965 and our results are reinforced by the convincing structural 
evidence that oxalate is bound in the pyruvate binding site at the CT domain of PC 
(Lietzan and St Maurice 2013b). Thus, we are confident that our Ki value and mode of 
inhibition are accurate. As an additional measure to assess whether our procedure for 
determining Ki values was accurate, the mode of inhibition for oxalate with respect to 
ATP was determined. Oxalate was a mixed-type inhibitor with respect to ATP, with a Ki 
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value of 2.5 µM and a value equal to 0.92 strongly favoring a noncompetitive mode of 
inhibition.  
 Compounds 98 and 114 were determined to be competitive inhibitors with respect 
to pyruvate and noncompetitive inhibitors with respect to ATP (see Figure 4-8, B2 and 
B3). The Ki values for pyruvate inhibition are reported in Table 4-4 with Compound 98 
being the most potent inhibitor, with a Ki value of 0.74 µM. The predictive Ki values were 
determined for Compound 98 (1.1 µM) and Compound 114 (2.4 µM). As the predictive 
Ki values were consistent with the kinetically determined Ki values, and due to the 
consistent competitive inhibition mode for oxalate, Compound 98 and Compound 114, 
competitive predictive Ki values were mathematically determined for 3BP (7 µM), 
Compound 17 (3 µM) and Compound 122 (3 µM). These results indicate that these 
compounds directly compete with pyruvate in the CT domain active site. Furthermore, 
their binding affinity is not altered by the presence of ATP binding in the BC domain 
active site. Consistent with our hypothesis, a-keto acids specifically target the pyruvate 










Figure 4-8. Compound 98 is Competitive with Respect to Pyruvate and 




Figure 4-8. Compound 98 is competitive with respect to pyruvate and noncompetitive 
with respect to ATP. Oxalate is a mixed type inhibitor with respect to pyruvate (strongly 
favors competitive inhibition) and mixed type with respect to ATP (strongly favors 
noncompetitive inhibition). A) Global fit of Compound 98 as a competitive inhibitor with 
respect to pyruvate, Ki value = 0.74 µM. B) Lineweaver-Burk plot demonstrating 
competitive inhibition of Compound 98 with respect to pyruvate. C) Lineweaver-Burk 
plot demonstrating noncompetitive inhibition of Compound 98 with respect to ATP, Ki 
value = 5.2 µM. D) Global fit of oxalate as a mixed type inhibitor with respect to 
pyruvate, Ki value = 0.29 µM. E) Lineweaver-Burk plot demonstrating mixed inhibition 
of oxalate with respect to pyruvate. F) Lineweaver-Burk plot demonstrating mixed 
inhibition of oxalate with respect to ATP, Ki value = 2.5 µM. 
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Substantial efforts were dedicated to X-ray crystallography with Compounds 17 
and 98 with the goal of directly visualizing these high affinity compounds bound in the 
CT domain of PC. These efforts included soaking and co-crystallization crystallization 
attempts with full-length, DBC and DBCDBCCP variants of SaPC, LmPC and RePC 
(these efforts are outlined in Appendix C). The most promising crystallization conditions 
included the reproduction of RePCDBCDBCCP crystals (Lietzan and St Maurice 2013b) 
from Lietzan et al. and SaPCDBC crystals that were refined through a PC-specific general 
screen developed from previously published crystallization conditions of PC. The 
refinement of the RePCDBCDBCCP crystals were never progressed to X-ray diffraction 
at the Advance Photon Source (APS) as they did not diffract past ~5-6 Å. The SaPCDBC 
crystals however, diffracted to ~3-2.3 Å and were progressed to X-ray diffraction at the 
APS. Data were collected on various crystals that were either co-crystallized with 
Compound 17 or soaked with Compound 98 (described in Section 4.2.6). Those 
crystallization attempts with SaPCDBC were deemed unsuccessful as the crystal 
structures did not reveal significant electron density of any small molecules in the CT 
domain active site. However, as the SaPCDBC structure was consistent with previous 
structures that highlighted the CT domain in the open conformation (Lietzan and St 
Maurice 2013a, St Maurice et al. 2007), the structure was utilized as an important 
structure in subsequent docking studies.  
 As an alternative approach to structural characterization, docking studies were 
performed to computationally predict the binding affinity of the most potent inhibitors for 
the CT domain of PC, and to visualize the predicted binding site. Several considerations 
such as the conformation of the CT domain and the enol/keto form of the compounds 
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were accounted for in the docking studies. As mentioned in the introduction, the CT 
domain has been crystallized in two conformations, the open and closed conformation. 
Without pyruvate bound, the CT domain is in the open conformation (Lietzan and St 
Maurice 2013a). Upon the binding of pyruvate, the CT domain adopts a closed 
conformation that promotes the binding of carboxybiotin (Lietzan and St Maurice 2013a) 
(see Figure 4-9). As the crystal structure of SaPCDBC was determined to be the open 
conformation, it was utilized as the comparison to the closed conformation of the CT 
domain in SaPC (pdb i.d. 3bg5). As a majority of the kinetic studies described in this 
chapter were assayed with SaPC, these structures were determined to be the most 
appropriate. Based on a surface view of the CT domain tunnel in the closed 
conformation, the active site is less accessible relative to the open conformation (see 
Figure 4-9). For the more sterically bulky compounds, this can be expected to affect their 
docking score and, thus, docking was performed against both conformations.  
Additionally, the enol/keto form was considered for docking with the most potent 
compounds. As shown in Figure 4-10, docking with the enol and keto form of Compound 
98 in the open conformation, closed conformation and closed conformation with biotin 
present all resulted in varying poses within the CT domain. Due to the importance of the 
enolic characteristics of the compounds, all compounds were docked in their enol form 
(docking scores are recorded in Table 4-4) unless otherwise stated. Docking scores 
account for hydrogen bonds, Coulombic and Van der Waal interactions (Pagadala, Syed, 
and Tuszynski 2017), with a more negative docking score correlating with a higher 
predicted binding affinity.   
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 To investigate the accuracy of the predictive binding poses of the compounds 
through docking, the docking poses of pyruvate bound in CT domain were compared to 
the crystal structures of pyruvate bound in the closed conformation (see Figure 4-11). 
While there are some variances in the binding orientation of pyruvate crystallized with 
RePCDBCDBCCP (Lietzan and St Maurice 2013a) and SaPC (Xiang and Tong 2008a) in 
the closed conformation, all structures show that the carboxyl moiety of pyruvate forms a 
salt bridge Arg621 and the carbonyl oxygen of pyruvate is within hydrogen bonding 
distance of Arg548, Gln552 and oriented towards the Mn2+/Zn2+ metal ion (see Figure 4-
11A and B). Surprisingly, the docking poses of pyruvate in the closed conformation and 
closed conformation with biotin present did not demonstrate the same orientation of 
pyruvate as the crystal structures (see Figure 4-11C). However, when the Mn2+/Zn2+ 
metal ion was removed, the docking poses of pyruvate did align with the orientation of 
pyruvate in the crystal structures (see Figure 4-11D). This indicated that the carboxyl 
moieties in the docking program will be preferentially coordinated with the Mn2+/Zn2+ 
metal rather than the active site amino acids.  
To assess whether it was possible to remove the Mn2+/Zn2+ metal for all docking 
experiments for more accurate docking poses, Compound 98 was docked in the closed 
conformation without the metal ion. Regardless if the metal ion was removed or not, the 
a-keto acid group was oriented towards the water and metal ion, while the aromatic rings 
were positioned near the catalytic amino acids (see Figure 4-11E). Additionally, when the 
metal ion was overlaid, it was apparent that the compound was occupying the same space 
as the metal ion and it was decided that the metal ion would remain present in all docking 
studies. Ultimately, the pyruvate docking controls demonstrated that there is a clear 
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difference in the way the docking software predicts how the a-keto acids bind to how 
they are oriented in the crystal structure.  
As Compound 98 was the most potent compound discovered from SBDD, it was 
studied further in the docking program in both the closed conformation and closed 
conformation with biotin present. Those two conformations were selected due to the 
completely different predictive binding orientations of Compound 98 in the CT domain. 
Based on the docking structure in the closed conformation, the nitrogen in the quinoline 
group was predicted to be within hydrogen bonding distance of Thr882 and Gln552, while 
the a-keto acid group was predicted to coordinate with an ordered water molecule, the 
active site metal and the guanidinium group of Arg548 (see Figure 4-12A-C). All three 
amino acids are conserved in PC while Gln552/ Arg548 are conserved within the broader 
DRE-TIM metalloenzyme family that catalyze reactions that proceed through an enol 
intermediate (Forouhar et al. 2006). Additionally, the aromatic rings of Compound 98 
occupy the space that biotin has been shown to occupy in several X-ray crystal structures 
(Xiang and Tong 2008a) (see Figure 4-12C). Alternatively, the docking of Compound 98 
in the closed conformation with biotin present seems to suggest that the orientation of 
Compound 98 was impacted by the presence of biotin. This docking pose had a similar 
orientation as the a-keto acid group of pyruvate, but the aromatic ring coordination with 
the water and metal ion were unusual. The nitrogen in the quinoline compound was 
within hydrogen bond distance of Gln552 while the carboxyl moiety of the compound 
formed a salt bridge with Arg621. The carboxyl moiety of Compound 98 does not interfere 
with the binding location of biotin. Until a crystal structure can elucidate the true binding 
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orientation of Compound 98, the docking studies are useful in visualizing the predictive 
spatial availability of the CT domain with bound compounds in various conformations.  
 




Figure 4-9. Cartoon and surface view of the CT domain in the open and closed 
conformation. Conformational changes were determined by the overlay of full length 
SaPC (closed conformation, pbd i.d. 3bg5) and SaPCDBC (open, conformation, 
unpublished) as described in Section 4.2.5. In all panels the open conformation is 
represented by the blue cartoon and surface view and the closed conformation is 
represented by the green cartoon and surface view. Pyruvate is represented by the yellow 
stick model, water by the red sphere and the metal Mn2+/Zn2+ ion by the grey sphere. A) 
Cartoon representation of the CT domain in the closed and open conformation. Upon 
pyruvate binding, the CT adopts a closed conformation and several a-helices shift ~5 Å 
towards the center of the CT domain. B) Surface representation of the open conformation 
with the overlay of pyruvate from the closed conformation. C) Surface representation of 
the same view of pyruvate in the closed conformation highlighting the less accessible 
active site.    
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Figure 4-10. Different Docking Poses of the Enol and Keto Form of Compound 98 
 
 
Figure 4-10. Different docking poses of the enol and keto form of Compound 98. In the 
right panels, the keto or enol forms of Compound 98 were docked in either the open 
conformation (periwinkle), closed conformation (green) or closed conformation with 
biotin present in the CT domain (grey). Crystallized pyruvate is represented by the yellow 
stick model. A) Structure of the keto form of Compound 98 and the various positions of 
the compound docked in the CT domain. B) Structure of the enol form of Compound 98 
and the various positions of the compound docked from the same view as the keto form. 
The Mn2+/Zn2+ metal ion is represented by the grey sphere and the displaceable overlaid 















Figure 4-11. Crystallized and Docked Pyruvate Orientation in the CT Domain 
 
 
Figure 4-11. Crystallized and docked pyruvate orientation in the CT domain.  A) Crystal 
structure of private (yellow) bound in the CT domain of SaPC. Upon the binding of 
pyruvate, the CT domain adopts a closed conformation where the carboxyl moiety of 
pyruvate forms a salt bridge Arg621 and the carbonyl oxygen of pyruvate is within 
hydrogen bonding distance of Arg548 and Gln552. These residues are responsible for 
stabilizing the enolpyruvate intermediate that is formed when biotin transfers CO2 
through a proton shuttle to pyruvate via Thr882. In the closed conformation, Tyr628 forms a 
hydrogen bond with Asp590. B) Comparison of pyruvate bound in SaPC crystal structure 
(yellow) and RePC (periwinkle). C) Comparison of pyruvate docked in the closed 
conformation (pink) and closed conformation with biotin present (purple). D) 
Comparison of pyruvate docked in the closed conformation (pink) and the closed 
conformation with biotin present with the removal of the metal ion. E) Compound 98 
docked in the closed conformation with the removal of the metal ion. The metal ion was 





Figure 4-12. Docking Pose of Compound 98 in the Closed Conformation of the CT 
Domain  
 
Figure 4-12. Docking pose of Compound 98 in the closed conformation of the CT 
domain. Panels A-C represent Compound 98 that was docked in the closed conformation 
without biotin present. Panels D-F represent Compound 98 that was docked in the closed 
conformation with biotin present. In all images, the water is represented by the red sphere 
and the Mn2+/Zn2+ metal ion is represented by the grey sphere. A) Forward view of 
Compound 98 and the a-keto acid group orientation towards the water and metal ion. B) 
The nitrogen in the quinoline compound is within hydrogen bond distance of Gln552 and 
Thr882. C) The aromatic rings of Compound 98 occupy the binding location of biotin. D) 
Forward view of Compound 98 and the a-keto acid group orientation towards the 
catalytic amino acids while the aromatic rings coordinate with the water and metal. E) 
The nitrogen in the quinoline compound is within hydrogen bond distance of Gln552 while 
the carboxyl moiety of the compound forms a salt bridge with Arg621. F) The carboxyl 












The inhibitors described in this chapter, developed using SBDD, have produced 
relatively high affinity small molecule fragments that can serve as a foundation for the 
ongoing development of specific and potent small molecule inhibitors of PC. We have 
determined that a-keto acids are amenable scaffolds that can be modified to 
accommodate increased steric bulk, leading to increasingly potent inhibitors. 
Phenylpyruvic acids, in particular, served as the core scaffold that demonstrated 
increased potency and provided initial evidence that the enol tautomer is a more potent 
inhibitor. It was originally hypothesized that the enol tautomer of the compounds would 
result in more potent inhibitors as they would mimic the enolpyruvate intermediate and 
therefore act as a transition state analogue. As such, it was predicted that the a-keto acid 
inhibitors would orient in a similar position as pyruvate and the various a-keto acid 
substrate analogues that had previously been crystallized in the CT domain (Lietzan and 
St Maurice 2013b). This includes the binding of the inhibitor such that the carboxylic 
moiety of the compound would form a stabilizing salt bridge with the guanidine group of 
Arg621 and the carbonyl oxygen of the a-keto acid would be within hydrogen bonding 
distance of Arg548 and Gln552. It is through these catalytic amino acids that the 
enolpyruvate intermediate is stabilized and so, hypothetically, should the enolic 
inhibitors.  
As mentioned in Section 4.3.3, phenylpyruvic acids are predominately in the enol 
form in DMSO and deuterated NMR solutions (Sciacovelli et al. 1976, Takai et al. 1998). 
However, the inhibition of the compounds that were assessed in our assays only 
contained a maximum of 5% DMSO and represented the inhibition of PC in an aqueous 
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solution. Indeed, studies have demonstrated that the enol-keto tautomerization of 
phenylpyruvic acids are highly dependent on the solvent, temperature, pH and para, meta 
and ortho substitution groups of the phenylpyruvic acids (Takai et al. 1998, Sciacovelli et 
al. 1976, Carpy, Haasbroek, and Oliver 2004, Geratz 1965, KNOX and PITT 1957, 
Yamaji and Saito 2018, Larsen and Wieczorkowska 1974). In particular, the transition of 
the enol to keto tautomer has been demonstrated to progress rapidly in water (Takai et al. 
1998) such that the keto form dominates 95% of the solution in water (Sciacovelli et al. 
1976).  
There is evidence that the para, meta and ortho substitutions of phenylpyruvic 
acids influence the enol-keto tautomer form in various solutions (Larsen and 
Wieczorkowska 1974, Takai et al. 1998). In deuterated NMR solutions such as CD3CN, 
regardless of the electron donating or withdrawing group that was substituted in the para 
or meta position, the enol form dominated while the electron withdrawing groups in the 
ortho position favored the keto form (Takai et al. 1998). The para and meta aromatic ring 
substitutions from our study demonstrated that they contributed to lower IC50 values 
when compared to ortho substitutes, providing initial evidence that the enol tautomer was 
important in the potency of the inhibitor. Again, the inhibition studies were done in an 
aqueous assay buffer and not CD3CN, thus those studies do not explain why we see a 
clear trend in the increased potency of the compounds that contain electron donating 
groups in the para position. Intuitively, this trend does not seem consistent with the 
formation of the anionic intermediate, enolpyruvate, that is stabilized in the CT domain 
reaction (Zeczycki et al. 2009). However, as previously reported by Larsen et al., there is 
evidence that an electron donating group, such as an hydroxyl group in the para position 
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of phenylpyruvic acid, promotes the enol form in an aqueous solution (17%) compared to 
the unsubstituted phenyl pyruvic acid (10%) (Larsen and Wieczorkowska 1974). The 
Hammett plot therefore may provide some insights into the enol-keto form of the 
inhibitors. If the electron donating properties of the para substitutions do increase the 
enol form of the compounds in an aqueous solution, then the positive slope of the 
Hammett plot is consistent with the hypothesis that the enol tautomer is important in the 
inhibition of the CT domain reaction.  
As Larsen et al. demonstrated, the para substitution did not demonstrate a 100% 
enol tautomer solution. Therefore, the enol-keto ratio could have an impact on several of 
the SBDD studies described in this chapter. First, if the enol form is the predominate 
tautomer that results in potent inhibition and it is present in only ~10-20 % of the 
solution, then the kinetically determined Ki values are likely an underestimation of the 
true Ki values from the form of the compound that inhibits the reaction. Second, the enol-
keto ratio could have a significant impact on the success of crystallization studies. As 
mentioned in Section 4.3.4, we were unable to crystallize the compounds with SaDBC. 
This may be due to the unexpected lower concentration of the enol compound that is able 
to bind in the CT domain and thus impact the saturation of the compound present in the 
crystallization conditions.  
Based on the original hypothesis, the compounds have been proposed to have 
enhanced potency due to enolic characteristic that mimic the enolpyruvate intermediate 
transition state. However, the visualization of the predictive binding orientation of the 
compounds docked in the CT domain have provided an additional explanation as to why 
the enolic characters of the compounds may be important in the inhibition of PC. In a 
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majority of the docking poses, the a-keto acid moiety directly coordinates with the metal 
ion and does not form any stabilizing bonds with the key catalytic amino acids. Enol 
intermediates can be stabilized through coordination with metals, and certain enzymatic 
reactions are accelerated with an enolate/enol and metal intermediate (Ming 2009). In 
particular, metal-enolate bonds are more stable than metal-keto bonds (Ming 2009). This 
coordination with the metal ion highlights the potential of the compounds to specifically 
inhibit the CT domain reaction through the metal ion as an enol tautomer. 
It has been recognized that docking is a predictive model (Chen 2015) and based 
on the inability of the docking software to correctly dock pyruvate in an orientation 
similar to the crystal structure, we realize that the models may not be an accurate. 
However, the docking studies did allow us to visualize the compounds bound in the CT 
domain. This was beneficial as the docking studies demonstrated that it was spatially 
unlikely that the bulkier compounds such as Compound 98, could sterically orient such 
that their a-keto groups are oriented similarly to pyruvate. Due to docking studies 
prediction that the a-keto acid moiety directly coordinates with the metal ion, it raised 
new concerns that these compounds may act as promiscuous metal chelators against a 
range of metalloenzymes.  
Nearly one third of all proteins are estimated to be metalloenzymes (Day and 
Cohen 2013) (Valdez et al. 2014). Metalloenzyme inhibitors are commonly hydroxamic 
acids or carboxylic acids that coordinate to the active site metal (Day and Cohen 2013). 
There are concerns that these metalloenzyme inhibitors are indiscriminate, but several 
recent studies by Day et al. and Chen et al. demonstrate that this might be a broad 
misconception. Day et al. concluded that metalloenzyme inhibitors are indeed specific for 
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their intended targets and do not demonstrate off-target activity, even at high 
concentrations (Day and Cohen 2013).  Chen et al. followed this study by rudimentarily 
creating an in vivo like environment by assaying multiple metalloenzymes in the presence 
of inhibitors. They demonstrated that the potency of metalloenzyme inhibitors was not 
affected by the presence of other metalloenzymes.  
It is hopeful that our compounds are not broad binding, metal chelators or non-
specific inhibitors in general. It is reassuring to note that our most potent compound 
(Compound 98) does not display nonspecific inhibition against MDH or LDH, nor is it 
used as a substrate by LDH. Both MDH and LDH utilize substrates such as OAA  
(Bernstein and Everse 1978) and pyruvate (Coulson and Rabin 1969) respectively, 
similarly to PC. If the compounds were promiscuous inhibitors for enzyme reactions that 
utilize the same CT domain substrates as PC, then it may be expected to see inhibition 
with both MDH and LDH. While it is still very possible that these compounds are non-
specific for PC and have broad binding capabilities, these initial results are promising for 
future compound development.  
 In lieu of a crystal structure, the docking studies may be able to provide a 
foundation for future compound development and to elucidate possible inhibition 
interactions, with the caveat that these are only predictive models. It has been previously 
shown that competitive inhibitors of PC can promote carboxybiotin decarboxylation in 
the CT domain of PC (Goodall et al. 1981). While pyruvate binding is not required for 
biotin decarboxylation, the CT domain needs a ligand to be bound in the active site in 
order for biotin to access to the CT domain active site (Xiang and Tong 2008a, Attwood, 
Tipton, and Cleland 1986). Inhibitors that promote carboxybiotin decarboxylation are 
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fluoropyruvate, hydroxypyruvate, oxamate and glyoxylate (Goodall et al. 1981). Notably, 
these are all a-keto acids. Inhibitors that do not promote carboxybiotin decarboxylation 
are propionate, lactate and acetaldehyde that lack either the carboxyl or carbonyl group 
(Goodall et al. 1981). When pyruvate binds in the CT domain, the active site loop adopts 
a closed conformation and a salt bridge forms between the carboxyl moiety and Arg621 
(Lietzan and St Maurice 2013a). This rearranges an active site loop and repositions Tyr628 
in the active site. Biotin binding is promoted in the closed conformation, with the 
thiopene ring of biotin positioned directly above the repositioned aromatic ring of Tyr628 
to form a sulfur-p interaction that contributes directly to biotin binding (Lietzan and St 
Maurice 2013a, Xiang and Tong 2008a). There is support for such sulfur-p interaction in 
the literature, where it has been proposed that divalent sulfides near the plane of aromatic 
rings will stabilize protein ligand complexes (Reid, Lindley, and Thornton 1985, 
Maveyraud et al. 1996). Based on this information and the docking poses of Compound 
98 bound in the CT domain, I have developed several possible models that may describe 
the mechanism of inhibition and why Compound 98 in particular is the most potent 
compound discovered thus far:  
 
Model #1: Compound bindsà Closed Loopà Compound Aromatic p-p Interaction 
with Tyr628 
Compound 98 outcompetes pyruvate and binds in the open conformation of the CT 
domain. Like previously known inhibitors of PC, it promotes the closed loop 
conformation. In this position, the aromatic rings of Compound 98 and Tyr628 are within 
distance for p-p interactions (~ 3.2 A). Since the aromatic rings are positioned in the 
same location as biotin, carboxybiotin is unable to access the CT domain active site.   
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Model #2: Compound bindsà Closed Loopà Biotin Bindsà Compound Aromatic 
p-p Interaction with Tyr628 and Compound Aromatic p-sulfur interaction with 
Biotin 
Compound 98 outcompetes pyruvate and binds in the open conformation of the CT 
domain. It promotes the closed loop conformation. In this position, the aromatic rings of 
Compound 98 and Tyr628 are within distance for p-p interactions. Carboxybiotin is still 
able to access the CT domain active site, but the thiopene ring of biotin is positioned near 
the aromatic rings of Compound 98 to form an p electron cloud and contribute to 
carboxybiotin binding. The interactions of Compound 98 and carboxybiotin may impact 
the movement of the BCCP domain, thus interfering with enzyme activity. With this 
model, it may be possible for the compounds to become carboxylated and utilized as a 
substrate for PC (see Figure 4-13).  
 
Figure 4-13. Proposed Mechanism for the CT Domain Carboxylation of Aromatic 
Phenylpyruvic Acids 
 
Figure 4-13. Proposed Mechanism for the CT Domain Carboxylation of Aromatic 
Phenylpyruvic Acids 
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Model #3: Compound bindsà Open Loopà Biotin Binds (?)à Compound 
Aromatic p-sulfur interaction with Biotin (?) 
Compound 98 outcompetes pyruvate and binds in the open conformation of the CT 
domain. It does not promote the closed loop conformation. The change from the open to 
closed conformation is based on studies that utilized smaller a-keto acids such a 
pyruvate, 3BP and 3HP (Lietzan and St Maurice 2013b) that demonstrate the importance 
of the position of the carboxylic acid of the a-keto acids. If the docking poses are correct 
in predicting that the a-keto acids are coordinating with the metal ion and not with the 
catalytic amino acids, then there would be no “signal” for the CT domain to adopt the 
closed conformation. While the docking poses for Compound 98 do indicate that it can 
bind both the open and closed conformation with equal probability, this might not be the 
case, especially for sterically bulkier compounds. In this position, the aromatic rings of 
Compound 98 and Tyr628 are not within distance for p-p interactions. Carboxybiotin may 
still able to access the CT domain active site if random movements allow it to come in to 
contact with the CT domain and position the thiopene ring near the aromatic rings of 
Compound 98 to form a p electron cloud and contribute to carboxybiotin binding. The 
interactions of Compound 98 and carboxybiotin may impact the movement of the BCCP 
domain, thus interfering with enzyme activity. However, based on this model, there 
would be no ligand-induced biotin binding pocket in the CT domain.  
 
4.5 Future directions 
 
 
To assess the mechanism of inhibition with regards to the models described, a 
crystal structure is needed. A crystal structure would provide additional insight into if the 
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compounds promote the closed conformation or remain bound in the open conformation. 
Additionally, a crystal structure would highlight the preferred orientation of the 
compounds in the CT domain and provide a measure to assess the accuracy of the 
docking poses. The inhibitory effect of the enol or keto form of the compounds should be 
an emphasis for future compound designs as the keto-enol ratio may impact the docking 
studies (Martin 2009), X-ray crystallography and the potency of the compounds. A NMR 
study of the compounds prepared in assay buffer could determine the percent of enol vs 
keto tautomer present as well as the effect the electron donating groups have on the 
stabilization of the enol tautomer in an aqueous solution that represents our kinetic 
conditions. The confidence in establishing the enol-keto tautomer preference of the 
compounds in our system would greatly direct the future studies on the most appropriate 
crystallization conditions to utilize such as the percent of DMSO that will enhance the 
enol form without affecting crystallization, what compounds prefer the enol form and the 
appropriate concentration of the compounds to use for crystallization. Lastly, NMR 
studies could also eliminate or confirm the ability of the compounds to be carboxylated 
by PC as a substrate.  
Other experiments such as the effect of amino acid mutations of Tyr628 and 
Lys1119 in isothermal titration calorimetry (ITC) or fluorescent polarization (described in 
Chapter 5) binding studies could be implemented to assess the hypothetical role of the 
aromatic p interactions as described in the models. Direct binding rather than enzyme 
activity would have to be utilized as Tyr628 and Lys1119 are important in the catalysis of 
the PC reaction and display reduced enzyme activity when mutated (Lietzan and St 
Maurice 2013a, Lietzan, Lin, and St Maurice 2014). Tyr628 is hypothesized to be 
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important in p-p interactions between the aromatic ring of tyrosine and the compounds. 
Mutating tyrosine to phenylalanine, another aromatic amino acid, would hypothetically 
have no effect on the binding of the compounds to the CT domain. However, mutating 
tyrosine to alanine, an amino acid with a methyl side chain, should decrease the binding 
affinity of the compounds for the CT domain of PC if Tyr628 was important in the binding 
of the compounds. Lys1119 is the residue that biotin is tethered to in the BCCP domain 
(Lietzan et al. 2011) and hypothesized to interact with the compounds via an p electron 
cloud stabilization. Mutating the lysine to glutamine would maintain the spatial size of 
lysine but prevent the covalent linkage of biotin and determine whether or not biotin 
specifically contributes to the binding of the compounds. Alternatively, binding studies 
with a DBCCP truncation where the BCCP domain is removed and therefore lacks biotin 














CHAPTER 5: DISCUSSION  
 
 
This dissertation describes the development, validation and implementation of 
several innovative methods that have been used to discover novel small molecule 
inhibitors of PC. Through the validation of the FVB fixed time assay, a procedure for 
screening numerous small molecule effectors has been established that will provide the 
platform for future HTS endeavors. In combination with HTS, a SBDD project has been 
implemented in collaboration with the Donaldson and Dockendorff laboratories in the 
Marquette University Chemistry Department. This rational approach of developing small 
molecule inhibitors for PC has led to the establishment of the most potent inhibitors of 
PC to be documented. These first-generation compounds have the potential to be 
optimized as specific and potent tools to study the structure, regulation and the role PC 
plays in certain types of diseases and infections.    
 
5.1 PC as a Small Molecule Target 
 
 
PC expression has been linked to several diseases such as breast cancer (Christen 
et al. 2016) and type 2 diabetes (Hasan et al. 2008), as well as certain bacterial infections 
like listeriosis (Schar et al. 2010). Small molecules that are developed in vitro to elucidate 
the effect of the small molecules on the structure and regulation of PC also have the 
potential to be translated to in vivo studies. Specific and potent small molecules for PC 
can be used to further study the role of PC in those diseases and infections. By expanding 
the tools in which to study PC through both approaches, the small molecules developed 
with the techniques described in this dissertation have the potential to be utilized as the 
foundation for future drug development against PC.  
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5.1.1 Application of Small Molecule Effectors to in Vitro Studies 
 
 
As demonstrated by the SBDD and HTS projects, bacterial enzymes exhibited 
varying sensitivity in vitro to 3BP, 3HP and oxalate in the FVB assay and MDH assay.  
Generally, SaPC was more sensitive to the compounds followed by LmPC. The least 
sensitive enzyme was RePC. This trend was commonly observed in most cases where 
compounds were tested against all three bacterial enzymes. As described in Chapter 3, 
the difference in IC50 values may be due to differences in KM values for pyruvate among 
the various bacterial PCs. However, this is insufficient to explain the difference in 
inhibitor potency between RePC and LmPC that have around the same KM values for 
pyruvate. IC50 values are not measures of direct binding constants and only represent the 
concentration of the inhibitor at which the enzymatic reaction is 50% inhibited (Yang, 
Copeland, and Lai 2009). These values are dependent on the binding affinity of the 
inhibitor, the KM value of the substrate, the concentration of the substrates and the mode 
of inhibition. Ki values represent true dissociation constants and offer a more precise 
representation of the relative binding affinities amongst various bacterial PC enzymes.  
The estimated Ki values from the MDH assay do support the notion that bacterial 
PC may have varying sensitives to CT domain inhibitors in vitro. SaPC had the lowest 
estimated Ki with oxalate (0.43 µM), LmPC had the lowest estimated Ki with 3BP (1.1 
µM) while RePC had the highest Ki value with oxalate (140 µM). It is reassuring to note 
that the predictive Ki value of oxalate (0.43 µM) in SaPC aligned well with the kinetically 
determined Ki value in SaPC (0.29 µM). In a previous study, the KD of oxalate for the CT 
domain of RePC was determined to be 130 µM (Lietzan and St Maurice 2013b), 
providing evidence that the estimated Ki values are accurate and that species-specific 
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inhibition in bacterial PC is possible. Additionally, when comparing structural overlays 
of the open conformation of the CT domain in SaPCDBC (unpublished), LmPC (pdb i.d. 
4qsl, (Sureka et al. 2014)) and RePC (pdb i.d. 2qf7, (St Maurice et al. 2007)), there are 
slight shifts in the helices lining the CT domain tunnel such that RePC appears to have a 
tighter tunnel than LmPC or SaPC (see Figure B4). SaPC appears to have the most open 
CT domain that may allow it to bind a variety of compounds with greater flexibility. 
Other studies have also demonstrated that inhibitors can regulate enzyme activity and 
have varying degrees of inhibition based on species specificity (Kishor et al. 2013, 
Lawrence et al. 2008, Kruger and Overington 2012). For example, methionine 
aminopeptidases (MetAPs) are essential enzymes that are found in most organisms and 
the increased activity of MetAPs have been correlated to certain bacterial infections and 
cancer (Kishor et al. 2013). MetAPs are difficult to target due their conserved active sites. 
However, despite this conserved protein structure, Kishor et al. designed species-specific 
inhibitors of M. tuberculosis, E. faecalis and human MetAPs through SAR studies. The 
results in this dissertation chapter highlight the possibility that compounds can be 
discovered in vitro that are species-specific for bacterial PC and could be a promising 
direction for the development of future antimicrobial agents.  
 Small molecule effectors can elucidate structural and kinetic information on the 
regulation of PC activity in vitro. Through the SBDD project, the most potent small 
molecule inhibitors of PC activity to be documented have been discovered and 
developed. The compounds have been assessed in various in vitro methods such as IC50 
determinations, SAR studies and kinetic assays that have determined the mode of 
inhibition and Ki values of the most potent compounds. These compounds are aromatic a-
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keto acids and are competitive with respect to pyruvate, indicating that they are targeting 
the unique CT domain of PC. There is a demonstrated positive relationship between the 
potency and the enol-like characteristics of the compounds. The enol form of the 
compounds is hypothesized to either: 1) mimic the stabilizing enolpyruvate intermediate 
or 2) coordinate with the Mn2+/Zn2+ metal ion of the CT domain. In the absence of a 
crystal structure, it is difficult to elucidate the exact mechanism of inhibition. A crystal 
structure in particular, would be able to determine if the compounds induce the closed 
conformation in the CT domain and whether or not coordination with the metal ion or the 
mimic of a transition state intermediate is the preferred inhibition mechanism. A crystal 
structure could give insight into how the enol form of the compounds are important in 
inhibition. For example, if the compounds do not induce the closed conformation of the 
CT domain then what specific amino acids are important in the coordination of the enol 
compounds in the active site? 
The aromatic a-keto acid inhibitors discovered in this dissertation not only have 
the potential to be utilized as valuable in vitro tools to study the structure and regulation 
of PC but may also be applied to study other enzymes that catalyze reactions that proceed 
through a stabilizing enol-intermediate if they are not specific for PC. 
Phosphoenolpyruvate carboxykinase (PEPCK) catalyzes the reversible conversion of 
phosphoenolpyruvate to OAA with GTP through a enolpyruvate intermediate (Yang, 
Kalhan, and Hanson 2009) (Hanson and Patel 1994). PEPCK can also use ITP for 
catalysis but not ATP, displaying nucleotide specificity that has been hypothesized to be 
a function of the tautomerization of the keto and enol form of the guanosine and inosine 
nucleotide purine ring (Yang, Kalhan, and Hanson 2009). Studies have demonstrated that 
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the guanosine and inosine nucleotides prefer the keto tautomer in solution, but the 
binding pocket of PEPCK has been proposed to impose selectivity for the enol tautomer 
(Yang, Kalhan, and Hanson 2009). If the keto:enol ratio of the compounds discovered in 
this dissertation is important in PC inhibition, the compounds may be a useful tool in 
probing the binding pockets of enzymes like PEPCK that also catalyze reactions that 
proceed through an enol-intermediate. However, as the goal of the chemical probe 
development project is to develop potent and specific small molecule inhibitors of PC, it 
would be hopeful that the small molecules discovered through SBDD would not be 
specific for PEPCK. Regardless, the possibility of assessing the enol-like characteristics 
of the compounds in enzymes like PEPCK for either selectivity against PC or as a study 
on enol intermediates could be informative for in vitro studies.    
   
5.1.2 Application of Small Molecule Effectors to in Vivo Studies 
 
 
Small molecule inhibitors of PC are not only important tools that can aid in 
understanding the regulation of PC in vitro, but can also be utilized in cell-based assays 
to study the role of PC in certain types of diseases and infections, such as cancer and 
listeriosis respectively. While we have not assessed our most potent hit compounds in 
vivo, small molecules such as 3BP have previously been applied in other studies as 
anticancer drugs (Dasari and Tchounwou 2014, Pedersen 2012). Prior to this dissertation, 
3BP had been structurally characterized as a PC inhibitor (Lietzan and St Maurice 
2013b), but previous studies did not determine an IC50 value of 3BP for PC. As described 
in Chapter 4, 3BP was found to inhibit SaPC, RePC and LmPC activity with IC50 values 
of 51 µM, 1 mM and 7 µM respectively. Given the importance of PC in certain types of 
cancers (Lao-On, Attwood, and Jitrapakdee 2018) and the use of 3BP (Pedersen 2012) as 
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an anticancer drug, it highlights the possibility of the compounds discovered in this 
dissertation to be applied to cell-based assays that assess the role of PC in cancer.    
3BP is a highly reactive electrophilic alkylator that may have many interactions 
with various metabolic targets (Shoshan 2012). For example, 3BP is thought to inhibit 
succinate dehydrogenase (Pereira da Silva et al. 2009), glyceraldehyde-3-phosphate 
dehydrogenase (Pereira da Silva et al. 2009, Dell'Antone 2009, Ganapathy-Kanniappan et 
al. 2010) and can be used as a substrate by LDH (Dell'Antone 2009). Additionally, it is 
an inhibitor of isocitrate lyase (Pham et al. 2017). Based on the results from Chapter 4, it 
is now a known inhibitor of another important metabolic enzyme, PC. Despite the many 
possible and known metabolic targets of 3BP, it has been used in studies as an anticancer 
drug that is surprisingly specific for tumor cells and demonstrates limited toxicity in 
noncancerous cells (Ko et al. 2004, Shoshan 2012, Attia et al. 2015, Yun et al. 2009). For 
example, when treated with 30 µM of 3BP, AS-30D HCC cells (cells used to model 
hepatocellular carcinoma) viability decreased from 100% to 10%, while noncancerous 
hepatocytes remained unaffected (Ko et al. 2004). However, it appears the sensitivity of 
cancer cells to 3BP is not universal and depends on the cancer cell line.  
In particular, 3BP has been shown to be an effective anticancer drug in cancer cell 
lines where PC is highly expressed. 3BP has been used to study tumor reduction in 
combination with tamoxifen (a drug that is standard endocrine therapy for breast cancer) 
(Attia et al. 2015) and cancer cell toxicity in breast cancer cell lines (Kwiatkowska et al. 
2016, Wu et al. 2014, Xintaropoulou et al. 2015). It was found that breast cancer cell 
lines with a high metastatic profile such as MDA-MB-231 cells, were more sensitive to 
3BP treatment than the noninvasive tumorigenic MCF-7 breast cancer cell lines 
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(Kwiatkowska et al. 2016). This is interesting because PC is highly expressed in MDA-
MB-231 breast cancer cell lines and not in MCF-7 cells lines (Phannasil et al. 2015).  
Additionally, 3BP has selective toxicity to cells with KRAS and BRAF mutations that are 
related to colorectal, pancreatic, melanoma and lung cancer (Yun et al. 2009). KRAS 
mutations in particular are commonly associated with non-small cell lung cancer 
(NSCLC) (Roman et al. 2018, Riely, Marks, and Pao 2009). In combination with 
rapamycin (inhibitor of mTOR, a positive regulator of the Warburg effect), 3BP was 
shown to have enhanced antitumor efficacy for NSCLC cell lines (Zhang et al. 2015). 
Given the importance of 3BP toxicity in certain cancer cell lines that have high PC 
expression and the research in this dissertation that demonstrates that 3BP inhibits PC, a 
more thorough understanding of 3BP inhibition of PC could greatly benefit future in vivo 
studies on the role PC plays in cancer metabolism as 3BP is currently in transition 
towards clinical trials (Ko et al. 2012) .   
 
5.1.3 Application of Small Molecules as Drugs 
 
 
The compounds discovered in this dissertation were not developed with the 
intention of being progressed through a drug development project, but to be utilized as 
the foundation for chemical probes that can be applied to in vivo and in vitro studies. 
Currently, the discovery of small molecule effectors of PC is in the hit development 
stage. We have implemented several methods such as HTS and SBBD, that have 
developed the first-generation small molecule inhibitors of PC. We are screening and 
assessing for hit compounds that can be progressed towards lead compound optimization. 
If the future goal of this project is to eventually transition to a drug discovery program, 
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then several considerations should be made with regards to the target selection and 
compound hit refinements while the project is still in the hit generation stage.  
An emphasis has been placed on potent and specific small molecule effectors of 
PC throughout this dissertation. This is not only important for in vivo assays, but also 
important for future drug development. Drugs should be designed to obtain maximum 
safety and efficiency with the lowest dosage of drug (Teague and Valko 2017). In 
particular, the drugability of a target should be carefully considered (Bleicher et al. 2003). 
Drugability is the ability of a target to be effectively regulated by a small molecule 
effector that has been developed with these properties in mind: absorption, distribution, 
metabolism, excretion and pharmacokinetics (ADME/PK) (Eddershaw, Beresford, and 
Bayliss 2000). ADME/PK studies assess the chemical bioavailability of the compounds 
in various tissues, the transfer ability of the compounds from body compartments, the 
breakdown and removal of the compounds from the body, as well as the toxicity of the 
compounds (Bleicher et al. 2003, Eddershaw, Beresford, and Bayliss 2000).  
The steps of drug development are: 1) Hit generation where targets and hits are 
identified, 2) lead generation where hits are refined, 3) lead optimization where leads are 
refined and 4) clinical development (see Figure 5-1) (Bleicher et al. 2003). Target 
selection is important in the outcome of hit development. Hits are progressed to leads by 
comprehensive evaluation of the chemical integrity, SAR studies and ADME/PK studies 
of the compounds (Eddershaw, Beresford, and Bayliss 2000). Rigorous and educated 
selections on hit and lead compounds at each stage will help decrease the high risk of 
attrition as the compounds progress through the drug development stages. While SAR 
studies described in Chapter 4 have demonstrated that the enol form of the compounds 
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may be important in the inhibition of PC, there have been no comprehensive chemical 
evaluations of the most potent compounds, such as ADME/PK studies, as we are still in 
the hit generation stage. Some examples of ADME/PK studies that could be utilized with 
compounds that are eventually transitioned to lead generation are metabolite toxicity 
assessment with liver microsomes (Jia and Liu 2007) or intestinal permeability evaluation 
in a cell-based Caco-2 model (Li 2001).  
 
Figure 5-1. Drug Discovery and Development Workflow 
Figure 5-1. Drug discovery and development workflow. Robust selection of compounds 
at every stage of drug development will decrease the high attrition rates of compounds 
that are removed in drug development projects. We are currently at the hit generation 
stage (Bleicher et al. 2003) .   
 
 
5.1.4 PC as a Drug Target  
 
 
An ideal drug target should have a demonstrated role in the pathophysiology of a 
disease, an available structure, the ability to be assayed in a HTS and differing expression 
levels throughout the body (Gashaw et al. 2012). PC meets many of the requirements of a 
good drug target, as PC expression is increased in certain types of cancers (Christen et al. 
2016), is essential for L. monocytogenes virulence (Schar et al. 2010) and is differentially 
expressed in certain tissues (Jitrapakdee et al. 2008). Importantly, PC can now be assayed 
in a validated FVB-based HTS. In particular, SaPC, LmPC and RePC are bacterial PC 
enzymes that have been purified and assayed in the HTS and SBDD projects. Several 
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concentrated efforts have also been made to purify human PC (HsPC) as a target to 
screen potential inhibitors against. Unfortunately, there has been limited success in 
purifying active, soluble HsPC from an E. coli bacterial expression system in our 
research laboratory.  
Attempts were made to increase the solubility of full-length HsPC with an N-
terminal tagged maltose binding protein (MBP). MBPs are one of the most effective 
solubilizing agents for proteins that improperly fold or aggregate in bacterial expression 
systems (Sun, Tropea, and Waugh 2011). Despite the addition of the MBP, a majority of 
the purified full-length HsPC was aggregated and less than 1 mg of purified protein was 
collected (compared to ~40 mg of SaPC). However, the enzyme was slightly active with 
a specific activity of 4.4 µmol min- mg- in the presence of acetyl CoA (see Figure C2). 
Additionally, when the MBP tagged HsPC was utilized in the FVB assay in the presence 
of acetyl CoA, it had a Z-factor of 0.74 (see Figure C3). Other efforts were made to 
purify active and soluble HsPC protein with a BC domain truncation (HsPCDBC) and 
while ~3 mgs of protein were purified (see Figure C1), the protein was inactive as it had 
no OAA decarboxylation activity in the LDH assay. As demonstrated by Xiang et al., 
while full-length expression of HsPC in E. coli resulted in aggregated protein, 
crystallization of active HsPCDBC was successful (Xiang and Tong 2008a). It is 
unknown, then, exactly why our HsPCDBC protein was inactive. It may have been due to 
a protein purification error or due to the lack of protein purification optimization for 
HsPCDBC.  
The difficulties of purifying active, soluble full-length HsPC in a bacterial 
expression system may be due to eukaryotic post-translational modifications that do not 
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occur in E. coli but are essential for human protein structure and activity (Schein 1991). It 
may also be due to differences in codon bias (Quax et al. 2015) between human and 
bacteria that affect translation. As it was difficult to purify enough active HsPC for the 
HTS and SBDD projects, it was not used as the target PC enzyme for the studies 
described in this dissertation. Instead, bacterial PC enzymes such as RePC, LmPC and 
SaPC were utilized in both HTS and SBDD with an emphasis on SaPC in SBDD. SaPC 
shares 49% sequence similarity with HsPC and the CT domain structures of both SaPC 
and HsPC, when overlaid, differ by only 0.6 Å rms (Xiang and Tong 2008a). There is, 
however a slight difference in the C-terminal extension of the CT domain in HsPC 
compared to SaPC (Xiang and Tong 2008a). Additionally, in comparing the open and 
closed conformation of SaPC with the available structures of RePC (open and closed) and 
LmPC (closed) in preparation for the docking studies, it was noticed that there are only 
slight shifts in the helices lining the CT domain tunnel such that RePC appears to have a 
tighter tunnel than LmPC or SaPC (~2.5 Å rms difference between SaPC and RePC). 
Overall, all CT domain structures of bacterial and human PC enzymes are very similar.  
  Based on the structural similarity of HsPC, LmPC, RePC and SaPC it might be 
assumed that the selection of the PC target does not matter for HTS, SBDD or future drug 
discovery efforts. It may be assumed that screening against SaPC for example, will result 
in hit compounds that will also be hit compounds for LmPC or HsPC. However, as it has 
been demonstrated in this dissertation, bacterial enzymes exhibited varying sensitivity to 
3BP and oxalate. Generally, SaPC was more sensitive to the compounds followed by 
LmPC, providing some evidence that species specific inhibition in bacterial PC is 
possible. It has been established that PC isolated from S. aureus and L. monocytogenes 
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can be differentially regulated by an allosteric inhibitor, c-di-AMP (Sureka et al. 2014). 
Sureka et al. confirmed that c-di-AMP is a potent allosteric inhibitor of LmPC and not 
SaPC, as the c-di-AMP binding site is not present in SaPC (Sureka et al. 2014). This 
highlights the importance of target selection in HTS as it is a nonbiased approach to 
discovering small molecule effectors of PC that may then reveal novel, species specific 
binding locations. It may be possible that screening against SaPC will reveal novel 
binding locations that are SaPC specific and not LmPC or HsPC specific.  
 If the goal of the HTS project is to eventually be utilized as the foundation for a 
drug development program that specifically targets PC, then the most ideal PC drug 
target should be selected for screening. As a reminder, an ideal drug target is one that can 
be assayed in a HTS and has a demonstrated role in the pathophysiology of a disease 
(Gashaw et al. 2012). Bacterial PCs could be utilized as drug targets for antibiotic drug 
development while human PC could be a drug target for cancer therapy. If the goal is to 
develop drugs that will act as antibiotics against bacterial PC, then considerations should 
be made in to which bacterium in particular is being targeted, and how to limit off target 
effects against human PC. If the goal of the program is to discover compounds that will 
target human PC for future cancer therapy, then purification and utilization of human PC 
is essential as screening against bacterial PC may not result in inhibitors that are specific 
for human PC. In both instances, a protocol for purifying human PC, or at the very least 
mammalian PC, will need to be established. Methods such as HsPC purification from 
insect cells using the baculovirus system (Petchampai et al. 2004), mammalian PC 
extraction from either sheep or pig liver (Rylatt, Keech, and Wallace 1977, Khew-
Goodall et al. 1991, Warren and Tipton 1974), or purification of recombinant HsPC from 
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293T kidney cells (Jitrapakdee, Walker, and Wallace 1999) should be considered as 
future directions for purifying human or mammalian PC.  
Due to the difficulties of purifying sufficient amounts of human PC for HTS, 
combined with the relative ease of purifying bacterial PC, and the importance of PC in 
certain bacterial infections, a future drug development program should focus on bacterial 
PC as the ideal drug target. Both LmPC and SaPC could be potential drug targets as they 
have been found to be important in the virulence of L. monocytogenes (Sureka et al. 
2014) and S. aureus (Benton et al. 2004) respectively. In particular,  LmPC has a unique 
allosteric binding location (c-di-AMP) and due to the interrupted TCA cycle of L. 
monocytogenes (Schar et al. 2010) (Section 1.1.4), it may have other unique binding 
locations that have evolved to regulate LmPC in the interrupted TCA cycle of L. 
monocytogenes. These novel binding locations could be discovered through HTS and 
may be able to provide the foundation for LmPC specific antibiotics. Given the rise of 
antibiotic resistant bacteria (Gillings et al. 2008) and the limited number of antibiotics 
that have been developed recently (Fischbach and Walsh 2009), targeting central 
metabolic enzymes like PC may a possible direction for the future of antibiotic drug 
development (Haag, Velk, and Wu 2012, Murima, McKinney, and Pethe 2014). 
Targeting metabolic enzymes may bypass the antibiotic resistant pathways that bacteria 
have currently established against existing antibiotics (Haag, Velk, and Wu 2012).  This 
is not a novel idea or unheard of direction as drugs like trimethoprim (TMP), Prontosil 
and Bedaquiline all target bacterial metabolic enzymes that have human homologs 
(Murima, McKinney, and Pethe 2014). TMP inhibits bacterial dihydrofolate reductase 
(DHFR) magnitudes higher than the human counterpart through cooperative binding of 
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TMP and a DHFR-cofactor, nicotinamide adenine dinucleotide phosphate (Baccanari and 
Kuyper 1993, Kwon, Higgins, and Rabinowitz 2010). Bedaquiline is another example of 
an antibiotic that displays targeted selection for the bacterial enzyme over the human 
enzyme as mycobacterium ATP synthase is at least 20,000´ more sensitive to 
Bedaquiline than the human ATP synthase (Haagsma et al. 2009).  
 
5.2 Future Directions for Pyruvate Carboxylase Small Molecule Effector Discovery  
 
In addition to the contribution of this dissertation work towards the discovery of 
specific and potent chemical probes for PC, it also describes the development of a 
diazonium based, HTS assay. The FVB assay can not only function as a HTS assay for 
PC, but also has the potential to be used as a HTS for other enzymes that utilize or 
produce OAA, much like how FVB was originally used to detect phosphoenolpyruvate 
carboxylase and aspartate transaminase activity (Sax and Moore 1967, Cockburn et al. 
1990, Lombarts and Peters 1971, Norris, Atkinson, and Smith 1975, Babson et al. 1962a). 
Enzymes such as MDH, phosphoenolpyruvate carboxykinase and OAA decarboxylase 
could benefit from the optimization of a fixed time assay that can measure OAA levels 
(Minárik et al. 2002, Yang, Kalhan, and Hanson 2009, Sender et al. 2004). In particular, 
phosphoenolpyruvate carboxykinase is an important enzyme that maintains blood glucose 
levels and has been identified as a potential drug target for diabetes and obesity 
(Matsuoka et al. 2015). Currently, the FVB assay is utilized as the primary screen in both 
the HTS and SBBD projects that are described in this dissertation.  
With regards to HTS, libraries of compounds are initially screened in the FVB 
assay with a single point determination in 384-well plates (each single well contains one 
compound), whereas in the SBDD project, rationally designed compounds are initially 
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evaluated with a dose dependent response in the FVB assay. If a compound has been 
identified as a potential hit compound either in HTS or SBDD, the IC50 value of the 
compound is confirmed in both the FVB and secondary MDH assay (96-well plates). 
Potent compounds (IC50 <30 mM) that do not inhibit MDH, are kinetically characterized 
by their mode of inhibition and Ki values via the 96-well MDH assay. The MDH assay 
was specifically chosen to determine Ki values as it records initial velocity measurements. 
From Equation 10 and 13 in Section 4.2.8, those initial velocities are used to determine Ki 
values. The FVB assay can be utilized to determine initial velocity measurements as well, 
but it requires precise manual inactivation of the enzyme with EDTA over numerous time 
points and is more labor intensive than the MDH assay. As the LDH assay was 
determined to be an inappropriate secondary assay to assess aromatic a-keto acid 
inhibition of PC, it has been removed from the screening process. However, a recently 
optimized secondary assay has been established as a future secondary assay that 
could assess the broad metal binding capabilities of the compounds against carbonic 
anhydrase (Day and Cohen 2013). This metalloenzyme assay was optimized in 96-well 
plates by undergraduate researcher, Mallory Mews. The assay may give some insight into 
whether or not a compound is a promiscuous metal chelator. This assay will only be used 
for the most potent and promising inhibitors that have been thoroughly characterized as it 
is estimated to cost $14/plate to test against carbonic anhydrase. 
Depending on the number of compounds that are tested in the future through both 
the HTS and SBDD projects, as well as the number of researchers dedicated to evaluating 
the compounds, the screening flow may have to be altered. For example, we receive on 
average one compound per week from our collaborators. This rate is very manageable for 
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an undergraduate researcher to assess the dose dependent response in both the FVB and 
MDH assay each week. If this rate were to increase (hypothetically to 10 
compounds/week), it would be recommended that the researcher test the compounds at 
50-100 µM in the FVB assay and confirm potential hits with a dose dependent response 
in the MDH assay. As more promising and potent hits are discovered, the limits for 
progressing compounds to the secondary assays should be reevaluated to reflect the needs 
of the project. In particular, potential hit compounds from HTS may become too 
numerous to manage effectively with the current screening procedure and the 
development of additional secondary assays may be essential in developing a robust HTS 
program in conjunction with SBDD. For the remainder of this discussion, I will highlight 
potential resources and areas for improvement for the HTS and SBDD projects. 
 
5.2.1 Future Assay Development  
 
 
Compounds from SBDD and HTS displayed higher potency against SaPC than 
against LmPC or RePC, thus SaPC was the most appropriate PC enzyme that was utilized 
in the FVB and MDH assays. However, for future assay development, consideration 
should be given to determining the appropriate concentration of substrates based on the 
PC enzyme (SaPC, RePC, LmPC etc.) that is being targeted in the assay. The sub-
saturating concentration of 2 mM pyruvate in the FVB assay is optimal for maximizing 
the signal to noise ratio of the assay in RePC, but it has not been optimized for SaPC and 
LmPC. The concentration of the substrates in an assay can impact the number and type of 
inhibitors that are identified in a screening process (Acker and Auld 2014, Yang, 
Copeland, and Lai 2009). The FVB assay in particular, should be modified to maximize 
the signal to noise ratio (Glickman 2004) while also considering the KM value (Yang, 
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Copeland, and Lai 2009) of pyruvate for each selected enzyme in HTS. Intuitively it 
might be thought that as competitive inhibitors are generally more specific for enzyme 
active sites (Acker and Auld 2014), then the assay should be modified to have pyruvate 
concentrations below the KM value to increase the number of hits that may be competitive 
inhibitors (Yang, Copeland, and Lai 2009) for the unique CT domain of PC. However, 
noncompetitive inhibitors may be more preferable to discover in a screening approach as 
those compounds generally bind at evolutionary less conserved allosteric sites and 
increase selectivity of the compound for the target (Lindsley 2014). At all concentrations 
of pyruvate, there should be the ability to identify noncompetitive inhibitors, therefore, 
pyruvate concentrations below the KM value may be selective for both competitive and 
noncompetitive inhibitors.  
Depending on the number of hits that are routinely identified from HTS and 
SBDD, a series of additional secondary assays must be established (Janzen 2014). These 
secondary assays should ideally eliminate compounds that are either false positives or 
compounds that target the conserved BC domain of PC. With these secondary assays in 
place, the majority of the compounds that are progressed to dose dependent response 
assays to confirm IC50 values will be compounds that: 1) inhibit the PC reaction and 2) 
target the unique CT domain of PC.   
The LDH assay measures the rate of oxamate-induced OAA decarboxylation in 
the CT domain and was utilized to facilitate inhibition assays of the CT domain in 
isolation. However, it was determined that several compounds inhibited LDH at 
concentrations greater than 1 mM and, furthermore, that some compounds act as 
substrates for LDH. These findings greatly complicate the use of an LDH-coupled assay 
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to assess CT domain specific inhibition in PC and lead to the conclusion that the LDH 
assay is inappropriate for assessing CT domain inhibitors of PC. While the FVB assay 
procedure is currently designed to measure pyruvate carboxylation and can be an 
alternative to the MDH coupled-enzyme assay, it could possibly be modified to assay 
OAA decarboxylation to pyruvate as an alternative to the LDH coupled-enzyme assay. 
This would be a beneficial secondary assay that could specifically assay the CT domain 
reaction of PC.  
To initiate the reaction, OAA would act as the substrate for the PC reaction 
instead of the substrates that are used in the pyruvate carboxylation reaction (ATP, 
bicarbonate and pyruvate). The assay would have to be optimized with and without 
oxamate to determine if the substrate is necessary in this modified FVB assay. As 
oxamate promotes OAA decarboxylation by accepting the carboxyl group from OAA to 
form pyruvate and carbamyl oxamate (Lietzan, Lin, and St Maurice 2014), it greatly 
increases the rate of the reaction. However, as the FVB assay is a fixed-time assay, if the 
rate of the reaction is slow, the time to enzyme inactivation can be extended to increase 
the signal to noise background. Instead of measuring the increase of FVB-OAA colored 
adduct formation as for the pyruvate carboxylation assay, the decrease in absorbance of 
the FVB-OAA colored adduct would be measured to report on OAA conversion to 
pyruvate. Additionally, truncated versions of PC (DBC) could be applied in the assay so 
only the CT domain is contributing to the reaction. Hits that are not true inhibitors of the 
CT domain reaction would be identified by the decrease in FVB-OAA colored adduct 
absorbance.  
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 In addition to the modified OAA decarboxylation FVB assay, other secondary 
HTS assays that utilize ATP cleavage or fluorescent polarization could be developed to 
assess CT domain inhibition. To assay if the compounds are inhibiting the conserved BC 
domain of PC, a standard coupled ATPase assay with urea carboxylase (UC) could be 
optimized for HTS. This assay measures the initial rate of ATP cleavage from the 
conserved BC domain of UC with several coupled enzymes that include pyruvate kinase 
and LDH (Lin, Boese, and St Maurice 2016).  If a compound inhibits the ATP cleavage 
reaction, it should be removed from follow up studies as it is an inhibitor that targets the 
BC domain from UC or a possible inhibitor of the coupled-enzymes, pyruvate 
kinase/LDH. Regardless if the inhibition is due to the inhibition of the BC domain from 
UC or due the inhibition of pyruvate kinase/LDH, the compound is not specific for the 
CT domain of PC as it can target other enzymes as well. However, LDH has been shown 
to reduce aromatic a-keto acids (Friedrich et al. 1987) and we have demonstrated that 
Compound 17 is utilized as a substrate by LDH, thus LDH may mask any inhibition in 
this assay. A control should then be established in the secondary assay that measures the 
possible reduction of the compounds by LDH. This control would include LDH, the 
compound and NADH. If LDH reduces the compound and oxidizes NADH to NAD+, this 
can be readily observed by measuring the change in absorbance of NADH at 340 nm.  
Fluorescent polarization (FP) is a technique that could expand the ability to assess 
the binding of small molecules to the BC or CT domains of PC. FP is a method that 
utilizes the fluorescent properties of a compound based on the orientation of the 
compound in solution relative to excited and emitted polarizing light (Lea and Simeonov 
2011, Huang and Aulabaugh 2016). For example, if a fluorescent small molecule is not 
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bound to PC and is constantly rotating in space, when it is excited by plane-polarized 
light, the emitted light will become depolarized. If a fluorescent small molecule is bound 
to PC, the movement of the small molecule becomes more limited and when it is excited 
by plane-polarized light, the emitted light will be polarized. This technique can be used 
with various PC domain truncations that could assess the binding of fluorescent small 
molecules to either the BC domain or CT domain. For small molecules that are not 
fluorescent, competition assays could be established with fluorescent compounds that are 
known to bind to PC. For example, Compound 98 is a fluorescent small molecule due to 
its conjugated aromatic rings and could be used to determine if a more potent inhibitor 
was outcompeting it from the CT domain.  
 
5.2.2 Future Directions in HTS 
 
 
Based on the previous experiences of HTS from Chapter 3, it is recommended 
that future screening be performed with libraries from which potential hits can be pursued 
and confirmed in secondary assays. For example, we were unable to follow up on 
potential hit compounds from the screens performed at UWM due to the compounds were 
not made available for follow up studies. Synthesizing those potential hit compounds 
would have required a major investment of resources and the compounds themselves 
were no longer stored by the laboratory that performed the initial synthesis (Frankowski 
et al. 2011). Or in the case of the NCI DTP library, NMR studies demonstrated that all of 
the hit compounds were impure.  
While there are a wide range of libraries that are currently available commercially 
and through academic investigators, only several have been briefly highlighted. The 
research group of Dr. Matt Scaglione at the Medical College of Wisconsin currently has a 
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library consisting of ~40,000 compounds and funding for a technician to train other 
researchers on the HTS instruments. The Scaglione library consists of the NCI DTP 
Diversity IV set, a Life Chemical Diversity set (35,200 compounds), and a FDA 
approved drug set. The High Throughput Analysis Laboratory at Northwestern 
University also has a wide range of chemical libraries that can be utilized for HTS. The 
High Throughput Analysis Laboratory can provide a ChemDiv Structural-Diversity set 
(30,000 compounds), ChemBridge Drug-Like set (20,000 compounds), the Kozmin 
Library (7000 compounds), and the Silverman Collection (custom library) to potential 
collaborators. Lastly, the Molecular Libraries Probe Production Centers Network 
(MLPCN) is an organization that partners with investigators that have developed novel 
assays and have been approved to screen their library of compounds through an 
application process. The MLPCN library consists of 350,000 chemically diverse 
compounds with the additional support of medicinal chemists that optimize the validated 
hits from the screens (Roy et al. 2010).  
 
5.2.3 Future Directions in Structure Based Drug Design 
 
 
The SBDD project has resulted in the discovery of the most inhibitors of PC 
activity to be documented. As determined in Chapter 4, Compound 98 and para 
substituted phenylpyruvic acids such as Compounds 17 and 114 are the most promising 
hit compounds to be developed thus far. These inhibitors are competitive with respect to 
pyruvate, contain aromatic a-keto acids and are hypothesized to inhibit the CT domain 
reaction based on their enolic characteristics either by mimicking the enolpyruvate 
intermediate or coordinating with the metal ion in the CT domain. Several compounds 
have been designed centered on observations made through the docking, SAR and Ki 
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determination studies. As Compound 98 is currently our most potent compound with a Ki 
value of 0.74 µM, the structure of the compound was used as a scaffold for Compound A 
and Compound B (see Table 5.1). The scaffold was modified with the addition of a fused 
aromatic ring (Compound A) or linked aromatic ring (Compound B). The docking studies 
suggest that aromatic p-p interactions between the compounds and Tyr628 may be a 
possible coordination that is occurring. It is hypothesized that an additional aromatic ring 
would increase the predictive binding affinity of the compound. However, aromatic 
compounds are prone to solubility issues due to p-p interactions between the compound 
molecules (Ritchie and Macdonald 2009), thus a carbon link was introduced in 
Compound B to mitigate those possible effects. A study by Ritchie et al. suggests that the 
more aromatic rings (specifically more than three) that are in a drug candidate, the more 
likely it will face drug attrition (Ritchie and Macdonald 2009). While the compounds that 
contain multiple aromatic rings may not be ideal drug candidates, they would be 
beneficial to use in competitive FP assays to assess the binding of compounds that are not 
fluorescent.  
Lastly, the importance of the enol form was considered for future compound 
development. As it had been demonstrated by the Hammett plot in Figure 4-5, the lower 
the s value, the lower the IC50 value. Electron donating groups may promote the enol 
form of the compounds in aqueous solutions (Larsen and Wieczorkowska 1974) and 
therefore may be better inhibitors. Compound C is a NH2  para substituted phenylpyruvic 
acid with a s value of -0.66. The lowest para substituted s value that has been currently 
tested is -0.37 (Compound 17, IC50 value of 22 µM). The hypothetical future compounds 
were docked in the open conformation of the CT domain of SaPCDBC. As a majority of 
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predictive docking poses suggest, the compounds are not oriented in the same position as 
pyruvate and thus are unlikely to promote the closed conformation of the CT domain. 
The docking scores do not predict that Compound A, B or C will bind with greater 
affinity than previously docked compounds and the docking poses suggest that 
Compound C would coordinate more closely to the metal ion than A or B (see Figure 5-
2). Despite the increased bulk of the additional aromatic ring, the docking poses predict 
that the Compound A and B would still be able to access the CT domain, however, the 
poses do not suggest any p-p interactions would occur.  
 
Table 5-1. Hypothetical Future Compound Designs  
























Figure 5-2. Docking Poses of the Hypothetical Future Compounds  
 
Figure 5-2. Docking poses of the hypothetical future compounds. Compound A is 
represented by the pink stick model, Compound B by the yellow stick model and 
Compound D by the green stick model. The compounds were docked in the open 
conformation of the CT domain of SaPCDBC that is represented by the periwinkle 









5.2.4 Future Directions in Cell-Based Assays 
 
 
To expand the direction of the project towards cell-based assays, several 
possibilities for testing well validated, stable and soluble compounds in assays for 
antimicrobial and anticancer activity are briefly described. Minimum inhibitory 
concentration (MIC) assays are standardized assays that can assess the antimicrobial 
activity of compounds (Wiegand, Hilpert, and Hancock 2008). MIC assays could be 
applied to determine the MIC of the compounds with L. monocytogenes, S. aureus, and 
E. coli cultures. As PEPC replaces the function of PC by converting PEP to OAA in 
enteric bacteria, PC is not present in E. coli (Jitrapakdee et al. 2008), and would serve as 
the control for compounds that display PC specific antimicrobial activity. Dr. Ming You 
at the Medical College of Wisconsin has published several studies that have investigated 
the cell toxicity and anticancer effects of 3BP with NSCLC (Zhang et al. 2015, Zhang et 
al. 2012) and may be a resource for testing the compounds in cytotoxicity assays such as 
the MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) assay (Zhang 
et al. 2012). MTT is reduced by metabolically active cells and can be utilized in a 
colorimetric assay to measure cell viability and proliferation (van de Loosdrecht et al. 
1994).  
The NCI DTP is also another option to screen the compounds against cancer cell 
lines as the program offers a free NCI-60 human tumor screen that will screen mailed 
compounds against 60 cancer cell lines. The compounds are assessed for potential 
anticancer properties, unique inhibition profiles and are compared to submitted 
compounds that have been previously analyzed. In particular, the DTP has a total of 9 
NSCLC cell lines, 7 breast cancer cell lines that include MCF-7 (low PC expression) and 
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MDA-MB-231 (high PC expression) cancer cell lines (Shoemaker 2006). As PC is 
known to have varying expression levels in certain cancer cell lines, this screen in 
particular could demonstrate if the compounds: 1) have anticancer activity and 2) are 
possibly specific for cancer cell lines that have high PC expression.  
 
5.3 Conclusion  
  
 
PC is an important metabolic enzyme that has been implicated in a wide range of 
diseases and infection. Despite the importance of PC in these diseases and infections, 
there are no specific and potent small molecule effectors available to study the structure, 
regulation and specific role of PC in the cellular context. The methods developed in this 
dissertation aimed to discover novel and potent small molecule effectors of PC activity. 
The research presented in this dissertation describes a novel fixed time assay that has 
been developed based on the reaction of the diazonium salt, FVB, with the final product 
of the PC catalyzed reaction, OAA. This assay has been validated and can screen 
numerous compounds in both HTS and SBDD projects. Through SBDD, potent inhibitors 
that are specific for the CT domain reaction of PC have been discovered and developed. 
These compounds can be utilized as the foundation for specific and potent chemical 
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APPENDIX A: Fast Violet B Assay Optimization and Validation 
 
Figure A1. Reagent Stability at Varying Temperatures 
 
 
Figure A1. Reagent stability at varying temperatures. For both A and B, the background 
signal (black) is the inactivated PC reaction with 12.7 mM EDTA. The reaction signal 
(teal) is the PC reaction in the absence of added effectors. The activation signal (orange) 
is the PC reaction in the presence of acetyl CoA (0.25 mM). The inactivation signal 
(blue) is the PC reaction in the presence of the inhibitor, oxalate (5 mM). A) Reagents 
used in the FVB-based assay are not stable in all reactions for up to 8 hours at when kept 
on ice. B) All reagents used in the FVB-based assay are stable in all reactions for up to 8 
hours at 22° C. Due to the stability of the reagents at 22° C, assay optimization 
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Table A1. Validation Checklist for Plate Uniformity Assessment as Determined by 






















 3-Day Inh. 
Check manually for drift/ edge effects in all 
plates Yes Yes Yes 
All max (HI) signal CV’s < 20 % Yes Yes Yes 
All mid signal (unnormalized) CV’s < 20 % Yes Yes Yes 
All normalized mid signal (mid %) SD’s < 20 Yes Yes Yes 
All min (LO) SD’s < Min (max (HI) SD, mid SD) Yes Yes Yes 
All SW’s >2  Yes Yes Yes 
All Z’ Factors > 0.4 (and < 1; must pass one of 6 




   
All within-day fold shifts < 2 Yes Yes Yes 
All Average (between-)Day fold shifts < 2 Yes Yes Yes 
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Figure A2. 96-Well Plate Format Procedure Optimization to 384-Well Plate Format  
The background signal (black) is the inactivated PC reaction with 12.7 mM EDTA. The 
reaction signal (teal) is the PC reaction in the absence of added effectors. The activation 
signal (orange) is the PC reaction in the presence of acetyl CoA (0.25 mM). The 
inactivation signal (blue) is the PC reaction in the presence of the inhibitor, oxalate (5 
mM). The 96-well plate procedure was followed as described in Figure 3-4, except all 
volumes were reduced by half so that the final volume was 60 µL. Consistent absorbance 
values were observed for all reactions across the entire plate demonstrating that the 96-
well plate format could be modified to 384-well plate format with high signal variance 



























Figure A3. Inhibition plate uniformity validation tests for RePC with oxalate in the 384-
well plate format. Uniformity tests show consistent signals across all plates and across 
multiple days. There are no edge or drift effects in the plates and all statistical measures 
are acceptable. 3-day inhibition plate uniformity assessment with 5 mM oxalate for the 
minimal signal (blue diamonds), 90 µM oxalate for the middle signal (pink squares) and 
the uninhibited PC reaction for the maximal signal (green triangles). The plate uniformity 
validation test provided additional support for the robustness of the 384-well plate 












Figure A4. 384-Well Plate FVB Assay LOPAC Screen 
 
Figure A4. Results from the LOPAC (Library of Pharmacologically Active Compounds) 
screens. A) Absorbance signals for individual plate controls, with 250 µM acetyl CoA 
(pink squares) served as the activated reaction, PC reaction in the absence of effectors 
(purple squares) served as the unaltered reaction and 5mM oxalate (blue squares) served 
as the inhibited reaction. B) 3 plates in the LOPAC screen had excellent Z-factors, while 
one did not. C) Screening data for the plates that were run in the LOPAC screen for A 
and B in percent of inhibition. The two hit compounds that were consistently identified 
across all three screens in the 96-well plate format, cisplatin and pyriplatin (Figure 3-12), 
are the two compounds with the highest percent of inhibition (>90%). It was promising to 
observe the same two consistent hits appear in both plate formats and these results 






Figure A5. University of Wisconsin-Milwaukee Screening Against RePC   
 
Figure A5. Results from the University of Wisconsin-Milwaukee screens against RePC 
A) Absorbance signals for individual plate controls, with 250 µM acetyl CoA (pink 
squares) served as the activated reaction, PC reaction in the absence of effectors (purple 
squares) served as the unaltered reaction and 5mM oxalate (blue squares) served as the 
inhibited reaction. B) All 33 plates in the screen had excellent Z-factors except for the 
first plate. C) Screening data for the plates that were run in the screen for A and B in 
percent of activation. All results indicate that the 384-well plate format for the FVB assay 
can be used to screen larger libraries of compounds. Despite screening a larger library, 








Figure A6. Comparison of University of Wisconsin-Milwaukee Screening Against 
RePC and LmPC.   
 
 
Figure A6. Comparison of University of Wisconsin-Milwaukee Screening Against RePC 







































PC Origin KM (mM) 
KM with Acetyl 
CoA 
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2.0 ± 0.2 0.56 ± 0.03 0.58 ± 0.1 
    

















250 ± 10 1400 ± 16 1300 ± 2 
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Figure A7. FVB-OAA Colored Adduct Decrease in Absorbance with Increasing 
Concentrations of CoA.  
 
Figure A7. FVB-OAA Colored Adduct Decrease in Absorbance with Increasing 
Concentrations of CoA. The interference of CoA with the FVB-OAA colored adduct was 
first observed when increasing titrations of CoA or acetyl CoA resulted in a decrease in 
the activation signals in the FVB assay at high concentrations of the activator. This had 
previously never been documented before, so a series of controls were established. 
Increasing CoA concentrations decreased the FVB-OAA colored adduct absorbance 
(teal) in the presence of 300 µM OAA and standard assay conditions (blue). Even at 250 
µM, the concentration that is used in the FVB assay for activation controls has a slight 
decrease in absorbance. The error bars represent the standard deviation of the signal 











APPENDIX B: Structure Based Drug Design  
 
Figure B1: IC50 Determination for Substrate-Analog Inhibitors of Bacterial PC in 
the MDH Assay 
 
Figure B1. IC50 determination for substrate-analog inhibitors of bacterial PC in the MDH 
assay. For all plots, the RePC inhibited reaction is represented by the green line, the 
LmPC inhibited reaction is represented by the purple line, the SaPC inhibited reaction is 
represented by the teal line and the FVB-OAA colored adduct inhibition is represented by 
the black line. In all panels, the error bars represent the standard deviation across eight 
wells.  A) The IC50 values for oxalate were 51 µM, 21 µM and 3 µM for RePC, LmPC 
and SaPC respectively. B) The IC50 values for 3BP were 1 mM, 7 µM and 51 µM RePC, 
LmPC and SaPC respectively. The SaPC IC50 value was determined by Mallory Mews 












Table B1. Aromatic Ring Substitution SAR of PC Inhibitors and Percent of 
Inhibition of the Assay Signal at 1 mM or 200 µM 
 
                                           
                 Aromatic a-keto acids ring substitutions     
                              R1= Ortho position 
                                        R2= Para position 
           R3= Meta position 
 
Compound R1 R2 R3 FVB 1mM/ 200 µM % 
MDH 1mM/ 200 µM 
% 
96 H H H 6/-10 78/0 
19 N2O H H ND ND 
110 H N2O H ND ND 
115 Br H H ND ND 
97 H Br H 45/-10 9/0 
108 H H Br 28/-11 ND/0 
112 H H CH3 21/-10 74/13 
114 H CH3 H 18/-10 10/-3 
120 H Cl H 36/-12 12/2 
106 H OCH3 H 25/-10 ND/-15 
119 H B(OH)2 H 34/-10 -48/17 
109 H CF3 H 20/-10 ND/-11 
107 H F H 35/-12 78/23 
17 H OH H 64/-10 9/-17 
117 H CH3 CH3 14/-11 -17/3 











Table B2. Additional Docking Scores with Various Protein PDB Files  
 









- -45 -24 -22/-25 -24/-42 





- -41 -24 -28/-42 -37-18 





- -40 -20 -42/-44 -40/-40 





- -20 -17 -22/ND -20/ND 




- -42 -17 -36/-31 -35/-38 
Ki= 0.74, IC50= 8 + -22 -15 -17/-22 --- 
Compound 114 
 
 - -31 --- -22 -35 





- -56 --- -44 -49 





























- -40 --- -37 -38 





- -9 --- -12 -22 






- -14 --- -19 -22 
Ki= , IC50= + -9 --- -10 --- 







































Table B3. Enol and Keto Docking Scores of Pyruvate, Compound 17 and 
Compound 110 
 








-25 -25 -42 
17-keto 
 
-37 -32 -38 
17-enol 
 
-39 -41 -37 
110-keto 
 
-44 -47 -40 
110-enol 
 
-41 -39 -35 
 
Compound 110= EWG (s 0.778, IC50= >1000 µM), keto 






























Figure B2. Oxalate, Compound 98, Compound 114 and Compound 103 are 
Noncompetitive with Respect to ATP  
 
 
Figure B2. Oxalate, Compound 98, Compound 114 and Compound 103 are 
noncompetitive with respect to ATP. Left panels are global fits and right panels are 
Lineweaver-Burk plots. A) Oxalate is a mixed type inhibitor (strongly favors 
noncompetitive inhibition), Ki value = 2.5 µM. B) Compound 98 is a noncompetitive 
inhibitor, Ki value = 5.2 µM. C) Compound 114 is a noncompetitive inhibitor, Ki value = 







Figure B3. Oxalate, Compound 98, Compound 114 and Compound 103 are 






Figure B3. Oxalate, Compound 98, Compound 114 and Compound 103 are competitive 
with respect to pyruvate. Left panels are global fits and right panels are Lineweaver-Burk 
plots. A) Oxalate is a mixed type inhibitor (strongly favors competitive inhibition), Ki 
value = 0.29 µM. B) Compound 98 is a competitive inhibitor, Ki value = 0.74 µM. C) 
Compound 114 is a competitive inhibitor, Ki value = 2.4 µM. D) Compound 103 is a 
competitive inhibitor, Ki value = 141 µM.   
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Figure B4. Cartoon Representation of SaPC, RePC and LmPC CT Domain Active 




Figure B4. Cartoon representation of SaPC, RePC and LmPC CT domain active site in the 
open conformation. Structural overlays of the open conformation of the CT domain in 
SaPCDBC (unpublished, blue), LmPC (pdb i.d. 4qsl- green (Sureka et al. 2014)) and 
RePC (pdb i.d. 2qf7-orange (St Maurice et al. 2007)), there are slight shifts in the helices 
lining the CT domain tunnel such that RePC appears to have a tighter tunnel than LmPC 






























All cloning methods for LmPCDBC, LmPCDBCDBCCP and HsPCDBC proceeded 
through the same method described in Section 4.2.5. For the BC domain truncations, 
Lys458 and Lys490 were determined represented the C-terminal end of the BC domain of 
LmPC and HsPC respectively. For the LmPCDBCDBCCP truncation was determined that 
Asn1059 represented the C-terminal end of the allosteric domain. The construct therefore 
ended at Asn1059 and a stop codon, TGA, was incorporated at residue 1060 in the primer 
design. All BC and BC/BCCP domain truncations were cloned into the pET-28a-(His)8-
TEV expression vector from PCR amplified from the wild-type LmPC pET-28a-(His)8-
TEV template or wild-type MBP-HsPC pKLD116 (see Section 5.1.4). All clones were 
verified by sequencing of the complete gene by Functional Biosciences Inc. The forward 
and reverse primers for LmPCDBC, LmPCDBCDBCCP and HsPCDBC were as followed:  
 
LmPCDBC: 
5’- GCCTGCAGCATATTCGCGACCGT- 3’ (forward; PstI restriction enzyme) 
5’- GCGCGCTCGAGTCAAATTCTGTTTAC- 3’ (forward; XhoI restriction enzyme) 
 
LmPCDBCDBCCP: 
5’- GCCTGCAGCATATTCGCGACCGT- 3’ (forward; PstI restriction enzyme) 
5’- CGCCTCGAGTCAGTTCATATCTTGGAT - 3’ (forward; XhoI restriction enzyme) 
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HsPCDBC: 
 5’- CGCATATGCGGCCTGCACAG - 3’ (forward; NdeI restriction enzyme) 
5’- ATGCGGCCGCTCACTCGATCTC - 3’ (reverse; NotI restriction enzyme) 
 
Protein purification of LmPCDBC, LmPCDBCDBCCP and HsPCDBC followed the 
methods outlined in Chapter 2 with LmPC, SaPC, SaPCDBC and SaPCDBCDBCCP.  
 
Figure C1. Protein Purification SDS Gel of HsPCDBC 
 
 
Figure C1. Protein purification SDS gel of HsPCDBC. ~ 3 mgs of 2.5 mg/mL HsPCDBC 
was collected following the protein purification method outlined in Chapter 2. 1) Marker, 
2) total fraction, 3) insoluble fraction, 4) soluble fraction 5) Ni2+ column run through after 
the addition of protein to the column, 6) after 300 mL of lysis and wash buffer was 
applied to the column to remove nonspecific protein, 7) eluted protein from the Ni2+ 
column, 8) Q-Sepharose run through after the addition of protein to the column and 9) 













Figure C2. Specific Activity of MBP-HsPC  
 
 
Figure C2. Specific activity of MBP-HsPC. MBP- HsPC was co-expressed from a 
modified pKLD116 vector (designed by Ann Menefee, previous post-doctoral researcher) 
with a pCY216 vector encoding E. coli biotin protein ligase (BirA) in E. coli HMS cells. 
After elution from the Ni2+-NTA Profinity resin column in Ni2+-affinity chromatography 
(represented by the first SDS gel), the soluble protein was isolated from the aggregated 
by fast protein liquid chromatography (FPLC). The aggregated protein eluted in fractions 
7-12 with very little specific activity. The active form of the enzyme eluted in fractions 
13-17. The purified, active and soluble protein is represented by the SDS-gel 
corresponding to the 150 kDa bands from each fraction. The highest specific activity of 
HsPC in the presence of acetyl CoA when isolated from the soluble protein was 4.4 µmol 
min- mg- while the specific activity of the aggregated protein was 0.19 µmol min- mg-.  
 
 187 
Figure C3. Activity of MBP-HsPC in the FVB Assay  
 
Figure C3. Activity of MBP-HsPC in the FVB assay. The activity of MBP-HsPC purified 
from FPLC (fractions 13-17 collected from Figure C2) and MBP-HsPC collected before 
FPLC (Ni2+-affinity chromatography) was measured in the FVB assay in the presence of 
EDTA (black), the unaffected reaction in the presence of assay buffer (grey) and in the 
presence of acetyl CoA (green). The FPLC samples demonstrated higher specific activity 
in Figure C2, but were not as active as the protein samples before FPLC in the FVB 
assay. The Z-factors for activation were 0.74 and 0.72 for the FPLC purified MBP-HsPC 













Compound Crystallization Conditions of Hit Refinements  
  
A variety of hit RePC, LmPC and SaPC crystals were refined from crystallization 
conditions in hanging drop/sitting drop vapor diffusion and batch crystallization. These 
conditions were pursued in the hopes of crystallizing PC with small molecule 
compounds. The most promising crystals were diffracted on SaPCDBC crystals, and data 
was collected as described in Chapter 4 (see Table C1). General screening solutions from 
the St. Maurice research laboratory (144 conditions) were successful in the establishment 
of several hit conditions for RePC, LmPC, SaPC, SaPCDBC and SaPCDBCDBCCP. The 
most successful refinements based on those hit conditions are listed in Table C2. 
However, the general screen was not successful in identifying crystals for LmPCDBC and 
LmPCDBCDBCCP. Due to the unsuccessful screening of LmPC truncation crystals, a PC 
general screen was created based on published crystallization conditions (see Table C3). 
The PC general screen did not result in crystal hits for LmPC, but resulted in numerous 










Table C1. Data Collection and Refinement Statistics  




Space Group P42212 P4212 
Cell Dimensions    
a, b, c (Å) 125.9, 125.9, 97.5 126.9, 126.9, 97.1 
a, b, g (°) 90, 90, 90 90, 90, 90 




Redundancy  5.96 (5.22) 5.84 (4.25) 
Completeness (%) 99.8 (98.0) 98.1 (84.6) 
Unique Reflections 13475 18253 
Rmerge (%) 0.223 (0.581) 0.255 (0.744) 
Average I/s 4.8 (1.9) 4.1 (1.0) 
Refinement: In Progress 
Rcrystal 0.2690 0.2368 
Rfree 0.3155 0.2889 
Xtal371 is SaPCDBC co-crystallized with 10 mM Compound 17  





















Table C2. Refined Crystallization Hits for PC  
 
 RePC RePC 
DBCDBCCP LmPC 
Protein [ ] 10.8 mg/mL 15 mg/mL 11.7 mg/mL 





50-100 mM CaCl2 
12% PEG 4K 
140 mM MES 
pH 6.0 
345 mM TMACl 
11% PEG 8K 




16% PEG 8K 
100 mM TEA pH 7.5 
Compound 200- 400 µM TNP-ATP apo 
10 mM CoA 
10 mM CoA with 10 
mM Compound 17 
Crystal 
morphology 
Large, clustered, thin 
3D plates, ~ 1 cluster 
per drop 
Medium, individual 
spherical crystals, ~5 
per drop 
Large, broken crystals 
~1 crystal per drop 
Additional 
Techniques 
Stocks of TNP-ATP 
were prepared under 
red light and plating 
the protein with the 
crystallization 
conditions were 
performed under red 
light 
--- 
Crystallized well in 
both hanging and 
sitting, appeared to do 
well with the addition 














Table C3. The BW PC General Screen  
 1 2 3 4 5 6 
A 










































































100 mM Bis 
Tris pH 6 
 















100 mM Bis 























































































A1-A6                                                                 B1-B6 
200 mM Ammonium tartrate constant               15% PEG 3350 
0-25% PEG 3350                                                Varying salts  
 
C1-C6, D1-D6 
Varying PEGs  
Varying pH 
Varying salts 
